{"id":334269,"date":"2025-06-10T09:18:00","date_gmt":"2025-06-10T01:18:00","guid":{"rendered":"https:\/\/pingtungtimes.com.tw\/?p=334269"},"modified":"2025-06-10T09:18:00","modified_gmt":"2025-06-10T01:18:00","slug":"%e3%80%902025-eha%e3%80%91%e4%ba%9e%e7%9b%9b%e9%86%ab%e8%97%a5%e6%a0%b8%e5%bf%83%e7%94%a2%e5%93%81%e8%80%90%e7%ab%8b%e5%85%8b%e5%92%8capg-2575%e7%ad%8913%e9%a0%85%e9%80%b2%e5%b1%95%e5%85%a5","status":"publish","type":"post","link":"https:\/\/pingtungtimes.com.tw\/?p=334269","title":{"rendered":"\u30102025 EHA\u3011\u4e9e\u76db\u91ab\u85e5\u6838\u5fc3\u7522\u54c1\u8010\u7acb\u514b\u00ae\u548cAPG-2575\u7b4913\u9805\u9032\u5c55\u5165\u90782025\u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703\u5e74\u6703"},"content":{"rendered":"
\n\n\n\n
<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u7f8e\u570b\u99ac\u91cc\u862d\u5dde\u7f85\u514b\u7dad\u723e\u5e02\u548c\u4e2d\u570b\u8607\u5dde<\/span> 2025\u5e746\u670810\u65e5<\/span> \u00a0\/\u7f8e\u901a\u793e\/ — \u81f4\u529b\u65bc\u5728\u816b\u7624\u7b49\u9818\u57df\u958b\u767c\u5275\u65b0\u85e5\u7269\u7684\u9818\u5148\u7684\u751f\u7269\u91ab\u85e5\u4f01\u696d\u2014\u2014\u4e9e\u76db\u91ab\u85e5\uff08\u7d0d\u65af\u9054\u514b\u4ee3\u78bc\uff1aAAPG\uff1b\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a6855\uff09\u5ba3\u5e03\uff0c\u6d89\u53ca\u516c\u53f8\u539f\u52751\u985e\u65b0\u85e5\u5967\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae<\/b><\/sup>\uff09\u3001Bcl-2\u6291\u5236\u5291APG-2575\u3001EED\u6291\u5236\u5291APG-5918\u7b49\u91cd\u78c5\u54c1\u7a2e\u768413\u9805\u7814\u7a76\u9032\u5c55\u5c07\u57282025\u5e746\u670812\u65e5\u81f315\u65e5\u65bc\u610f\u5927\u5229\u7c73\u862d\u8209\u884c\u76842025\u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703\uff08EHA\uff09\u5e74\u6703\u4e0a\u516c\u5e03\uff0c\u5176\u4e2d\u5305\u62ec1\u9805\u53e3\u982d\u5831\u544a\uff0c\u53ca\u591a\u9805\u58c1\u5831\u5c55\u793a\u548c\u7dda\u4e0a\u767c\u8868\u3002<\/p>\n

\n<\/p><\/div>\n

EHA\u5e74\u6703\u4f5c\u70ba\u6b50\u6d32\u8840\u6db2\u5b78\u9818\u57df\u898f\u6a21\u6700\u5927\u7684\u570b\u969b\u6703\u8b70\uff0c\u6bcf\u5e74\u5438\u5f15\u4f86\u81ea\u5168\u7403100\u591a\u500b\u570b\u5bb6\u76841\u842c\u591a\u540d\u5c08\u696d\u4eba\u58eb\u8207\u6703\uff0c\u5206\u4eab\u5168\u7403\u6700\u524d\u6cbf\u7684\u7814\u7a76\u9032\u5c55\u548c\u7a81\u7834\u6027\u81e8\u5e8a\u6578\u64da\u3002<\/p>\n

\u53e3\u982d\u5831\u544a<\/b> <\/p>\n

Integrating Genomic and Transcriptomic Insights for Predicting Responses and Outcomes in Patients with CML Receiving 3rd-Generation TKI Therapy
\u6574\u5408\u57fa\u56e0\u7d44\u548c\u8f49\u9304\u7d44\u5b78\u898b\u89e3\u4ee5\u9810\u6e2c\u63a5\u53d7\u4e09\u4ee3TKI\u6cbb\u7642\u7684CML\u60a3\u8005\u7684\u7642\u6548\u548c\u7d50\u5c40<\/p>\n

    \n
  • \u6458\u8981\u7de8\u865f\uff1aS162<\/li>\n
  • \u5206\u6703\u5834\uff1aCML\u6cbb\u7642\u7642\u6548\u53ca\u8010\u85e5\u7684\u751f\u7269\u5b78\uff08Biology of CML treatment response and resistance\uff09<\/li>\n
  • \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u665a\u4e0a23:30-23:45\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u4e0b\u534817:30-17:45\uff09<\/li>\n
  • \u4e3b\u8981\u4f5c\u8005\uff1a\u5317\u4eac\u5927\u5b78\u4eba\u6c11\u91ab\u9662\u6c5f\u5029\u6559\u6388\uff0c\u5317\u4eac\u5927\u5b78\u4eba\u6c11\u91ab\u9662\u5f35\u5c0f\u5e25<\/li>\n<\/ul>\n

    \u58c1\u5831\u5c55\u793a<\/b> <\/p>\n

    Frontline Chemotherapy-Free Combination of Olverembatinib with Venetoclax and Azacitidine in Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia: Preliminary Outcomes of a Prospective Study
    \u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u7dad\u5948\u514b\u62c9\u8207\u963f\u624e\u80de\u7518\u7528\u65bc\u7121\u5316\u7642\u4e00\u7dda\u6cbb\u7642\u65b0\u8a3a\u65b7\u7684Ph+\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff1a\u4e00\u9805\u524d\u77bb\u6027\u7814\u7a76\u7684\u521d\u6b65\u7d50\u679c<\/p>\n

      \n
    • \u6458\u8981\u7de8\u865f\uff1aPF384<\/li>\n
    • \u5206\u6703\u5834\uff1a\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76\uff08Acute lymphoblastic leukemia – Clinical\uff09<\/li>\n
    • \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u51cc\u666800:30-01:30\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670813\u65e5\uff0c\u5468\u4e94\uff0c\u665a\u4e0a18:30-19:30\uff09<\/li>\n
    • \u4e3b\u8981\u4f5c\u8005\uff1a\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662\u5510\u66c9\u6587\u6559\u6388\uff0c\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662\u5f35\u6b23<\/li>\n<\/ul>\n

      A Phase 2 Study of Olverembatinib for the Treatment of Myeloid\/Lymphoid Neoplasms with FGFR1 Rearrangement
      \u4e00\u9805\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u7528\u65bc\u6cbb\u7642\u4f34FGFR1\u91cd\u6392\u7684\u9ad3\u7cfb\/\u6dcb\u5df4\u7cfb\u816b\u7624\u7684II\u671f\u7814\u7a76<\/p>\n

        \n
      • \u6458\u8981\u7de8\u865f\uff1aPF390<\/li>\n
      • \u5206\u6703\u5834\uff1a\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76\uff08Acute lymphoblastic leukemia – Clinical\uff09<\/li>\n
      • \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u51cc\u666800:30-01:30\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670813\u65e5\uff0c\u5468\u4e94\uff0c\u665a\u4e0a18:30-19:30\uff09<\/li>\n
      • \u4e3b\u8981\u4f5c\u8005\uff1a\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662\u9673\u8607\u5be7\u6559\u6388\uff0c\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662\u8521\u6587\u6cbb<\/li>\n<\/ul>\n

        Efficacy and Safety of Regimen with Olverembatinib and Blinatumomab for the Frontline Treatment of Ph-Positive or Ph-Like Acute Lymphoblastic Leukemia
        \u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u8c9d\u6797\u59a5\u6b50\u55ae\u6297\u4e00\u7dda\u6cbb\u7642\u8cbb\u57ce\u67d3\u8272\u9ad4\uff08Ph\uff09\u967d\u6027\u6216Ph\u6a23\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\u7684\u7642\u6548\u548c\u5b89\u5168\u6027<\/p>\n

          \n
        • \u6458\u8981\u7de8\u865f\uff1aPS1367<\/li>\n
        • \u5206\u6703\u5834\uff1a\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76\uff08Acute lymphoblastic leukemia – Clinical\uff09<\/li>\n
        • \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670815\u65e5\uff0c\u5468\u65e5\uff0c\u51cc\u666800:30-01:30\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u665a\u4e0a18:30-19:30 \uff09<\/li>\n
        • \u4e3b\u8981\u4f5c\u8005\uff1a\u5357\u65b9\u91ab\u79d1\u5927\u5b78\u5357\u65b9\u91ab\u9662\u5468\u7d05\u5347\u6559\u6388\uff0c\u5357\u65b9\u91ab\u79d1\u5927\u5b78\u5357\u65b9\u91ab\u9662\u8a31\u79c0\u9e97<\/li>\n<\/ul>\n

          Combination of Olverembatinib and VP Regimen as First-Line Therapy for Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Single-Arm, Multicentre, Phase 2 Trial
          \u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408VP\u65b9\u6848\u4e00\u7dda\u6cbb\u7642\u6210\u4eba\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff1a\u4e00\u9805\u55ae\u81c2\u3001\u591a\u4e2d\u5fc3II\u671f\u7814\u7a76<\/p>\n

            \n
          • \u6458\u8981\u7de8\u865f\uff1aPS1372<\/li>\n
          • \u5206\u6703\u5834\uff1a\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76\uff08Acute lymphoblastic leukemia – Clinical\uff09<\/li>\n
          • \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670815\u65e5\uff0c\u5468\u65e5\uff0c\u51cc\u666800:30-01:30\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u665a\u4e0a18:30-19:30\uff09<\/li>\n
          • \u4e3b\u8981\u4f5c\u8005\uff1a\u6d59\u6c5f\u5927\u5b78\u91ab\u5b78\u9662\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662\u91d1\u6f54\u6559\u6388\uff0c\u6d59\u6c5f\u5927\u5b78\u91ab\u5b78\u9662\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662\u8a31\u6539\u9999<\/li>\n<\/ul>\n

            Efficacy and Safety of The Third-Generation Tyrosine Kinase Inhibitor Olverembatinib in Combination with Inotuzumab Ozogamicin for the Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients With Relapsed Disease or Persistent Minimal Residual Disease Bridging to Hematopoietic Stem Cell Transplantation: A Phase II Study
            \u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u5967\u52a0\u4f0a\u59a5\u73e0\u55ae\u6297\u6cbb\u7642\u5fa9\u767c\u6216\u9020\u8840\u5e72\u7d30\u80de\u79fb\u690d\u524d\u6301\u7e8cMRD\u967d\u6027\u6210\u4ebaPh+ ALL\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\uff1a\u4e00\u9805\u2161\u671f\u7814\u7a76<\/span><\/p>\n

              \n
            • \u6458\u8981\u7de8\u865f\uff1aPS1387<\/li>\n
            • \u5206\u6703\u5834\uff1a\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76\uff08Acute lymphoblastic leukemia – Clinical\uff09<\/li>\n
            • \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670815\u65e5\uff0c\u5468\u65e5\uff0c\u51cc\u666800:30-01:30\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u665a\u4e0a18:30-19:30\uff09<\/li>\n
            • \u4e3b\u8981\u4f5c\u8005\uff1a\u4e2d\u570b\u91ab\u5b78\u79d1\u5b78\u9662\u5317\u4eac\u5354\u548c\u91ab\u5b78\u9662\u8840\u6db2\u75c5\u91ab\u9662\u59dc\u723e\u70c8\u6559\u6388\uff0c\u4e2d\u570b\u91ab\u5b78\u79d1\u5b78\u9662\u5317\u4eac\u5354\u548c\u91ab\u5b78\u9662\u8840\u6db2\u75c5\u91ab\u9662\u5f35\u701f\u4e88<\/li>\n<\/ul>\n

              Embryonic Ectoderm Development (EED) Inhibitor APG-5918 Exhibits Potent Antitumor Activity and Synergizes with Histone Deacetylase Inhibitor Tucidinostat in Preclinical
              T-Cell Lymphoma (TCL) Models
              \u80da\u80ce\u5916\u80da\u5c64\u767c\u80b2\u86cb\u767d\uff08EED\uff09\u6291\u5236\u5291APG-5918\u5728T\u7d30\u80de\u6dcb\u5df4\u7624\uff08TCL\uff09\u81e8\u5e8a\u524d\u6a21\u578b\u4e2d\u5c55\u73fe\u5f37\u6548\u6297\u816b\u7624\u6d3b\u6027\uff0c\u4e26\u8207\u7d44\u86cb\u767d\u53bb\u4e59\u9170\u5316\u9176\u6291\u5236\u5291\u897f\u9054\u672c\u80fa\u5354\u540c\u589e\u6548<\/p>\n

                \n
              • \u6458\u8981\u7de8\u865f\uff1aPS1993<\/li>\n
              • \u5206\u6703\u5834\uff1a\u6dcb\u5df4\u7624\u751f\u7269\u5b78\u8207\u8f49\u5316\u7814\u7a76\uff08Lymphoma biology & translational research\uff09<\/li>\n
              • \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670815\u65e5\uff0c\u5468\u65e5\uff0c\u51cc\u666800:30-01:30\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u665a\u4e0a18:30-19:30\uff09<\/li>\n
              • \u4e3b\u8981\u4f5c\u8005\uff1a\u4e9e\u76db\u91ab\u85e5Eric Liang\u535a\u58eb<\/li>\n<\/ul>\n

                \u5728\u7dda\u767c\u5e03<\/b> <\/p>\n

                Alternating Low-Dose Inotuzumab Ozogamicin and Blinatumomab in Maintenance Therapy for Ph+ ALL: A Single-Center Retrospective Analysis
                \u4f4e\u5291\u91cf\u5967\u52a0\u4f0a\u59a5\u73e0\u55ae\u6297\u548c\u8c9d\u6797\u59a5\u6b50\u55ae\u6297\u4ea4\u66ff\u7dad\u6301\u6cbb\u7642\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\uff08Ph+\uff09\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08ALL\uff09\uff1a\u4e00\u9805\u55ae\u4e2d\u5fc3\u56de\u9867\u6027\u5206\u6790<\/p>\n

                  \n
                • \u6458\u8981\u7de8\u865f\uff1aPB2384<\/li>\n
                • \u4e3b\u8981\u4f5c\u8005\uff1a\u6cb3\u5317\u91ab\u79d1\u5927\u5b78\u7b2c\u4e8c\u91ab\u9662\u8076\u5b50\u5143\u6559\u6388<\/li>\n<\/ul>\n

                  Efficacy and Safety of Blinatumomab in Newly-Diagnosed Patients with Ph-Positive\/Negative B-Cell Acute Lymphoblastic Leukemia
                  \u8c9d\u6797\u59a5\u6b50\u55ae\u6297\u6cbb\u7642\u65b0\u78ba\u8a3a\u7684 Ph \u967d\u6027\/\u9670\u6027 B \u7d30\u80de\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\u60a3\u8005\u7684\u7642\u6548\u548c\u5b89\u5168\u6027<\/p>\n

                    \n
                  • \u6458\u8981\u7de8\u865f\uff1aPB2363<\/li>\n
                  • \u4e3b\u8981\u4f5c\u8005\uff1a\u83ef\u4e2d\u79d1\u6280\u5927\u5b78\u540c\u6fdf\u91ab\u5b78\u9662\u9644\u5c6c\u5354\u548c\u91ab\u9662\u5f35\u5bc5\u5b19<\/li>\n<\/ul>\n

                    Efficacy and Safety of the Third-Generation TKI Olverembatinib in Relapsed and Persistent MRD Positive Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients
                    \u7b2c\u4e09\u4ee3TKI\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u5fa9\u767c\u548c\u6301\u7e8cMRD\u967d\u6027\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\u60a3\u8005\u7684\u7642\u6548\u8207\u5b89\u5168\u6027<\/p>\n

                      \n
                    • \u6458\u8981\u7de8\u865f\uff1aPB2360<\/li>\n
                    • \u4e3b\u8981\u4f5c\u8005\uff1a\u6cb3\u5317\u91ab\u79d1\u5927\u5b78\u7b2c\u4e8c\u91ab\u9662\u8523\u854a\u6eab<\/li>\n<\/ul>\n

                      Clinical Features and Genetic Abnormalities Predict Outcomes in Patients with Chronic Myeloid Leukemia in the Accelerated-Phase Receiving Olverembatinib Therapy: A Retrospective Multicenter Study
                      \u81e8\u5e8a\u7279\u5fb5\u548c\u57fa\u56e0\u7570\u5e38\u7528\u65bc\u9810\u6e2c\u63a5\u53d7\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7684\u52a0\u901f\u671f\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u60a3\u8005\u7684\u6cbb\u7642\u7d50\u5c40\uff1a\u4e00\u9805\u56de\u9867\u6027\u591a\u4e2d\u5fc3\u7814\u7a76<\/p>\n

                        \n
                      • \u6458\u8981\u7de8\u865f\uff1aPB2701<\/li>\n
                      • \u4e3b\u8981\u4f5c\u8005\uff1a\u5317\u4eac\u5927\u5b78\u4eba\u6c11\u91ab\u9662\u539f\u5922\u7464<\/li>\n<\/ul>\n

                        A Real-World Study of Olverembatinib in the Treatment of Chronic Myeloid Leukemia from China: A Single-Center Retrospective Study
                        \u4e00\u9805\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u7528\u65bc\u6cbb\u7642\u4e2d\u570b\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u60a3\u8005\u7684\u771f\u5be6\u4e16\u754c\u7814\u7a76\uff1a\u4e00\u9805\u55ae\u4e2d\u5fc3\u56de\u9867\u6027\u7814\u7a76<\/p>\n

                          \n
                        • \u6458\u8981\u7de8\u865f\uff1aPB2714<\/li>\n
                        • \u4e3b\u8981\u4f5c\u8005\uff1a\u56db\u5ddd\u5927\u5b78\u83ef\u897f\u91ab\u9662\u8463\u5929<\/li>\n<\/ul>\n

                          Synergistic Effects of Olverembatinib (HQP1351) Combined with Bcl-2 Inhibitor Lisaftoclax (APG-2575) and Bcl-2\/Bcl-xL Inhibitor Pelcitoclax (APG-1252) in T-Cell Acute Lymphoblastic Leukemia (T-ALL)
                          \u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u806f\u5408Bcl-2\u6291\u5236\u5291lisaftoclax\uff08APG-2575\uff09\u548cBcl-2\/Bcl-xL\u6291\u5236\u5291pelcitoclax\uff08APG-1252\uff09\u5728T\u7d30\u80de\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08T-ALL\uff09\u4e2d\u7684\u5354\u540c\u4f5c\u7528<\/p>\n

                            \n
                          • \u6458\u8981\u7de8\u865f\uff1aPB2341<\/li>\n
                          • \u4e3b\u8981\u4f5c\u8005\uff1a\u4e9e\u76db\u91ab\u85e5\u5f6d\u6ce2<\/li>\n<\/ul>\n

                            \u95dc\u65bc\u4e9e\u76db\u91ab\u85e5<\/b> <\/p>\n

                            \u4e9e\u76db\u91ab\u85e5\u662f\u4e00\u5bb6\u7d9c\u5408\u6027\u7684\u5168\u7403\u751f\u7269\u91ab\u85e5\u4f01\u696d\uff0c\u81f4\u529b\u65bc\u7814\u767c\u5275\u65b0\u85e5\uff0c\u4ee5\u89e3\u6c7a\u816b\u7624\u7b49\u9818\u57df\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u30022019\u5e7410\u670828\u65e5\uff0c\u516c\u53f8\u5728\u9999\u6e2f\u806f\u4ea4\u6240\u4e3b\u677f\u639b\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u78bc\uff1a6855.HK\uff1b2025\u5e741\u670824\u65e5\uff0c\u516c\u53f8\u5728\u7f8e\u570b\u7d0d\u65af\u9054\u514b\u8b49\u5238\u4ea4\u6613\u6240\u639b\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u78bc\uff1aAAPG\u3002<\/p>\n

                            \u4e9e\u76db\u91ab\u85e5\u5df2\u5efa\u7acb\u8c50\u5bcc\u7684\u5275\u65b0\u85e5\u7522\u54c1\u7ba1\u7dda\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u548c MDM2-p53 \u7b49\u7d30\u80de\u51cb\u4ea1\u901a\u8def\u95dc\u9375\u86cb\u767d\u7684\u6291\u5236\u5291\uff1b\u65b0\u4e00\u4ee3\u91dd\u5c0d\u764c\u75c7\u6cbb\u7642\u4e2d\u51fa\u73fe\u7684\u6fc0\u9176\u7a81\u8b8a\u9ad4\u7684\u6291\u5236\u5291\u7b49\u3002<\/p>\n

                            \u516c\u53f8\u6838\u5fc3\u54c1\u7a2e\u8010\u7acb\u514b\u00ae<\/b><\/sup>\u662f\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\uff0c\u4e14\u7372\u6279\u9069\u61c9\u75c7\u5747\u88ab\u6210\u529f\u7d0d\u5165\u570b\u5bb6\u91ab\u4fdd\u85e5\u54c1\u76ee\u9304\uff0c\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u8010\u7acb\u514b\u00ae<\/b><\/sup>\u4e00\u9805\u7372\u7f8e\u570bFDA\u8a31\u53ef\u7684\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff08POLARIS-2\uff09\uff0c\u7528\u65bc\u6cbb\u7642\u65e2\u5f80\u63a5\u53d7\u904e\u6cbb\u7642\u7684\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CML-CP\uff09\u6210\u5e74\u60a3\u8005\u3002\u6b64\u5916\uff0c\u8010\u7acb\u514b\u00ae<\/b><\/sup>\u806f\u5408\u6cbb\u7642\u65b0\u8a3a\u65b7\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u60a3\u8005\u548c\u6cbb\u7642\u7425\u73c0\u9178\u812b\u6c2b\u9176\uff08SDH\uff09\u7f3a\u9677\u578b\u80c3\u8178\u9053\u9593\u8cea\u7624\uff08GIST\uff09\u60a3\u8005\u7684\u5168\u7403\u8a3b\u518aIII\u671f\u7814\u7a76\u6b63\u5728\u958b\u5c55\u4e2d\u3002<\/p>\n

                            \u516c\u53f8\u53e6\u4e00\u91cd\u78c5\u54c1\u7a2e\uff0c\u65b0\u578bBcl-2\u9078\u64c7\u6027\u6291\u5236\u5291APG-2575\uff08Lisaftoclax\uff09\u7684\u65b0\u85e5\u4e0a\u5e02\u7533\u8acb\uff08NDA\uff09\u5df2\u7372CDE\u53d7\u7406\uff0c\u4e26\u88ab\u7d0d\u5165\u512a\u5148\u5be9\u8a55\u3002\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55APG-2575\uff08Lisaftoclax\uff09\u56db\u9805\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u5206\u5225\u70ba\u7372\u7f8e\u570bFDA\u8a31\u53ef\u7684\u6cbb\u7642\u7d93\u6cbb\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u7684\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff08GLORA\uff09\uff1b\u6cbb\u7642\u521d\u6cbbCLL\/SLL\u60a3\u8005\u7684\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff1b\u4e00\u7dda\u6cbb\u7642\u65b0\u8a3a\u65b7\u8001\u5e74\u6216\u9ad4\u5f31\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08AML\uff09\u7684\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff1b\u4ee5\u53ca\u6cbb\u7642\u65b0\u8a3a\u65b7\u4e2d\u9ad8\u5371\u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u75c7\uff08MDS\uff09\u60a3\u8005\u7684\u8a3b\u518aIII\u671f\u7814\u7a76\u3002<\/p>\n

                            \u622a\u81f3\u76ee\u524d\uff0c\u516c\u53f84\u500b\u5728\u7814\u65b0\u85e5\u5171\u737216\u9805FDA\u548c1\u9805\u6b50\u76df\u5b64\u5152\u85e5\u8cc7\u683c\u8a8d\u5b9a\uff0c2\u9805FDA\u5feb\u901f\u901a\u9053\u8cc7\u683c\u4ee5\u53ca2\u9805FDA\u5152\u7ae5\u7f55\u898b\u75c5\u8cc7\u683c\u8a8d\u8b49\u3002\u6191\u501f\u5f37\u5927\u7684\u7814\u767c\u80fd\u529b\uff0c\u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u5168\u7403\u7bc4\u570d\u5167\u9032\u884c\u77e5\u8b58\u7522\u6b0a\u5e03\u5c40\uff0c\u4e26\u8207\u6b66\u7530\u3001\u9ed8\u6c99\u6771\u3001\u963f\u65af\u5229\u5eb7\u3001\u8f1d\u745e\u3001\u4fe1\u9054\u7b49\u9818\u5148\u7684\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u4ee5\u53ca\u6885\u5967\u91ab\u5b78\u4e2d\u5fc3\uff08Mayo Clinic\uff09\u3001\u4e39\u5a1c\u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662\uff08Dana-Farber Cancer Institute\uff09\u3001\u7f8e\u570b\u570b\u5bb6\u764c\u75c7\u7814\u7a76\u6240\uff08NCI\uff09\u548c\u5bc6\u897f\u6839\u5927\u5b78\u7b49\u5b78\u8853\u6a5f\u69cb\u9054\u6210\u5168\u7403\u5408\u4f5c\u95dc\u4fc2\u3002<\/p>\n

                            \u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u539f\u5275\u65b0\u85e5\u7814\u767c\u8207\u81e8\u5e8a\u958b\u767c\u9818\u57df\u5efa\u7acb\u7d93\u9a57\u8c50\u5bcc\u7684\u570b\u969b\u5316\u4eba\u624d\u5718\u968a\uff0c\u4ee5\u53ca\u6210\u719f\u7684\u5546\u696d\u5316\u751f\u7522\u8207\u5e02\u5834\u71df\u92b7\u5718\u968a\u3002\u4e9e\u76db\u91ab\u85e5\u5c07\u4e0d\u65b7\u63d0\u9ad8\u7814\u767c\u80fd\u529b\uff0c\u52a0\u901f\u63a8\u9032\u516c\u53f8\u7522\u54c1\u7ba1\u7dda\u7684\u81e8\u5e8a\u958b\u767c\u9032\u5ea6\uff0c\u771f\u6b63\u8e10\u884c\u300c\u89e3\u6c7a\u4e2d\u570b\u4e43\u81f3\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u300d\u7684\u4f7f\u547d\uff0c\u4ee5\u9020\u798f\u66f4\u591a\u60a3\u8005\u3002<\/p>\n

                            \u524d\u77bb\u6027\u8072\u660e<\/b> <\/p>\n

                            \u672c\u65b0\u805e\u7a3f\u5305\u542b\u6839\u64da\u7f8e\u570b\u300a1995\u5e74\u79c1\u4eba\u8b49\u5238\u8a34\u8a1f\u6539\u9769\u6cd5\u6848\u300b\uff0c\u4ee5\u53ca\u7d93\u4fee\u8a02\u7684\u300a1933\u5e74\u8b49\u5238\u6cd5\u300b\u7b2c27A\u689d\u548c\u300a1934\u5e74\u8b49\u5238\u4ea4\u6613\u6cd5\u300b\u7b2c21E\u689d\u6240\u754c\u5b9a\u7684\u524d\u77bb\u6027\u9673\u8ff0\u3002\u9664\u6b77\u53f2\u4e8b\u5be6\u9673\u8ff0\u5916\uff0c\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u6240\u6709\u5167\u5bb9\u5747\u53ef\u80fd\u69cb\u6210\u524d\u77bb\u6027\u9673\u8ff0\uff0c\u5305\u62ec\u4e9e\u76db\u91ab\u85e5\u5c0d\u672a\u4f86\u4e8b\u4ef6\u3001\u7d93\u71df\u6210\u679c\u6216\u8ca1\u52d9\u72c0\u6cc1\u6240\u767c\u8868\u7684\u610f\u898b\u3001\u9810\u671f\u3001\u4fe1\u5ff5\u3001\u8a08\u5283\u3001\u76ee\u6a19\u3001\u5047\u8a2d\u6216\u9810\u6e2c\u3002<\/p>\n

                            \u9019\u4e9b\u524d\u77bb\u6027\u9673\u8ff0\u53d7\u5230\u8af8\u591a\u98a8\u96aa\u548c\u4e0d\u78ba\u5b9a\u6027\u7684\u5f71\u97ff\uff0c\u5177\u9ad4\u5167\u5bb9\u5df2\u5728\u4e9e\u76db\u91ab\u85e5\u5411\u7f8e\u570b\u8b49\u5238\u4ea4\u6613\u59d4\u54e1\u6703\uff08SEC\uff09\u63d0\u4ea4\u7684\u6587\u4ef6\u4e2d\u8a73\u7d30\u8aaa\u660e\uff0c\u5305\u62ec2025\u5e741\u670821\u65e5\u63d0\u4ea4\u7684\u7d93\u4fee\u8a02\u7684F-1\u8868\u683c\u8a3b\u518a\u8aaa\u660e\u66f8\u548c2025\u5e744\u670816\u65e5\u63d0\u4ea4\u768420-F\u8868\u683c\u4e2d\u7684\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u548c\u300c\u95dc\u65bc\u524d\u77bb\u6027\u9673\u8ff0\u53ca\u884c\u696d\u6578\u64da\u7684\u7279\u5225\u8aaa\u660e\u300d\u7ae0\u7bc0\u30012019\u5e7410\u670816\u65e5\u63d0\u4ea4\u7684\u9996\u6b21\u767c\u884c\u4e0a\u5e02\u62db\u80a1\u66f8\u4e2d\u7684\u300c\u524d\u77bb\u6027\u8072\u660e\u300d\u3001\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u7ae0\u7bc0\uff0c\u4ee5\u53ca\u6211\u5011\u4e0d\u6642\u5411SEC\u6216HKEX\u63d0\u4ea4\u7684\u5176\u4ed6\u6587\u4ef6\u3002\u9019\u4e9b\u56e0\u7d20\u53ef\u80fd\u5c0e\u81f4\u5be6\u969b\u696d\u7e3e\u3001\u904b\u71df\u6c34\u5e73\u3001\u7d93\u71df\u6210\u679c\u6216\u6210\u5c31\u8207\u524d\u77bb\u6027\u9673\u8ff0\u4e2d\u660e\u793a\u6216\u6697\u793a\u7684\u4fe1\u606f\u5b58\u5728\u91cd\u5927\u5dee\u7570\u3002\u672c\u524d\u77bb\u6027\u8072\u660e\u4e2d\u7684\u9673\u8ff0\u4e0d\u69cb\u6210\u516c\u53f8\u7ba1\u7406\u5c64\u7684\u5229\u6f64\u9810\u6e2c\u3002<\/p>\n

                            \u56e0\u6b64\uff0c\u8a72\u7b49\u524d\u77bb\u6027\u9673\u8ff0\u4e0d\u61c9\u88ab\u8996\u70ba\u5c0d\u672a\u4f86\u4e8b\u4ef6\u7684\u9810\u6e2c\u3002\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u524d\u77bb\u6027\u9673\u8ff0\u50c5\u57fa\u65bc\u4e9e\u76db\u91ab\u85e5\u7576\u524d\u5c0d\u672a\u4f86\u767c\u5c55\u53ca\u5176\u6f5b\u5728\u5f71\u97ff\u7684\u9810\u671f\u548c\u5224\u65b7\uff0c\u4e14\u50c5\u4ee3\u8868\u622a\u81f3\u9673\u8ff0\u767c\u8868\u4e4b\u65e5\u7684\u89c0\u9ede\u3002\u7121\u8ad6\u51fa\u73fe\u65b0\u4fe1\u606f\u3001\u672a\u4f86\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u6cc1\uff0c\u4e9e\u76db\u91ab\u85e5\u5747\u7121\u7fa9\u52d9\u66f4\u65b0\u6216\u4fee\u8a02\u4efb\u4f55\u524d\u77bb\u6027\u9673\u8ff0\u3002<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

                            \u7f8e\u570b\u99ac\u91cc\u862d\u5dde\u7f85\u514b\u7dad\u723e\u5e02\u548c\u4e2d\u570b\u8607…<\/p>\n","protected":false},"author":16,"featured_media":334270,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"fifu_image_url":"","fifu_image_alt":"","footnotes":""},"categories":[40567],"tags":[],"class_list":["post-334269","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-40567"],"acf":[],"yoast_head":"\n\u30102025 EHA\u3011\u4e9e\u76db\u91ab\u85e5\u6838\u5fc3\u7522\u54c1\u8010\u7acb\u514b\u00ae\u548cAPG-2575\u7b4913\u9805\u9032\u5c55\u5165\u90782025\u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703\u5e74\u6703 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831<\/title>\n<meta name=\"description\" content=\"\u7f8e\u570b\u99ac\u91cc\u862d\u5dde\u7f85\u514b\u7dad\u723e\u5e02\u548c\u4e2d\u570b\u8607\u5dde 2025\u5e746\u670810\u65e5 \u00a0\/\u7f8e\u901a\u793e\/ -- \u81f4\u529b\u65bc\u5728\u816b\u7624\u7b49\u9818\u57df\u958b\u767c\u5275\u65b0\u85e5\u7269\u7684\u9818\u5148\u7684\u751f\u7269\u91ab\u85e5\u4f01\u696d\u2014\u2014\u4e9e\u76db\u91ab\u85e5\uff08\u7d0d\u65af\u9054\u514b\u4ee3\u78bc\uff1aAAPG\uff1b\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a6855\uff09\u5ba3\u5e03\uff0c\u6d89\u53ca\u516c\u53f8\u539f\u52751\u985e\u65b0\u85e5\u5967\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff09\u3001Bcl-2\u6291\u5236\u5291APG-2575\u3001EED\u6291\u5236\u5291APG-5918\u7b49\u91cd\u78c5\u54c1\u7a2e\u768413\u9805\u7814\u7a76\u9032\u5c55\u5c07\u57282025\u5e746\u670812\u65e5\u81f315\u65e5\u65bc\u610f\u5927\u5229\u7c73\u862d\u8209\u884c\u76842025\u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703\uff08EHA\uff09\u5e74\u6703\u4e0a\u516c\u5e03\uff0c\u5176\u4e2d\u5305\u62ec1\u9805\u53e3\u982d\u5831\u544a\uff0c\u53ca\u591a\u9805\u58c1\u5831\u5c55\u793a\u548c\u7dda\u4e0a\u767c\u8868\u3002 EHA\u5e74\u6703\u4f5c\u70ba\u6b50\u6d32\u8840\u6db2\u5b78\u9818\u57df\u898f\u6a21\u6700\u5927\u7684\u570b\u969b\u6703\u8b70\uff0c\u6bcf\u5e74\u5438\u5f15\u4f86\u81ea\u5168\u7403100\u591a\u500b\u570b\u5bb6\u76841\u842c\u591a\u540d\u5c08\u696d\u4eba\u58eb\u8207\u6703\uff0c\u5206\u4eab\u5168\u7403\u6700\u524d\u6cbf\u7684\u7814\u7a76\u9032\u5c55\u548c\u7a81\u7834\u6027\u81e8\u5e8a\u6578\u64da\u3002 \u53e3\u982d\u5831\u544a Integrating Genomic and Transcriptomic Insights for Predicting Responses and Outcomes in Patients with CML Receiving 3rd-Generation TKI Therapy\u6574\u5408\u57fa\u56e0\u7d44\u548c\u8f49\u9304\u7d44\u5b78\u898b\u89e3\u4ee5\u9810\u6e2c\u63a5\u53d7\u4e09\u4ee3TKI\u6cbb\u7642\u7684CML\u60a3\u8005\u7684\u7642\u6548\u548c\u7d50\u5c40 \u6458\u8981\u7de8\u865f\uff1aS162 \u5206\u6703\u5834\uff1aCML\u6cbb\u7642\u7642\u6548\u53ca\u8010\u85e5\u7684\u751f\u7269\u5b78\uff08Biology of CML treatment response and resistance\uff09 \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u665a\u4e0a23:30-23:45\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u4e0b\u534817:30-17:45\uff09 \u4e3b\u8981\u4f5c\u8005\uff1a\u5317\u4eac\u5927\u5b78\u4eba\u6c11\u91ab\u9662\u6c5f\u5029\u6559\u6388\uff0c\u5317\u4eac\u5927\u5b78\u4eba\u6c11\u91ab\u9662\u5f35\u5c0f\u5e25 \u58c1\u5831\u5c55\u793a Frontline Chemotherapy-Free Combination of Olverembatinib with Venetoclax and Azacitidine in Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia: Preliminary Outcomes of a Prospective Study\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u7dad\u5948\u514b\u62c9\u8207\u963f\u624e\u80de\u7518\u7528\u65bc\u7121\u5316\u7642\u4e00\u7dda\u6cbb\u7642\u65b0\u8a3a\u65b7\u7684Ph+\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff1a\u4e00\u9805\u524d\u77bb\u6027\u7814\u7a76\u7684\u521d\u6b65\u7d50\u679c \u6458\u8981\u7de8\u865f\uff1aPF384 \u5206\u6703\u5834\uff1a\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76\uff08Acute lymphoblastic leukemia - Clinical\uff09 \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u51cc\u666800:30-01:30\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670813\u65e5\uff0c\u5468\u4e94\uff0c\u665a\u4e0a18:30-19:30\uff09 \u4e3b\u8981\u4f5c\u8005\uff1a\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662\u5510\u66c9\u6587\u6559\u6388\uff0c\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662\u5f35\u6b23 A Phase 2 Study of Olverembatinib for the Treatment of Myeloid\/Lymphoid Neoplasms with FGFR1 Rearrangement\u4e00\u9805\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u7528\u65bc\u6cbb\u7642\u4f34FGFR1\u91cd\u6392\u7684\u9ad3\u7cfb\/\u6dcb\u5df4\u7cfb\u816b\u7624\u7684II\u671f\u7814\u7a76 \u6458\u8981\u7de8\u865f\uff1aPF390 \u5206\u6703\u5834\uff1a\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76\uff08Acute lymphoblastic leukemia - Clinical\uff09 \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u51cc\u666800:30-01:30\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670813\u65e5\uff0c\u5468\u4e94\uff0c\u665a\u4e0a18:30-19:30\uff09 \u4e3b\u8981\u4f5c\u8005\uff1a\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662\u9673\u8607\u5be7\u6559\u6388\uff0c\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662\u8521\u6587\u6cbb Efficacy and Safety of Regimen with Olverembatinib and Blinatumomab for the Frontline Treatment of Ph-Positive or Ph-Like Acute Lymphoblastic Leukemia\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u8c9d\u6797\u59a5\u6b50\u55ae\u6297\u4e00\u7dda\u6cbb\u7642\u8cbb\u57ce\u67d3\u8272\u9ad4\uff08Ph\uff09\u967d\u6027\u6216Ph\u6a23\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\u7684\u7642\u6548\u548c\u5b89\u5168\u6027 \u6458\u8981\u7de8\u865f\uff1aPS1367 \u5206\u6703\u5834\uff1a\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76\uff08Acute lymphoblastic leukemia - Clinical\uff09 \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670815\u65e5\uff0c\u5468\u65e5\uff0c\u51cc\u666800:30-01:30\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u665a\u4e0a18:30-19:30 \uff09 \u4e3b\u8981\u4f5c\u8005\uff1a\u5357\u65b9\u91ab\u79d1\u5927\u5b78\u5357\u65b9\u91ab\u9662\u5468\u7d05\u5347\u6559\u6388\uff0c\u5357\u65b9\u91ab\u79d1\u5927\u5b78\u5357\u65b9\u91ab\u9662\u8a31\u79c0\u9e97 Combination of Olverembatinib and VP Regimen as First-Line Therapy for Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Single-Arm, Multicentre, Phase 2 Trial\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408VP\u65b9\u6848\u4e00\u7dda\u6cbb\u7642\u6210\u4eba\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff1a\u4e00\u9805\u55ae\u81c2\u3001\u591a\u4e2d\u5fc3II\u671f\u7814\u7a76 \u6458\u8981\u7de8\u865f\uff1aPS1372 \u5206\u6703\u5834\uff1a\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76\uff08Acute lymphoblastic leukemia - Clinical\uff09 \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670815\u65e5\uff0c\u5468\u65e5\uff0c\u51cc\u666800:30-01:30\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u665a\u4e0a18:30-19:30\uff09 \u4e3b\u8981\u4f5c\u8005\uff1a\u6d59\u6c5f\u5927\u5b78\u91ab\u5b78\u9662\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662\u91d1\u6f54\u6559\u6388\uff0c\u6d59\u6c5f\u5927\u5b78\u91ab\u5b78\u9662\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662\u8a31\u6539\u9999 Efficacy and Safety of The Third-Generation Tyrosine Kinase Inhibitor Olverembatinib in Combination with Inotuzumab Ozogamicin for the Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients With Relapsed Disease or Persistent Minimal Residual Disease Bridging to Hematopoietic Stem Cell Transplantation: A Phase II Study\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u5967\u52a0\u4f0a\u59a5\u73e0\u55ae\u6297\u6cbb\u7642\u5fa9\u767c\u6216\u9020\u8840\u5e72\u7d30\u80de\u79fb\u690d\u524d\u6301\u7e8cMRD\u967d\u6027\u6210\u4ebaPh+ ALL\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\uff1a\u4e00\u9805\u2161\u671f\u7814\u7a76 \u6458\u8981\u7de8\u865f\uff1aPS1387 \u5206\u6703\u5834\uff1a\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76\uff08Acute lymphoblastic leukemia - Clinical\uff09 \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670815\u65e5\uff0c\u5468\u65e5\uff0c\u51cc\u666800:30-01:30\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u665a\u4e0a18:30-19:30\uff09 \u4e3b\u8981\u4f5c\u8005\uff1a\u4e2d\u570b\u91ab\u5b78\u79d1\u5b78\u9662\u5317\u4eac\u5354\u548c\u91ab\u5b78\u9662\u8840\u6db2\u75c5\u91ab\u9662\u59dc\u723e\u70c8\u6559\u6388\uff0c\u4e2d\u570b\u91ab\u5b78\u79d1\u5b78\u9662\u5317\u4eac\u5354\u548c\u91ab\u5b78\u9662\u8840\u6db2\u75c5\u91ab\u9662\u5f35\u701f\u4e88 Embryonic Ectoderm Development (EED) Inhibitor APG-5918 Exhibits Potent Antitumor Activity and Synergizes with Histone Deacetylase Inhibitor Tucidinostat in PreclinicalT-Cell Lymphoma (TCL) Models\u80da\u80ce\u5916\u80da\u5c64\u767c\u80b2\u86cb\u767d\uff08EED\uff09\u6291\u5236\u5291APG-5918\u5728T\u7d30\u80de\u6dcb\u5df4\u7624\uff08TCL\uff09\u81e8\u5e8a\u524d\u6a21\u578b\u4e2d\u5c55\u73fe\u5f37\u6548\u6297\u816b\u7624\u6d3b\u6027\uff0c\u4e26\u8207\u7d44\u86cb\u767d\u53bb\u4e59\u9170\u5316\u9176\u6291\u5236\u5291\u897f\u9054\u672c\u80fa\u5354\u540c\u589e\u6548 \u6458\u8981\u7de8\u865f\uff1aPS1993 \u5206\u6703\u5834\uff1a\u6dcb\u5df4\u7624\u751f\u7269\u5b78\u8207\u8f49\u5316\u7814\u7a76\uff08Lymphoma biology & translational research\uff09 \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670815\u65e5\uff0c\u5468\u65e5\uff0c\u51cc\u666800:30-01:30\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u665a\u4e0a18:30-19:30\uff09 \u4e3b\u8981\u4f5c\u8005\uff1a\u4e9e\u76db\u91ab\u85e5Eric Liang\u535a\u58eb \u5728\u7dda\u767c\u5e03 Alternating Low-Dose Inotuzumab Ozogamicin and Blinatumomab in Maintenance Therapy for Ph+ ALL: A Single-Center Retrospective Analysis\u4f4e\u5291\u91cf\u5967\u52a0\u4f0a\u59a5\u73e0\u55ae\u6297\u548c\u8c9d\u6797\u59a5\u6b50\u55ae\u6297\u4ea4\u66ff\u7dad\u6301\u6cbb\u7642\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\uff08Ph+\uff09\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08ALL\uff09\uff1a\u4e00\u9805\u55ae\u4e2d\u5fc3\u56de\u9867\u6027\u5206\u6790 \u6458\u8981\u7de8\u865f\uff1aPB2384 \u4e3b\u8981\u4f5c\u8005\uff1a\u6cb3\u5317\u91ab\u79d1\u5927\u5b78\u7b2c\u4e8c\u91ab\u9662\u8076\u5b50\u5143\u6559\u6388 Efficacy and Safety of Blinatumomab in Newly-Diagnosed Patients with Ph-Positive\/Negative B-Cell Acute Lymphoblastic Leukemia\u8c9d\u6797\u59a5\u6b50\u55ae\u6297\u6cbb\u7642\u65b0\u78ba\u8a3a\u7684 Ph \u967d\u6027\/\u9670\u6027 B \u7d30\u80de\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\u60a3\u8005\u7684\u7642\u6548\u548c\u5b89\u5168\u6027 \u6458\u8981\u7de8\u865f\uff1aPB2363 \u4e3b\u8981\u4f5c\u8005\uff1a\u83ef\u4e2d\u79d1\u6280\u5927\u5b78\u540c\u6fdf\u91ab\u5b78\u9662\u9644\u5c6c\u5354\u548c\u91ab\u9662\u5f35\u5bc5\u5b19 Efficacy and Safety of the Third-Generation TKI Olverembatinib in Relapsed and Persistent MRD Positive Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients\u7b2c\u4e09\u4ee3TKI\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u5fa9\u767c\u548c\u6301\u7e8cMRD\u967d\u6027\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\u60a3\u8005\u7684\u7642\u6548\u8207\u5b89\u5168\u6027 \u6458\u8981\u7de8\u865f\uff1aPB2360 \u4e3b\u8981\u4f5c\u8005\uff1a\u6cb3\u5317\u91ab\u79d1\u5927\u5b78\u7b2c\u4e8c\u91ab\u9662\u8523\u854a\u6eab Clinical Features and Genetic Abnormalities Predict Outcomes in Patients with Chronic Myeloid Leukemia in the Accelerated-Phase Receiving Olverembatinib Therapy: A Retrospective Multicenter Study\u81e8\u5e8a\u7279\u5fb5\u548c\u57fa\u56e0\u7570\u5e38\u7528\u65bc\u9810\u6e2c\u63a5\u53d7\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7684\u52a0\u901f\u671f\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u60a3\u8005\u7684\u6cbb\u7642\u7d50\u5c40\uff1a\u4e00\u9805\u56de\u9867\u6027\u591a\u4e2d\u5fc3\u7814\u7a76 \u6458\u8981\u7de8\u865f\uff1aPB2701 \u4e3b\u8981\u4f5c\u8005\uff1a\u5317\u4eac\u5927\u5b78\u4eba\u6c11\u91ab\u9662\u539f\u5922\u7464 A Real-World Study of Olverembatinib in the Treatment of Chronic Myeloid Leukemia from China: A Single-Center Retrospective Study\u4e00\u9805\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u7528\u65bc\u6cbb\u7642\u4e2d\u570b\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u60a3\u8005\u7684\u771f\u5be6\u4e16\u754c\u7814\u7a76\uff1a\u4e00\u9805\u55ae\u4e2d\u5fc3\u56de\u9867\u6027\u7814\u7a76 \u6458\u8981\u7de8\u865f\uff1aPB2714 \u4e3b\u8981\u4f5c\u8005\uff1a\u56db\u5ddd\u5927\u5b78\u83ef\u897f\u91ab\u9662\u8463\u5929 Synergistic Effects of Olverembatinib (HQP1351) Combined with Bcl-2 Inhibitor Lisaftoclax (APG-2575) and Bcl-2\/Bcl-xL Inhibitor Pelcitoclax (APG-1252) in T-Cell Acute Lymphoblastic Leukemia (T-ALL)\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u806f\u5408Bcl-2\u6291\u5236\u5291lisaftoclax\uff08APG-2575\uff09\u548cBcl-2\/Bcl-xL\u6291\u5236\u5291pelcitoclax\uff08APG-1252\uff09\u5728T\u7d30\u80de\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08T-ALL\uff09\u4e2d\u7684\u5354\u540c\u4f5c\u7528 \u6458\u8981\u7de8\u865f\uff1aPB2341 \u4e3b\u8981\u4f5c\u8005\uff1a\u4e9e\u76db\u91ab\u85e5\u5f6d\u6ce2 \u95dc\u65bc\u4e9e\u76db\u91ab\u85e5 \u4e9e\u76db\u91ab\u85e5\u662f\u4e00\u5bb6\u7d9c\u5408\u6027\u7684\u5168\u7403\u751f\u7269\u91ab\u85e5\u4f01\u696d\uff0c\u81f4\u529b\u65bc\u7814\u767c\u5275\u65b0\u85e5\uff0c\u4ee5\u89e3\u6c7a\u816b\u7624\u7b49\u9818\u57df\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u30022019\u5e7410\u670828\u65e5\uff0c\u516c\u53f8\u5728\u9999\u6e2f\u806f\u4ea4\u6240\u4e3b\u677f\u639b\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u78bc\uff1a6855.HK\uff1b2025\u5e741\u670824\u65e5\uff0c\u516c\u53f8\u5728\u7f8e\u570b\u7d0d\u65af\u9054\u514b\u8b49\u5238\u4ea4\u6613\u6240\u639b\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u78bc\uff1aAAPG\u3002 \u4e9e\u76db\u91ab\u85e5\u5df2\u5efa\u7acb\u8c50\u5bcc\u7684\u5275\u65b0\u85e5\u7522\u54c1\u7ba1\u7dda\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u548c MDM2-p53 \u7b49\u7d30\u80de\u51cb\u4ea1\u901a\u8def\u95dc\u9375\u86cb\u767d\u7684\u6291\u5236\u5291\uff1b\u65b0\u4e00\u4ee3\u91dd\u5c0d\u764c\u75c7\u6cbb\u7642\u4e2d\u51fa\u73fe\u7684\u6fc0\u9176\u7a81\u8b8a\u9ad4\u7684\u6291\u5236\u5291\u7b49\u3002 \u516c\u53f8\u6838\u5fc3\u54c1\u7a2e\u8010\u7acb\u514b\u00ae\u662f\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\uff0c\u4e14\u7372\u6279\u9069\u61c9\u75c7\u5747\u88ab\u6210\u529f\u7d0d\u5165\u570b\u5bb6\u91ab\u4fdd\u85e5\u54c1\u76ee\u9304\uff0c\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u8010\u7acb\u514b\u00ae\u4e00\u9805\u7372\u7f8e\u570bFDA\u8a31\u53ef\u7684\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff08POLARIS-2\uff09\uff0c\u7528\u65bc\u6cbb\u7642\u65e2\u5f80\u63a5\u53d7\u904e\u6cbb\u7642\u7684\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CML-CP\uff09\u6210\u5e74\u60a3\u8005\u3002\u6b64\u5916\uff0c\u8010\u7acb\u514b\u00ae\u806f\u5408\u6cbb\u7642\u65b0\u8a3a\u65b7\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u60a3\u8005\u548c\u6cbb\u7642\u7425\u73c0\u9178\u812b\u6c2b\u9176\uff08SDH\uff09\u7f3a\u9677\u578b\u80c3\u8178\u9053\u9593\u8cea\u7624\uff08GIST\uff09\u60a3\u8005\u7684\u5168\u7403\u8a3b\u518aIII\u671f\u7814\u7a76\u6b63\u5728\u958b\u5c55\u4e2d\u3002 \u516c\u53f8\u53e6\u4e00\u91cd\u78c5\u54c1\u7a2e\uff0c\u65b0\u578bBcl-2\u9078\u64c7\u6027\u6291\u5236\u5291APG-2575\uff08Lisaftoclax\uff09\u7684\u65b0\u85e5\u4e0a\u5e02\u7533\u8acb\uff08NDA\uff09\u5df2\u7372CDE\u53d7\u7406\uff0c\u4e26\u88ab\u7d0d\u5165\u512a\u5148\u5be9\u8a55\u3002\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55APG-2575\uff08Lisaftoclax\uff09\u56db\u9805\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u5206\u5225\u70ba\u7372\u7f8e\u570bFDA\u8a31\u53ef\u7684\u6cbb\u7642\u7d93\u6cbb\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u7684\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff08GLORA\uff09\uff1b\u6cbb\u7642\u521d\u6cbbCLL\/SLL\u60a3\u8005\u7684\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff1b\u4e00\u7dda\u6cbb\u7642\u65b0\u8a3a\u65b7\u8001\u5e74\u6216\u9ad4\u5f31\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08AML\uff09\u7684\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff1b\u4ee5\u53ca\u6cbb\u7642\u65b0\u8a3a\u65b7\u4e2d\u9ad8\u5371\u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u75c7\uff08MDS\uff09\u60a3\u8005\u7684\u8a3b\u518aIII\u671f\u7814\u7a76\u3002 \u622a\u81f3\u76ee\u524d\uff0c\u516c\u53f84\u500b\u5728\u7814\u65b0\u85e5\u5171\u737216\u9805FDA\u548c1\u9805\u6b50\u76df\u5b64\u5152\u85e5\u8cc7\u683c\u8a8d\u5b9a\uff0c2\u9805FDA\u5feb\u901f\u901a\u9053\u8cc7\u683c\u4ee5\u53ca2\u9805FDA\u5152\u7ae5\u7f55\u898b\u75c5\u8cc7\u683c\u8a8d\u8b49\u3002\u6191\u501f\u5f37\u5927\u7684\u7814\u767c\u80fd\u529b\uff0c\u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u5168\u7403\u7bc4\u570d\u5167\u9032\u884c\u77e5\u8b58\u7522\u6b0a\u5e03\u5c40\uff0c\u4e26\u8207\u6b66\u7530\u3001\u9ed8\u6c99\u6771\u3001\u963f\u65af\u5229\u5eb7\u3001\u8f1d\u745e\u3001\u4fe1\u9054\u7b49\u9818\u5148\u7684\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u4ee5\u53ca\u6885\u5967\u91ab\u5b78\u4e2d\u5fc3\uff08Mayo Clinic\uff09\u3001\u4e39\u5a1c\u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662\uff08Dana-Farber Cancer Institute\uff09\u3001\u7f8e\u570b\u570b\u5bb6\u764c\u75c7\u7814\u7a76\u6240\uff08NCI\uff09\u548c\u5bc6\u897f\u6839\u5927\u5b78\u7b49\u5b78\u8853\u6a5f\u69cb\u9054\u6210\u5168\u7403\u5408\u4f5c\u95dc\u4fc2\u3002 \u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u539f\u5275\u65b0\u85e5\u7814\u767c\u8207\u81e8\u5e8a\u958b\u767c\u9818\u57df\u5efa\u7acb\u7d93\u9a57\u8c50\u5bcc\u7684\u570b\u969b\u5316\u4eba\u624d\u5718\u968a\uff0c\u4ee5\u53ca\u6210\u719f\u7684\u5546\u696d\u5316\u751f\u7522\u8207\u5e02\u5834\u71df\u92b7\u5718\u968a\u3002\u4e9e\u76db\u91ab\u85e5\u5c07\u4e0d\u65b7\u63d0\u9ad8\u7814\u767c\u80fd\u529b\uff0c\u52a0\u901f\u63a8\u9032\u516c\u53f8\u7522\u54c1\u7ba1\u7dda\u7684\u81e8\u5e8a\u958b\u767c\u9032\u5ea6\uff0c\u771f\u6b63\u8e10\u884c\u300c\u89e3\u6c7a\u4e2d\u570b\u4e43\u81f3\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u300d\u7684\u4f7f\u547d\uff0c\u4ee5\u9020\u798f\u66f4\u591a\u60a3\u8005\u3002 \u524d\u77bb\u6027\u8072\u660e \u672c\u65b0\u805e\u7a3f\u5305\u542b\u6839\u64da\u7f8e\u570b\u300a1995\u5e74\u79c1\u4eba\u8b49\u5238\u8a34\u8a1f\u6539\u9769\u6cd5\u6848\u300b\uff0c\u4ee5\u53ca\u7d93\u4fee\u8a02\u7684\u300a1933\u5e74\u8b49\u5238\u6cd5\u300b\u7b2c27A\u689d\u548c\u300a1934\u5e74\u8b49\u5238\u4ea4\u6613\u6cd5\u300b\u7b2c21E\u689d\u6240\u754c\u5b9a\u7684\u524d\u77bb\u6027\u9673\u8ff0\u3002\u9664\u6b77\u53f2\u4e8b\u5be6\u9673\u8ff0\u5916\uff0c\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u6240\u6709\u5167\u5bb9\u5747\u53ef\u80fd\u69cb\u6210\u524d\u77bb\u6027\u9673\u8ff0\uff0c\u5305\u62ec\u4e9e\u76db\u91ab\u85e5\u5c0d\u672a\u4f86\u4e8b\u4ef6\u3001\u7d93\u71df\u6210\u679c\u6216\u8ca1\u52d9\u72c0\u6cc1\u6240\u767c\u8868\u7684\u610f\u898b\u3001\u9810\u671f\u3001\u4fe1\u5ff5\u3001\u8a08\u5283\u3001\u76ee\u6a19\u3001\u5047\u8a2d\u6216\u9810\u6e2c\u3002 \u9019\u4e9b\u524d\u77bb\u6027\u9673\u8ff0\u53d7\u5230\u8af8\u591a\u98a8\u96aa\u548c\u4e0d\u78ba\u5b9a\u6027\u7684\u5f71\u97ff\uff0c\u5177\u9ad4\u5167\u5bb9\u5df2\u5728\u4e9e\u76db\u91ab\u85e5\u5411\u7f8e\u570b\u8b49\u5238\u4ea4\u6613\u59d4\u54e1\u6703\uff08SEC\uff09\u63d0\u4ea4\u7684\u6587\u4ef6\u4e2d\u8a73\u7d30\u8aaa\u660e\uff0c\u5305\u62ec2025\u5e741\u670821\u65e5\u63d0\u4ea4\u7684\u7d93\u4fee\u8a02\u7684F-1\u8868\u683c\u8a3b\u518a\u8aaa\u660e\u66f8\u548c2025\u5e744\u670816\u65e5\u63d0\u4ea4\u768420-F\u8868\u683c\u4e2d\u7684\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u548c\u300c\u95dc\u65bc\u524d\u77bb\u6027\u9673\u8ff0\u53ca\u884c\u696d\u6578\u64da\u7684\u7279\u5225\u8aaa\u660e\u300d\u7ae0\u7bc0\u30012019\u5e7410\u670816\u65e5\u63d0\u4ea4\u7684\u9996\u6b21\u767c\u884c\u4e0a\u5e02\u62db\u80a1\u66f8\u4e2d\u7684\u300c\u524d\u77bb\u6027\u8072\u660e\u300d\u3001\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u7ae0\u7bc0\uff0c\u4ee5\u53ca\u6211\u5011\u4e0d\u6642\u5411SEC\u6216HKEX\u63d0\u4ea4\u7684\u5176\u4ed6\u6587\u4ef6\u3002\u9019\u4e9b\u56e0\u7d20\u53ef\u80fd\u5c0e\u81f4\u5be6\u969b\u696d\u7e3e\u3001\u904b\u71df\u6c34\u5e73\u3001\u7d93\u71df\u6210\u679c\u6216\u6210\u5c31\u8207\u524d\u77bb\u6027\u9673\u8ff0\u4e2d\u660e\u793a\u6216\u6697\u793a\u7684\u4fe1\u606f\u5b58\u5728\u91cd\u5927\u5dee\u7570\u3002\u672c\u524d\u77bb\u6027\u8072\u660e\u4e2d\u7684\u9673\u8ff0\u4e0d\u69cb\u6210\u516c\u53f8\u7ba1\u7406\u5c64\u7684\u5229\u6f64\u9810\u6e2c\u3002 \u56e0\u6b64\uff0c\u8a72\u7b49\u524d\u77bb\u6027\u9673\u8ff0\u4e0d\u61c9\u88ab\u8996\u70ba\u5c0d\u672a\u4f86\u4e8b\u4ef6\u7684\u9810\u6e2c\u3002\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u524d\u77bb\u6027\u9673\u8ff0\u50c5\u57fa\u65bc\u4e9e\u76db\u91ab\u85e5\u7576\u524d\u5c0d\u672a\u4f86\u767c\u5c55\u53ca\u5176\u6f5b\u5728\u5f71\u97ff\u7684\u9810\u671f\u548c\u5224\u65b7\uff0c\u4e14\u50c5\u4ee3\u8868\u622a\u81f3\u9673\u8ff0\u767c\u8868\u4e4b\u65e5\u7684\u89c0\u9ede\u3002\u7121\u8ad6\u51fa\u73fe\u65b0\u4fe1\u606f\u3001\u672a\u4f86\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u6cc1\uff0c\u4e9e\u76db\u91ab\u85e5\u5747\u7121\u7fa9\u52d9\u66f4\u65b0\u6216\u4fee\u8a02\u4efb\u4f55\u524d\u77bb\u6027\u9673\u8ff0\u3002\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pingtungtimes.com.tw\/?p=334269\" \/>\n<meta property=\"og:locale\" content=\"zh_TW\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u30102025 EHA\u3011\u4e9e\u76db\u91ab\u85e5\u6838\u5fc3\u7522\u54c1\u8010\u7acb\u514b\u00ae\u548cAPG-2575\u7b4913\u9805\u9032\u5c55\u5165\u90782025\u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703\u5e74\u6703 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\" \/>\n<meta property=\"og:description\" content=\"\u7f8e\u570b\u99ac\u91cc\u862d\u5dde\u7f85\u514b\u7dad\u723e\u5e02\u548c\u4e2d\u570b\u8607\u5dde 2025\u5e746\u670810\u65e5 \u00a0\/\u7f8e\u901a\u793e\/ -- \u81f4\u529b\u65bc\u5728\u816b\u7624\u7b49\u9818\u57df\u958b\u767c\u5275\u65b0\u85e5\u7269\u7684\u9818\u5148\u7684\u751f\u7269\u91ab\u85e5\u4f01\u696d\u2014\u2014\u4e9e\u76db\u91ab\u85e5\uff08\u7d0d\u65af\u9054\u514b\u4ee3\u78bc\uff1aAAPG\uff1b\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a6855\uff09\u5ba3\u5e03\uff0c\u6d89\u53ca\u516c\u53f8\u539f\u52751\u985e\u65b0\u85e5\u5967\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff09\u3001Bcl-2\u6291\u5236\u5291APG-2575\u3001EED\u6291\u5236\u5291APG-5918\u7b49\u91cd\u78c5\u54c1\u7a2e\u768413\u9805\u7814\u7a76\u9032\u5c55\u5c07\u57282025\u5e746\u670812\u65e5\u81f315\u65e5\u65bc\u610f\u5927\u5229\u7c73\u862d\u8209\u884c\u76842025\u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703\uff08EHA\uff09\u5e74\u6703\u4e0a\u516c\u5e03\uff0c\u5176\u4e2d\u5305\u62ec1\u9805\u53e3\u982d\u5831\u544a\uff0c\u53ca\u591a\u9805\u58c1\u5831\u5c55\u793a\u548c\u7dda\u4e0a\u767c\u8868\u3002 EHA\u5e74\u6703\u4f5c\u70ba\u6b50\u6d32\u8840\u6db2\u5b78\u9818\u57df\u898f\u6a21\u6700\u5927\u7684\u570b\u969b\u6703\u8b70\uff0c\u6bcf\u5e74\u5438\u5f15\u4f86\u81ea\u5168\u7403100\u591a\u500b\u570b\u5bb6\u76841\u842c\u591a\u540d\u5c08\u696d\u4eba\u58eb\u8207\u6703\uff0c\u5206\u4eab\u5168\u7403\u6700\u524d\u6cbf\u7684\u7814\u7a76\u9032\u5c55\u548c\u7a81\u7834\u6027\u81e8\u5e8a\u6578\u64da\u3002 \u53e3\u982d\u5831\u544a Integrating Genomic and Transcriptomic Insights for Predicting Responses and Outcomes in Patients with CML Receiving 3rd-Generation TKI Therapy\u6574\u5408\u57fa\u56e0\u7d44\u548c\u8f49\u9304\u7d44\u5b78\u898b\u89e3\u4ee5\u9810\u6e2c\u63a5\u53d7\u4e09\u4ee3TKI\u6cbb\u7642\u7684CML\u60a3\u8005\u7684\u7642\u6548\u548c\u7d50\u5c40 \u6458\u8981\u7de8\u865f\uff1aS162 \u5206\u6703\u5834\uff1aCML\u6cbb\u7642\u7642\u6548\u53ca\u8010\u85e5\u7684\u751f\u7269\u5b78\uff08Biology of CML treatment response and resistance\uff09 \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u665a\u4e0a23:30-23:45\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u4e0b\u534817:30-17:45\uff09 \u4e3b\u8981\u4f5c\u8005\uff1a\u5317\u4eac\u5927\u5b78\u4eba\u6c11\u91ab\u9662\u6c5f\u5029\u6559\u6388\uff0c\u5317\u4eac\u5927\u5b78\u4eba\u6c11\u91ab\u9662\u5f35\u5c0f\u5e25 \u58c1\u5831\u5c55\u793a Frontline Chemotherapy-Free Combination of Olverembatinib with Venetoclax and Azacitidine in Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia: Preliminary Outcomes of a Prospective Study\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u7dad\u5948\u514b\u62c9\u8207\u963f\u624e\u80de\u7518\u7528\u65bc\u7121\u5316\u7642\u4e00\u7dda\u6cbb\u7642\u65b0\u8a3a\u65b7\u7684Ph+\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff1a\u4e00\u9805\u524d\u77bb\u6027\u7814\u7a76\u7684\u521d\u6b65\u7d50\u679c \u6458\u8981\u7de8\u865f\uff1aPF384 \u5206\u6703\u5834\uff1a\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76\uff08Acute lymphoblastic leukemia - Clinical\uff09 \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u51cc\u666800:30-01:30\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670813\u65e5\uff0c\u5468\u4e94\uff0c\u665a\u4e0a18:30-19:30\uff09 \u4e3b\u8981\u4f5c\u8005\uff1a\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662\u5510\u66c9\u6587\u6559\u6388\uff0c\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662\u5f35\u6b23 A Phase 2 Study of Olverembatinib for the Treatment of Myeloid\/Lymphoid Neoplasms with FGFR1 Rearrangement\u4e00\u9805\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u7528\u65bc\u6cbb\u7642\u4f34FGFR1\u91cd\u6392\u7684\u9ad3\u7cfb\/\u6dcb\u5df4\u7cfb\u816b\u7624\u7684II\u671f\u7814\u7a76 \u6458\u8981\u7de8\u865f\uff1aPF390 \u5206\u6703\u5834\uff1a\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76\uff08Acute lymphoblastic leukemia - Clinical\uff09 \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u51cc\u666800:30-01:30\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670813\u65e5\uff0c\u5468\u4e94\uff0c\u665a\u4e0a18:30-19:30\uff09 \u4e3b\u8981\u4f5c\u8005\uff1a\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662\u9673\u8607\u5be7\u6559\u6388\uff0c\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662\u8521\u6587\u6cbb Efficacy and Safety of Regimen with Olverembatinib and Blinatumomab for the Frontline Treatment of Ph-Positive or Ph-Like Acute Lymphoblastic Leukemia\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u8c9d\u6797\u59a5\u6b50\u55ae\u6297\u4e00\u7dda\u6cbb\u7642\u8cbb\u57ce\u67d3\u8272\u9ad4\uff08Ph\uff09\u967d\u6027\u6216Ph\u6a23\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\u7684\u7642\u6548\u548c\u5b89\u5168\u6027 \u6458\u8981\u7de8\u865f\uff1aPS1367 \u5206\u6703\u5834\uff1a\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76\uff08Acute lymphoblastic leukemia - Clinical\uff09 \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670815\u65e5\uff0c\u5468\u65e5\uff0c\u51cc\u666800:30-01:30\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u665a\u4e0a18:30-19:30 \uff09 \u4e3b\u8981\u4f5c\u8005\uff1a\u5357\u65b9\u91ab\u79d1\u5927\u5b78\u5357\u65b9\u91ab\u9662\u5468\u7d05\u5347\u6559\u6388\uff0c\u5357\u65b9\u91ab\u79d1\u5927\u5b78\u5357\u65b9\u91ab\u9662\u8a31\u79c0\u9e97 Combination of Olverembatinib and VP Regimen as First-Line Therapy for Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Single-Arm, Multicentre, Phase 2 Trial\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408VP\u65b9\u6848\u4e00\u7dda\u6cbb\u7642\u6210\u4eba\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff1a\u4e00\u9805\u55ae\u81c2\u3001\u591a\u4e2d\u5fc3II\u671f\u7814\u7a76 \u6458\u8981\u7de8\u865f\uff1aPS1372 \u5206\u6703\u5834\uff1a\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76\uff08Acute lymphoblastic leukemia - Clinical\uff09 \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670815\u65e5\uff0c\u5468\u65e5\uff0c\u51cc\u666800:30-01:30\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u665a\u4e0a18:30-19:30\uff09 \u4e3b\u8981\u4f5c\u8005\uff1a\u6d59\u6c5f\u5927\u5b78\u91ab\u5b78\u9662\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662\u91d1\u6f54\u6559\u6388\uff0c\u6d59\u6c5f\u5927\u5b78\u91ab\u5b78\u9662\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662\u8a31\u6539\u9999 Efficacy and Safety of The Third-Generation Tyrosine Kinase Inhibitor Olverembatinib in Combination with Inotuzumab Ozogamicin for the Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients With Relapsed Disease or Persistent Minimal Residual Disease Bridging to Hematopoietic Stem Cell Transplantation: A Phase II Study\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u5967\u52a0\u4f0a\u59a5\u73e0\u55ae\u6297\u6cbb\u7642\u5fa9\u767c\u6216\u9020\u8840\u5e72\u7d30\u80de\u79fb\u690d\u524d\u6301\u7e8cMRD\u967d\u6027\u6210\u4ebaPh+ ALL\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\uff1a\u4e00\u9805\u2161\u671f\u7814\u7a76 \u6458\u8981\u7de8\u865f\uff1aPS1387 \u5206\u6703\u5834\uff1a\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76\uff08Acute lymphoblastic leukemia - Clinical\uff09 \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670815\u65e5\uff0c\u5468\u65e5\uff0c\u51cc\u666800:30-01:30\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u665a\u4e0a18:30-19:30\uff09 \u4e3b\u8981\u4f5c\u8005\uff1a\u4e2d\u570b\u91ab\u5b78\u79d1\u5b78\u9662\u5317\u4eac\u5354\u548c\u91ab\u5b78\u9662\u8840\u6db2\u75c5\u91ab\u9662\u59dc\u723e\u70c8\u6559\u6388\uff0c\u4e2d\u570b\u91ab\u5b78\u79d1\u5b78\u9662\u5317\u4eac\u5354\u548c\u91ab\u5b78\u9662\u8840\u6db2\u75c5\u91ab\u9662\u5f35\u701f\u4e88 Embryonic Ectoderm Development (EED) Inhibitor APG-5918 Exhibits Potent Antitumor Activity and Synergizes with Histone Deacetylase Inhibitor Tucidinostat in PreclinicalT-Cell Lymphoma (TCL) Models\u80da\u80ce\u5916\u80da\u5c64\u767c\u80b2\u86cb\u767d\uff08EED\uff09\u6291\u5236\u5291APG-5918\u5728T\u7d30\u80de\u6dcb\u5df4\u7624\uff08TCL\uff09\u81e8\u5e8a\u524d\u6a21\u578b\u4e2d\u5c55\u73fe\u5f37\u6548\u6297\u816b\u7624\u6d3b\u6027\uff0c\u4e26\u8207\u7d44\u86cb\u767d\u53bb\u4e59\u9170\u5316\u9176\u6291\u5236\u5291\u897f\u9054\u672c\u80fa\u5354\u540c\u589e\u6548 \u6458\u8981\u7de8\u865f\uff1aPS1993 \u5206\u6703\u5834\uff1a\u6dcb\u5df4\u7624\u751f\u7269\u5b78\u8207\u8f49\u5316\u7814\u7a76\uff08Lymphoma biology & translational research\uff09 \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670815\u65e5\uff0c\u5468\u65e5\uff0c\u51cc\u666800:30-01:30\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u665a\u4e0a18:30-19:30\uff09 \u4e3b\u8981\u4f5c\u8005\uff1a\u4e9e\u76db\u91ab\u85e5Eric Liang\u535a\u58eb \u5728\u7dda\u767c\u5e03 Alternating Low-Dose Inotuzumab Ozogamicin and Blinatumomab in Maintenance Therapy for Ph+ ALL: A Single-Center Retrospective Analysis\u4f4e\u5291\u91cf\u5967\u52a0\u4f0a\u59a5\u73e0\u55ae\u6297\u548c\u8c9d\u6797\u59a5\u6b50\u55ae\u6297\u4ea4\u66ff\u7dad\u6301\u6cbb\u7642\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\uff08Ph+\uff09\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08ALL\uff09\uff1a\u4e00\u9805\u55ae\u4e2d\u5fc3\u56de\u9867\u6027\u5206\u6790 \u6458\u8981\u7de8\u865f\uff1aPB2384 \u4e3b\u8981\u4f5c\u8005\uff1a\u6cb3\u5317\u91ab\u79d1\u5927\u5b78\u7b2c\u4e8c\u91ab\u9662\u8076\u5b50\u5143\u6559\u6388 Efficacy and Safety of Blinatumomab in Newly-Diagnosed Patients with Ph-Positive\/Negative B-Cell Acute Lymphoblastic Leukemia\u8c9d\u6797\u59a5\u6b50\u55ae\u6297\u6cbb\u7642\u65b0\u78ba\u8a3a\u7684 Ph \u967d\u6027\/\u9670\u6027 B \u7d30\u80de\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\u60a3\u8005\u7684\u7642\u6548\u548c\u5b89\u5168\u6027 \u6458\u8981\u7de8\u865f\uff1aPB2363 \u4e3b\u8981\u4f5c\u8005\uff1a\u83ef\u4e2d\u79d1\u6280\u5927\u5b78\u540c\u6fdf\u91ab\u5b78\u9662\u9644\u5c6c\u5354\u548c\u91ab\u9662\u5f35\u5bc5\u5b19 Efficacy and Safety of the Third-Generation TKI Olverembatinib in Relapsed and Persistent MRD Positive Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients\u7b2c\u4e09\u4ee3TKI\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u5fa9\u767c\u548c\u6301\u7e8cMRD\u967d\u6027\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\u60a3\u8005\u7684\u7642\u6548\u8207\u5b89\u5168\u6027 \u6458\u8981\u7de8\u865f\uff1aPB2360 \u4e3b\u8981\u4f5c\u8005\uff1a\u6cb3\u5317\u91ab\u79d1\u5927\u5b78\u7b2c\u4e8c\u91ab\u9662\u8523\u854a\u6eab Clinical Features and Genetic Abnormalities Predict Outcomes in Patients with Chronic Myeloid Leukemia in the Accelerated-Phase Receiving Olverembatinib Therapy: A Retrospective Multicenter Study\u81e8\u5e8a\u7279\u5fb5\u548c\u57fa\u56e0\u7570\u5e38\u7528\u65bc\u9810\u6e2c\u63a5\u53d7\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7684\u52a0\u901f\u671f\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u60a3\u8005\u7684\u6cbb\u7642\u7d50\u5c40\uff1a\u4e00\u9805\u56de\u9867\u6027\u591a\u4e2d\u5fc3\u7814\u7a76 \u6458\u8981\u7de8\u865f\uff1aPB2701 \u4e3b\u8981\u4f5c\u8005\uff1a\u5317\u4eac\u5927\u5b78\u4eba\u6c11\u91ab\u9662\u539f\u5922\u7464 A Real-World Study of Olverembatinib in the Treatment of Chronic Myeloid Leukemia from China: A Single-Center Retrospective Study\u4e00\u9805\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u7528\u65bc\u6cbb\u7642\u4e2d\u570b\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u60a3\u8005\u7684\u771f\u5be6\u4e16\u754c\u7814\u7a76\uff1a\u4e00\u9805\u55ae\u4e2d\u5fc3\u56de\u9867\u6027\u7814\u7a76 \u6458\u8981\u7de8\u865f\uff1aPB2714 \u4e3b\u8981\u4f5c\u8005\uff1a\u56db\u5ddd\u5927\u5b78\u83ef\u897f\u91ab\u9662\u8463\u5929 Synergistic Effects of Olverembatinib (HQP1351) Combined with Bcl-2 Inhibitor Lisaftoclax (APG-2575) and Bcl-2\/Bcl-xL Inhibitor Pelcitoclax (APG-1252) in T-Cell Acute Lymphoblastic Leukemia (T-ALL)\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u806f\u5408Bcl-2\u6291\u5236\u5291lisaftoclax\uff08APG-2575\uff09\u548cBcl-2\/Bcl-xL\u6291\u5236\u5291pelcitoclax\uff08APG-1252\uff09\u5728T\u7d30\u80de\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08T-ALL\uff09\u4e2d\u7684\u5354\u540c\u4f5c\u7528 \u6458\u8981\u7de8\u865f\uff1aPB2341 \u4e3b\u8981\u4f5c\u8005\uff1a\u4e9e\u76db\u91ab\u85e5\u5f6d\u6ce2 \u95dc\u65bc\u4e9e\u76db\u91ab\u85e5 \u4e9e\u76db\u91ab\u85e5\u662f\u4e00\u5bb6\u7d9c\u5408\u6027\u7684\u5168\u7403\u751f\u7269\u91ab\u85e5\u4f01\u696d\uff0c\u81f4\u529b\u65bc\u7814\u767c\u5275\u65b0\u85e5\uff0c\u4ee5\u89e3\u6c7a\u816b\u7624\u7b49\u9818\u57df\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u30022019\u5e7410\u670828\u65e5\uff0c\u516c\u53f8\u5728\u9999\u6e2f\u806f\u4ea4\u6240\u4e3b\u677f\u639b\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u78bc\uff1a6855.HK\uff1b2025\u5e741\u670824\u65e5\uff0c\u516c\u53f8\u5728\u7f8e\u570b\u7d0d\u65af\u9054\u514b\u8b49\u5238\u4ea4\u6613\u6240\u639b\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u78bc\uff1aAAPG\u3002 \u4e9e\u76db\u91ab\u85e5\u5df2\u5efa\u7acb\u8c50\u5bcc\u7684\u5275\u65b0\u85e5\u7522\u54c1\u7ba1\u7dda\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u548c MDM2-p53 \u7b49\u7d30\u80de\u51cb\u4ea1\u901a\u8def\u95dc\u9375\u86cb\u767d\u7684\u6291\u5236\u5291\uff1b\u65b0\u4e00\u4ee3\u91dd\u5c0d\u764c\u75c7\u6cbb\u7642\u4e2d\u51fa\u73fe\u7684\u6fc0\u9176\u7a81\u8b8a\u9ad4\u7684\u6291\u5236\u5291\u7b49\u3002 \u516c\u53f8\u6838\u5fc3\u54c1\u7a2e\u8010\u7acb\u514b\u00ae\u662f\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\uff0c\u4e14\u7372\u6279\u9069\u61c9\u75c7\u5747\u88ab\u6210\u529f\u7d0d\u5165\u570b\u5bb6\u91ab\u4fdd\u85e5\u54c1\u76ee\u9304\uff0c\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u8010\u7acb\u514b\u00ae\u4e00\u9805\u7372\u7f8e\u570bFDA\u8a31\u53ef\u7684\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff08POLARIS-2\uff09\uff0c\u7528\u65bc\u6cbb\u7642\u65e2\u5f80\u63a5\u53d7\u904e\u6cbb\u7642\u7684\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CML-CP\uff09\u6210\u5e74\u60a3\u8005\u3002\u6b64\u5916\uff0c\u8010\u7acb\u514b\u00ae\u806f\u5408\u6cbb\u7642\u65b0\u8a3a\u65b7\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u60a3\u8005\u548c\u6cbb\u7642\u7425\u73c0\u9178\u812b\u6c2b\u9176\uff08SDH\uff09\u7f3a\u9677\u578b\u80c3\u8178\u9053\u9593\u8cea\u7624\uff08GIST\uff09\u60a3\u8005\u7684\u5168\u7403\u8a3b\u518aIII\u671f\u7814\u7a76\u6b63\u5728\u958b\u5c55\u4e2d\u3002 \u516c\u53f8\u53e6\u4e00\u91cd\u78c5\u54c1\u7a2e\uff0c\u65b0\u578bBcl-2\u9078\u64c7\u6027\u6291\u5236\u5291APG-2575\uff08Lisaftoclax\uff09\u7684\u65b0\u85e5\u4e0a\u5e02\u7533\u8acb\uff08NDA\uff09\u5df2\u7372CDE\u53d7\u7406\uff0c\u4e26\u88ab\u7d0d\u5165\u512a\u5148\u5be9\u8a55\u3002\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55APG-2575\uff08Lisaftoclax\uff09\u56db\u9805\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u5206\u5225\u70ba\u7372\u7f8e\u570bFDA\u8a31\u53ef\u7684\u6cbb\u7642\u7d93\u6cbb\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u7684\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff08GLORA\uff09\uff1b\u6cbb\u7642\u521d\u6cbbCLL\/SLL\u60a3\u8005\u7684\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff1b\u4e00\u7dda\u6cbb\u7642\u65b0\u8a3a\u65b7\u8001\u5e74\u6216\u9ad4\u5f31\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08AML\uff09\u7684\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff1b\u4ee5\u53ca\u6cbb\u7642\u65b0\u8a3a\u65b7\u4e2d\u9ad8\u5371\u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u75c7\uff08MDS\uff09\u60a3\u8005\u7684\u8a3b\u518aIII\u671f\u7814\u7a76\u3002 \u622a\u81f3\u76ee\u524d\uff0c\u516c\u53f84\u500b\u5728\u7814\u65b0\u85e5\u5171\u737216\u9805FDA\u548c1\u9805\u6b50\u76df\u5b64\u5152\u85e5\u8cc7\u683c\u8a8d\u5b9a\uff0c2\u9805FDA\u5feb\u901f\u901a\u9053\u8cc7\u683c\u4ee5\u53ca2\u9805FDA\u5152\u7ae5\u7f55\u898b\u75c5\u8cc7\u683c\u8a8d\u8b49\u3002\u6191\u501f\u5f37\u5927\u7684\u7814\u767c\u80fd\u529b\uff0c\u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u5168\u7403\u7bc4\u570d\u5167\u9032\u884c\u77e5\u8b58\u7522\u6b0a\u5e03\u5c40\uff0c\u4e26\u8207\u6b66\u7530\u3001\u9ed8\u6c99\u6771\u3001\u963f\u65af\u5229\u5eb7\u3001\u8f1d\u745e\u3001\u4fe1\u9054\u7b49\u9818\u5148\u7684\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u4ee5\u53ca\u6885\u5967\u91ab\u5b78\u4e2d\u5fc3\uff08Mayo Clinic\uff09\u3001\u4e39\u5a1c\u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662\uff08Dana-Farber Cancer Institute\uff09\u3001\u7f8e\u570b\u570b\u5bb6\u764c\u75c7\u7814\u7a76\u6240\uff08NCI\uff09\u548c\u5bc6\u897f\u6839\u5927\u5b78\u7b49\u5b78\u8853\u6a5f\u69cb\u9054\u6210\u5168\u7403\u5408\u4f5c\u95dc\u4fc2\u3002 \u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u539f\u5275\u65b0\u85e5\u7814\u767c\u8207\u81e8\u5e8a\u958b\u767c\u9818\u57df\u5efa\u7acb\u7d93\u9a57\u8c50\u5bcc\u7684\u570b\u969b\u5316\u4eba\u624d\u5718\u968a\uff0c\u4ee5\u53ca\u6210\u719f\u7684\u5546\u696d\u5316\u751f\u7522\u8207\u5e02\u5834\u71df\u92b7\u5718\u968a\u3002\u4e9e\u76db\u91ab\u85e5\u5c07\u4e0d\u65b7\u63d0\u9ad8\u7814\u767c\u80fd\u529b\uff0c\u52a0\u901f\u63a8\u9032\u516c\u53f8\u7522\u54c1\u7ba1\u7dda\u7684\u81e8\u5e8a\u958b\u767c\u9032\u5ea6\uff0c\u771f\u6b63\u8e10\u884c\u300c\u89e3\u6c7a\u4e2d\u570b\u4e43\u81f3\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u300d\u7684\u4f7f\u547d\uff0c\u4ee5\u9020\u798f\u66f4\u591a\u60a3\u8005\u3002 \u524d\u77bb\u6027\u8072\u660e \u672c\u65b0\u805e\u7a3f\u5305\u542b\u6839\u64da\u7f8e\u570b\u300a1995\u5e74\u79c1\u4eba\u8b49\u5238\u8a34\u8a1f\u6539\u9769\u6cd5\u6848\u300b\uff0c\u4ee5\u53ca\u7d93\u4fee\u8a02\u7684\u300a1933\u5e74\u8b49\u5238\u6cd5\u300b\u7b2c27A\u689d\u548c\u300a1934\u5e74\u8b49\u5238\u4ea4\u6613\u6cd5\u300b\u7b2c21E\u689d\u6240\u754c\u5b9a\u7684\u524d\u77bb\u6027\u9673\u8ff0\u3002\u9664\u6b77\u53f2\u4e8b\u5be6\u9673\u8ff0\u5916\uff0c\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u6240\u6709\u5167\u5bb9\u5747\u53ef\u80fd\u69cb\u6210\u524d\u77bb\u6027\u9673\u8ff0\uff0c\u5305\u62ec\u4e9e\u76db\u91ab\u85e5\u5c0d\u672a\u4f86\u4e8b\u4ef6\u3001\u7d93\u71df\u6210\u679c\u6216\u8ca1\u52d9\u72c0\u6cc1\u6240\u767c\u8868\u7684\u610f\u898b\u3001\u9810\u671f\u3001\u4fe1\u5ff5\u3001\u8a08\u5283\u3001\u76ee\u6a19\u3001\u5047\u8a2d\u6216\u9810\u6e2c\u3002 \u9019\u4e9b\u524d\u77bb\u6027\u9673\u8ff0\u53d7\u5230\u8af8\u591a\u98a8\u96aa\u548c\u4e0d\u78ba\u5b9a\u6027\u7684\u5f71\u97ff\uff0c\u5177\u9ad4\u5167\u5bb9\u5df2\u5728\u4e9e\u76db\u91ab\u85e5\u5411\u7f8e\u570b\u8b49\u5238\u4ea4\u6613\u59d4\u54e1\u6703\uff08SEC\uff09\u63d0\u4ea4\u7684\u6587\u4ef6\u4e2d\u8a73\u7d30\u8aaa\u660e\uff0c\u5305\u62ec2025\u5e741\u670821\u65e5\u63d0\u4ea4\u7684\u7d93\u4fee\u8a02\u7684F-1\u8868\u683c\u8a3b\u518a\u8aaa\u660e\u66f8\u548c2025\u5e744\u670816\u65e5\u63d0\u4ea4\u768420-F\u8868\u683c\u4e2d\u7684\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u548c\u300c\u95dc\u65bc\u524d\u77bb\u6027\u9673\u8ff0\u53ca\u884c\u696d\u6578\u64da\u7684\u7279\u5225\u8aaa\u660e\u300d\u7ae0\u7bc0\u30012019\u5e7410\u670816\u65e5\u63d0\u4ea4\u7684\u9996\u6b21\u767c\u884c\u4e0a\u5e02\u62db\u80a1\u66f8\u4e2d\u7684\u300c\u524d\u77bb\u6027\u8072\u660e\u300d\u3001\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u7ae0\u7bc0\uff0c\u4ee5\u53ca\u6211\u5011\u4e0d\u6642\u5411SEC\u6216HKEX\u63d0\u4ea4\u7684\u5176\u4ed6\u6587\u4ef6\u3002\u9019\u4e9b\u56e0\u7d20\u53ef\u80fd\u5c0e\u81f4\u5be6\u969b\u696d\u7e3e\u3001\u904b\u71df\u6c34\u5e73\u3001\u7d93\u71df\u6210\u679c\u6216\u6210\u5c31\u8207\u524d\u77bb\u6027\u9673\u8ff0\u4e2d\u660e\u793a\u6216\u6697\u793a\u7684\u4fe1\u606f\u5b58\u5728\u91cd\u5927\u5dee\u7570\u3002\u672c\u524d\u77bb\u6027\u8072\u660e\u4e2d\u7684\u9673\u8ff0\u4e0d\u69cb\u6210\u516c\u53f8\u7ba1\u7406\u5c64\u7684\u5229\u6f64\u9810\u6e2c\u3002 \u56e0\u6b64\uff0c\u8a72\u7b49\u524d\u77bb\u6027\u9673\u8ff0\u4e0d\u61c9\u88ab\u8996\u70ba\u5c0d\u672a\u4f86\u4e8b\u4ef6\u7684\u9810\u6e2c\u3002\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u524d\u77bb\u6027\u9673\u8ff0\u50c5\u57fa\u65bc\u4e9e\u76db\u91ab\u85e5\u7576\u524d\u5c0d\u672a\u4f86\u767c\u5c55\u53ca\u5176\u6f5b\u5728\u5f71\u97ff\u7684\u9810\u671f\u548c\u5224\u65b7\uff0c\u4e14\u50c5\u4ee3\u8868\u622a\u81f3\u9673\u8ff0\u767c\u8868\u4e4b\u65e5\u7684\u89c0\u9ede\u3002\u7121\u8ad6\u51fa\u73fe\u65b0\u4fe1\u606f\u3001\u672a\u4f86\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u6cc1\uff0c\u4e9e\u76db\u91ab\u85e5\u5747\u7121\u7fa9\u52d9\u66f4\u65b0\u6216\u4fee\u8a02\u4efb\u4f55\u524d\u77bb\u6027\u9673\u8ff0\u3002\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pingtungtimes.com.tw\/?p=334269\" \/>\n<meta property=\"og:site_name\" content=\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/pingtungnews\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-10T01:18:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u7f8e\u901a\u793e\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u4f5c\u8005:\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u7f8e\u901a\u793e\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u9810\u4f30\u95b1\u8b80\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 \u5206\u9418\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=334269#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=334269\"},\"author\":{\"name\":\"\u7f8e\u901a\u793e\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/person\\\/683b937f29ec1537972f6c41e22a2cf3\"},\"headline\":\"\u30102025 EHA\u3011\u4e9e\u76db\u91ab\u85e5\u6838\u5fc3\u7522\u54c1\u8010\u7acb\u514b\u00ae\u548cAPG-2575\u7b4913\u9805\u9032\u5c55\u5165\u90782025\u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703\u5e74\u6703\",\"datePublished\":\"2025-06-10T01:18:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=334269\"},\"wordCount\":439,\"publisher\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=334269#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/Ascentage_APAC_Logo-7.jpg\",\"articleSection\":[\"\u7f8e\u901a\u793e\"],\"inLanguage\":\"zh-TW\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=334269\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=334269\",\"name\":\"\u30102025 EHA\u3011\u4e9e\u76db\u91ab\u85e5\u6838\u5fc3\u7522\u54c1\u8010\u7acb\u514b\u00ae\u548cAPG-2575\u7b4913\u9805\u9032\u5c55\u5165\u90782025\u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703\u5e74\u6703 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=334269#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=334269#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/Ascentage_APAC_Logo-7.jpg\",\"datePublished\":\"2025-06-10T01:18:00+00:00\",\"description\":\"\u7f8e\u570b\u99ac\u91cc\u862d\u5dde\u7f85\u514b\u7dad\u723e\u5e02\u548c\u4e2d\u570b\u8607\u5dde 2025\u5e746\u670810\u65e5 \u00a0\\\/\u7f8e\u901a\u793e\\\/ -- \u81f4\u529b\u65bc\u5728\u816b\u7624\u7b49\u9818\u57df\u958b\u767c\u5275\u65b0\u85e5\u7269\u7684\u9818\u5148\u7684\u751f\u7269\u91ab\u85e5\u4f01\u696d\u2014\u2014\u4e9e\u76db\u91ab\u85e5\uff08\u7d0d\u65af\u9054\u514b\u4ee3\u78bc\uff1aAAPG\uff1b\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a6855\uff09\u5ba3\u5e03\uff0c\u6d89\u53ca\u516c\u53f8\u539f\u52751\u985e\u65b0\u85e5\u5967\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff09\u3001Bcl-2\u6291\u5236\u5291APG-2575\u3001EED\u6291\u5236\u5291APG-5918\u7b49\u91cd\u78c5\u54c1\u7a2e\u768413\u9805\u7814\u7a76\u9032\u5c55\u5c07\u57282025\u5e746\u670812\u65e5\u81f315\u65e5\u65bc\u610f\u5927\u5229\u7c73\u862d\u8209\u884c\u76842025\u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703\uff08EHA\uff09\u5e74\u6703\u4e0a\u516c\u5e03\uff0c\u5176\u4e2d\u5305\u62ec1\u9805\u53e3\u982d\u5831\u544a\uff0c\u53ca\u591a\u9805\u58c1\u5831\u5c55\u793a\u548c\u7dda\u4e0a\u767c\u8868\u3002 EHA\u5e74\u6703\u4f5c\u70ba\u6b50\u6d32\u8840\u6db2\u5b78\u9818\u57df\u898f\u6a21\u6700\u5927\u7684\u570b\u969b\u6703\u8b70\uff0c\u6bcf\u5e74\u5438\u5f15\u4f86\u81ea\u5168\u7403100\u591a\u500b\u570b\u5bb6\u76841\u842c\u591a\u540d\u5c08\u696d\u4eba\u58eb\u8207\u6703\uff0c\u5206\u4eab\u5168\u7403\u6700\u524d\u6cbf\u7684\u7814\u7a76\u9032\u5c55\u548c\u7a81\u7834\u6027\u81e8\u5e8a\u6578\u64da\u3002 \u53e3\u982d\u5831\u544a Integrating Genomic and Transcriptomic Insights for Predicting Responses and Outcomes in Patients with CML Receiving 3rd-Generation TKI Therapy\u6574\u5408\u57fa\u56e0\u7d44\u548c\u8f49\u9304\u7d44\u5b78\u898b\u89e3\u4ee5\u9810\u6e2c\u63a5\u53d7\u4e09\u4ee3TKI\u6cbb\u7642\u7684CML\u60a3\u8005\u7684\u7642\u6548\u548c\u7d50\u5c40 \u6458\u8981\u7de8\u865f\uff1aS162 \u5206\u6703\u5834\uff1aCML\u6cbb\u7642\u7642\u6548\u53ca\u8010\u85e5\u7684\u751f\u7269\u5b78\uff08Biology of CML treatment response and resistance\uff09 \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u665a\u4e0a23:30-23:45\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u4e0b\u534817:30-17:45\uff09 \u4e3b\u8981\u4f5c\u8005\uff1a\u5317\u4eac\u5927\u5b78\u4eba\u6c11\u91ab\u9662\u6c5f\u5029\u6559\u6388\uff0c\u5317\u4eac\u5927\u5b78\u4eba\u6c11\u91ab\u9662\u5f35\u5c0f\u5e25 \u58c1\u5831\u5c55\u793a Frontline Chemotherapy-Free Combination of Olverembatinib with Venetoclax and Azacitidine in Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia: Preliminary Outcomes of a Prospective Study\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u7dad\u5948\u514b\u62c9\u8207\u963f\u624e\u80de\u7518\u7528\u65bc\u7121\u5316\u7642\u4e00\u7dda\u6cbb\u7642\u65b0\u8a3a\u65b7\u7684Ph+\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff1a\u4e00\u9805\u524d\u77bb\u6027\u7814\u7a76\u7684\u521d\u6b65\u7d50\u679c \u6458\u8981\u7de8\u865f\uff1aPF384 \u5206\u6703\u5834\uff1a\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76\uff08Acute lymphoblastic leukemia - Clinical\uff09 \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u51cc\u666800:30-01:30\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670813\u65e5\uff0c\u5468\u4e94\uff0c\u665a\u4e0a18:30-19:30\uff09 \u4e3b\u8981\u4f5c\u8005\uff1a\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662\u5510\u66c9\u6587\u6559\u6388\uff0c\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662\u5f35\u6b23 A Phase 2 Study of Olverembatinib for the Treatment of Myeloid\\\/Lymphoid Neoplasms with FGFR1 Rearrangement\u4e00\u9805\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u7528\u65bc\u6cbb\u7642\u4f34FGFR1\u91cd\u6392\u7684\u9ad3\u7cfb\\\/\u6dcb\u5df4\u7cfb\u816b\u7624\u7684II\u671f\u7814\u7a76 \u6458\u8981\u7de8\u865f\uff1aPF390 \u5206\u6703\u5834\uff1a\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76\uff08Acute lymphoblastic leukemia - Clinical\uff09 \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u51cc\u666800:30-01:30\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670813\u65e5\uff0c\u5468\u4e94\uff0c\u665a\u4e0a18:30-19:30\uff09 \u4e3b\u8981\u4f5c\u8005\uff1a\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662\u9673\u8607\u5be7\u6559\u6388\uff0c\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662\u8521\u6587\u6cbb Efficacy and Safety of Regimen with Olverembatinib and Blinatumomab for the Frontline Treatment of Ph-Positive or Ph-Like Acute Lymphoblastic Leukemia\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u8c9d\u6797\u59a5\u6b50\u55ae\u6297\u4e00\u7dda\u6cbb\u7642\u8cbb\u57ce\u67d3\u8272\u9ad4\uff08Ph\uff09\u967d\u6027\u6216Ph\u6a23\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\u7684\u7642\u6548\u548c\u5b89\u5168\u6027 \u6458\u8981\u7de8\u865f\uff1aPS1367 \u5206\u6703\u5834\uff1a\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76\uff08Acute lymphoblastic leukemia - Clinical\uff09 \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670815\u65e5\uff0c\u5468\u65e5\uff0c\u51cc\u666800:30-01:30\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u665a\u4e0a18:30-19:30 \uff09 \u4e3b\u8981\u4f5c\u8005\uff1a\u5357\u65b9\u91ab\u79d1\u5927\u5b78\u5357\u65b9\u91ab\u9662\u5468\u7d05\u5347\u6559\u6388\uff0c\u5357\u65b9\u91ab\u79d1\u5927\u5b78\u5357\u65b9\u91ab\u9662\u8a31\u79c0\u9e97 Combination of Olverembatinib and VP Regimen as First-Line Therapy for Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Single-Arm, Multicentre, Phase 2 Trial\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408VP\u65b9\u6848\u4e00\u7dda\u6cbb\u7642\u6210\u4eba\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff1a\u4e00\u9805\u55ae\u81c2\u3001\u591a\u4e2d\u5fc3II\u671f\u7814\u7a76 \u6458\u8981\u7de8\u865f\uff1aPS1372 \u5206\u6703\u5834\uff1a\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76\uff08Acute lymphoblastic leukemia - Clinical\uff09 \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670815\u65e5\uff0c\u5468\u65e5\uff0c\u51cc\u666800:30-01:30\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u665a\u4e0a18:30-19:30\uff09 \u4e3b\u8981\u4f5c\u8005\uff1a\u6d59\u6c5f\u5927\u5b78\u91ab\u5b78\u9662\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662\u91d1\u6f54\u6559\u6388\uff0c\u6d59\u6c5f\u5927\u5b78\u91ab\u5b78\u9662\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662\u8a31\u6539\u9999 Efficacy and Safety of The Third-Generation Tyrosine Kinase Inhibitor Olverembatinib in Combination with Inotuzumab Ozogamicin for the Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients With Relapsed Disease or Persistent Minimal Residual Disease Bridging to Hematopoietic Stem Cell Transplantation: A Phase II Study\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u5967\u52a0\u4f0a\u59a5\u73e0\u55ae\u6297\u6cbb\u7642\u5fa9\u767c\u6216\u9020\u8840\u5e72\u7d30\u80de\u79fb\u690d\u524d\u6301\u7e8cMRD\u967d\u6027\u6210\u4ebaPh+ ALL\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\uff1a\u4e00\u9805\u2161\u671f\u7814\u7a76 \u6458\u8981\u7de8\u865f\uff1aPS1387 \u5206\u6703\u5834\uff1a\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76\uff08Acute lymphoblastic leukemia - Clinical\uff09 \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670815\u65e5\uff0c\u5468\u65e5\uff0c\u51cc\u666800:30-01:30\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u665a\u4e0a18:30-19:30\uff09 \u4e3b\u8981\u4f5c\u8005\uff1a\u4e2d\u570b\u91ab\u5b78\u79d1\u5b78\u9662\u5317\u4eac\u5354\u548c\u91ab\u5b78\u9662\u8840\u6db2\u75c5\u91ab\u9662\u59dc\u723e\u70c8\u6559\u6388\uff0c\u4e2d\u570b\u91ab\u5b78\u79d1\u5b78\u9662\u5317\u4eac\u5354\u548c\u91ab\u5b78\u9662\u8840\u6db2\u75c5\u91ab\u9662\u5f35\u701f\u4e88 Embryonic Ectoderm Development (EED) Inhibitor APG-5918 Exhibits Potent Antitumor Activity and Synergizes with Histone Deacetylase Inhibitor Tucidinostat in PreclinicalT-Cell Lymphoma (TCL) Models\u80da\u80ce\u5916\u80da\u5c64\u767c\u80b2\u86cb\u767d\uff08EED\uff09\u6291\u5236\u5291APG-5918\u5728T\u7d30\u80de\u6dcb\u5df4\u7624\uff08TCL\uff09\u81e8\u5e8a\u524d\u6a21\u578b\u4e2d\u5c55\u73fe\u5f37\u6548\u6297\u816b\u7624\u6d3b\u6027\uff0c\u4e26\u8207\u7d44\u86cb\u767d\u53bb\u4e59\u9170\u5316\u9176\u6291\u5236\u5291\u897f\u9054\u672c\u80fa\u5354\u540c\u589e\u6548 \u6458\u8981\u7de8\u865f\uff1aPS1993 \u5206\u6703\u5834\uff1a\u6dcb\u5df4\u7624\u751f\u7269\u5b78\u8207\u8f49\u5316\u7814\u7a76\uff08Lymphoma biology & translational research\uff09 \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670815\u65e5\uff0c\u5468\u65e5\uff0c\u51cc\u666800:30-01:30\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u665a\u4e0a18:30-19:30\uff09 \u4e3b\u8981\u4f5c\u8005\uff1a\u4e9e\u76db\u91ab\u85e5Eric Liang\u535a\u58eb \u5728\u7dda\u767c\u5e03 Alternating Low-Dose Inotuzumab Ozogamicin and Blinatumomab in Maintenance Therapy for Ph+ ALL: A Single-Center Retrospective Analysis\u4f4e\u5291\u91cf\u5967\u52a0\u4f0a\u59a5\u73e0\u55ae\u6297\u548c\u8c9d\u6797\u59a5\u6b50\u55ae\u6297\u4ea4\u66ff\u7dad\u6301\u6cbb\u7642\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\uff08Ph+\uff09\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08ALL\uff09\uff1a\u4e00\u9805\u55ae\u4e2d\u5fc3\u56de\u9867\u6027\u5206\u6790 \u6458\u8981\u7de8\u865f\uff1aPB2384 \u4e3b\u8981\u4f5c\u8005\uff1a\u6cb3\u5317\u91ab\u79d1\u5927\u5b78\u7b2c\u4e8c\u91ab\u9662\u8076\u5b50\u5143\u6559\u6388 Efficacy and Safety of Blinatumomab in Newly-Diagnosed Patients with Ph-Positive\\\/Negative B-Cell Acute Lymphoblastic Leukemia\u8c9d\u6797\u59a5\u6b50\u55ae\u6297\u6cbb\u7642\u65b0\u78ba\u8a3a\u7684 Ph \u967d\u6027\\\/\u9670\u6027 B \u7d30\u80de\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\u60a3\u8005\u7684\u7642\u6548\u548c\u5b89\u5168\u6027 \u6458\u8981\u7de8\u865f\uff1aPB2363 \u4e3b\u8981\u4f5c\u8005\uff1a\u83ef\u4e2d\u79d1\u6280\u5927\u5b78\u540c\u6fdf\u91ab\u5b78\u9662\u9644\u5c6c\u5354\u548c\u91ab\u9662\u5f35\u5bc5\u5b19 Efficacy and Safety of the Third-Generation TKI Olverembatinib in Relapsed and Persistent MRD Positive Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients\u7b2c\u4e09\u4ee3TKI\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u5fa9\u767c\u548c\u6301\u7e8cMRD\u967d\u6027\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\u60a3\u8005\u7684\u7642\u6548\u8207\u5b89\u5168\u6027 \u6458\u8981\u7de8\u865f\uff1aPB2360 \u4e3b\u8981\u4f5c\u8005\uff1a\u6cb3\u5317\u91ab\u79d1\u5927\u5b78\u7b2c\u4e8c\u91ab\u9662\u8523\u854a\u6eab Clinical Features and Genetic Abnormalities Predict Outcomes in Patients with Chronic Myeloid Leukemia in the Accelerated-Phase Receiving Olverembatinib Therapy: A Retrospective Multicenter Study\u81e8\u5e8a\u7279\u5fb5\u548c\u57fa\u56e0\u7570\u5e38\u7528\u65bc\u9810\u6e2c\u63a5\u53d7\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7684\u52a0\u901f\u671f\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u60a3\u8005\u7684\u6cbb\u7642\u7d50\u5c40\uff1a\u4e00\u9805\u56de\u9867\u6027\u591a\u4e2d\u5fc3\u7814\u7a76 \u6458\u8981\u7de8\u865f\uff1aPB2701 \u4e3b\u8981\u4f5c\u8005\uff1a\u5317\u4eac\u5927\u5b78\u4eba\u6c11\u91ab\u9662\u539f\u5922\u7464 A Real-World Study of Olverembatinib in the Treatment of Chronic Myeloid Leukemia from China: A Single-Center Retrospective Study\u4e00\u9805\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u7528\u65bc\u6cbb\u7642\u4e2d\u570b\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u60a3\u8005\u7684\u771f\u5be6\u4e16\u754c\u7814\u7a76\uff1a\u4e00\u9805\u55ae\u4e2d\u5fc3\u56de\u9867\u6027\u7814\u7a76 \u6458\u8981\u7de8\u865f\uff1aPB2714 \u4e3b\u8981\u4f5c\u8005\uff1a\u56db\u5ddd\u5927\u5b78\u83ef\u897f\u91ab\u9662\u8463\u5929 Synergistic Effects of Olverembatinib (HQP1351) Combined with Bcl-2 Inhibitor Lisaftoclax (APG-2575) and Bcl-2\\\/Bcl-xL Inhibitor Pelcitoclax (APG-1252) in T-Cell Acute Lymphoblastic Leukemia (T-ALL)\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u806f\u5408Bcl-2\u6291\u5236\u5291lisaftoclax\uff08APG-2575\uff09\u548cBcl-2\\\/Bcl-xL\u6291\u5236\u5291pelcitoclax\uff08APG-1252\uff09\u5728T\u7d30\u80de\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08T-ALL\uff09\u4e2d\u7684\u5354\u540c\u4f5c\u7528 \u6458\u8981\u7de8\u865f\uff1aPB2341 \u4e3b\u8981\u4f5c\u8005\uff1a\u4e9e\u76db\u91ab\u85e5\u5f6d\u6ce2 \u95dc\u65bc\u4e9e\u76db\u91ab\u85e5 \u4e9e\u76db\u91ab\u85e5\u662f\u4e00\u5bb6\u7d9c\u5408\u6027\u7684\u5168\u7403\u751f\u7269\u91ab\u85e5\u4f01\u696d\uff0c\u81f4\u529b\u65bc\u7814\u767c\u5275\u65b0\u85e5\uff0c\u4ee5\u89e3\u6c7a\u816b\u7624\u7b49\u9818\u57df\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u30022019\u5e7410\u670828\u65e5\uff0c\u516c\u53f8\u5728\u9999\u6e2f\u806f\u4ea4\u6240\u4e3b\u677f\u639b\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u78bc\uff1a6855.HK\uff1b2025\u5e741\u670824\u65e5\uff0c\u516c\u53f8\u5728\u7f8e\u570b\u7d0d\u65af\u9054\u514b\u8b49\u5238\u4ea4\u6613\u6240\u639b\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u78bc\uff1aAAPG\u3002 \u4e9e\u76db\u91ab\u85e5\u5df2\u5efa\u7acb\u8c50\u5bcc\u7684\u5275\u65b0\u85e5\u7522\u54c1\u7ba1\u7dda\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u548c MDM2-p53 \u7b49\u7d30\u80de\u51cb\u4ea1\u901a\u8def\u95dc\u9375\u86cb\u767d\u7684\u6291\u5236\u5291\uff1b\u65b0\u4e00\u4ee3\u91dd\u5c0d\u764c\u75c7\u6cbb\u7642\u4e2d\u51fa\u73fe\u7684\u6fc0\u9176\u7a81\u8b8a\u9ad4\u7684\u6291\u5236\u5291\u7b49\u3002 \u516c\u53f8\u6838\u5fc3\u54c1\u7a2e\u8010\u7acb\u514b\u00ae\u662f\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\uff0c\u4e14\u7372\u6279\u9069\u61c9\u75c7\u5747\u88ab\u6210\u529f\u7d0d\u5165\u570b\u5bb6\u91ab\u4fdd\u85e5\u54c1\u76ee\u9304\uff0c\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u8010\u7acb\u514b\u00ae\u4e00\u9805\u7372\u7f8e\u570bFDA\u8a31\u53ef\u7684\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff08POLARIS-2\uff09\uff0c\u7528\u65bc\u6cbb\u7642\u65e2\u5f80\u63a5\u53d7\u904e\u6cbb\u7642\u7684\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CML-CP\uff09\u6210\u5e74\u60a3\u8005\u3002\u6b64\u5916\uff0c\u8010\u7acb\u514b\u00ae\u806f\u5408\u6cbb\u7642\u65b0\u8a3a\u65b7\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u60a3\u8005\u548c\u6cbb\u7642\u7425\u73c0\u9178\u812b\u6c2b\u9176\uff08SDH\uff09\u7f3a\u9677\u578b\u80c3\u8178\u9053\u9593\u8cea\u7624\uff08GIST\uff09\u60a3\u8005\u7684\u5168\u7403\u8a3b\u518aIII\u671f\u7814\u7a76\u6b63\u5728\u958b\u5c55\u4e2d\u3002 \u516c\u53f8\u53e6\u4e00\u91cd\u78c5\u54c1\u7a2e\uff0c\u65b0\u578bBcl-2\u9078\u64c7\u6027\u6291\u5236\u5291APG-2575\uff08Lisaftoclax\uff09\u7684\u65b0\u85e5\u4e0a\u5e02\u7533\u8acb\uff08NDA\uff09\u5df2\u7372CDE\u53d7\u7406\uff0c\u4e26\u88ab\u7d0d\u5165\u512a\u5148\u5be9\u8a55\u3002\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55APG-2575\uff08Lisaftoclax\uff09\u56db\u9805\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u5206\u5225\u70ba\u7372\u7f8e\u570bFDA\u8a31\u53ef\u7684\u6cbb\u7642\u7d93\u6cbb\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\\\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\\\/SLL\uff09\u60a3\u8005\u7684\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff08GLORA\uff09\uff1b\u6cbb\u7642\u521d\u6cbbCLL\\\/SLL\u60a3\u8005\u7684\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff1b\u4e00\u7dda\u6cbb\u7642\u65b0\u8a3a\u65b7\u8001\u5e74\u6216\u9ad4\u5f31\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08AML\uff09\u7684\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff1b\u4ee5\u53ca\u6cbb\u7642\u65b0\u8a3a\u65b7\u4e2d\u9ad8\u5371\u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u75c7\uff08MDS\uff09\u60a3\u8005\u7684\u8a3b\u518aIII\u671f\u7814\u7a76\u3002 \u622a\u81f3\u76ee\u524d\uff0c\u516c\u53f84\u500b\u5728\u7814\u65b0\u85e5\u5171\u737216\u9805FDA\u548c1\u9805\u6b50\u76df\u5b64\u5152\u85e5\u8cc7\u683c\u8a8d\u5b9a\uff0c2\u9805FDA\u5feb\u901f\u901a\u9053\u8cc7\u683c\u4ee5\u53ca2\u9805FDA\u5152\u7ae5\u7f55\u898b\u75c5\u8cc7\u683c\u8a8d\u8b49\u3002\u6191\u501f\u5f37\u5927\u7684\u7814\u767c\u80fd\u529b\uff0c\u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u5168\u7403\u7bc4\u570d\u5167\u9032\u884c\u77e5\u8b58\u7522\u6b0a\u5e03\u5c40\uff0c\u4e26\u8207\u6b66\u7530\u3001\u9ed8\u6c99\u6771\u3001\u963f\u65af\u5229\u5eb7\u3001\u8f1d\u745e\u3001\u4fe1\u9054\u7b49\u9818\u5148\u7684\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u4ee5\u53ca\u6885\u5967\u91ab\u5b78\u4e2d\u5fc3\uff08Mayo Clinic\uff09\u3001\u4e39\u5a1c\u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662\uff08Dana-Farber Cancer Institute\uff09\u3001\u7f8e\u570b\u570b\u5bb6\u764c\u75c7\u7814\u7a76\u6240\uff08NCI\uff09\u548c\u5bc6\u897f\u6839\u5927\u5b78\u7b49\u5b78\u8853\u6a5f\u69cb\u9054\u6210\u5168\u7403\u5408\u4f5c\u95dc\u4fc2\u3002 \u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u539f\u5275\u65b0\u85e5\u7814\u767c\u8207\u81e8\u5e8a\u958b\u767c\u9818\u57df\u5efa\u7acb\u7d93\u9a57\u8c50\u5bcc\u7684\u570b\u969b\u5316\u4eba\u624d\u5718\u968a\uff0c\u4ee5\u53ca\u6210\u719f\u7684\u5546\u696d\u5316\u751f\u7522\u8207\u5e02\u5834\u71df\u92b7\u5718\u968a\u3002\u4e9e\u76db\u91ab\u85e5\u5c07\u4e0d\u65b7\u63d0\u9ad8\u7814\u767c\u80fd\u529b\uff0c\u52a0\u901f\u63a8\u9032\u516c\u53f8\u7522\u54c1\u7ba1\u7dda\u7684\u81e8\u5e8a\u958b\u767c\u9032\u5ea6\uff0c\u771f\u6b63\u8e10\u884c\u300c\u89e3\u6c7a\u4e2d\u570b\u4e43\u81f3\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u300d\u7684\u4f7f\u547d\uff0c\u4ee5\u9020\u798f\u66f4\u591a\u60a3\u8005\u3002 \u524d\u77bb\u6027\u8072\u660e \u672c\u65b0\u805e\u7a3f\u5305\u542b\u6839\u64da\u7f8e\u570b\u300a1995\u5e74\u79c1\u4eba\u8b49\u5238\u8a34\u8a1f\u6539\u9769\u6cd5\u6848\u300b\uff0c\u4ee5\u53ca\u7d93\u4fee\u8a02\u7684\u300a1933\u5e74\u8b49\u5238\u6cd5\u300b\u7b2c27A\u689d\u548c\u300a1934\u5e74\u8b49\u5238\u4ea4\u6613\u6cd5\u300b\u7b2c21E\u689d\u6240\u754c\u5b9a\u7684\u524d\u77bb\u6027\u9673\u8ff0\u3002\u9664\u6b77\u53f2\u4e8b\u5be6\u9673\u8ff0\u5916\uff0c\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u6240\u6709\u5167\u5bb9\u5747\u53ef\u80fd\u69cb\u6210\u524d\u77bb\u6027\u9673\u8ff0\uff0c\u5305\u62ec\u4e9e\u76db\u91ab\u85e5\u5c0d\u672a\u4f86\u4e8b\u4ef6\u3001\u7d93\u71df\u6210\u679c\u6216\u8ca1\u52d9\u72c0\u6cc1\u6240\u767c\u8868\u7684\u610f\u898b\u3001\u9810\u671f\u3001\u4fe1\u5ff5\u3001\u8a08\u5283\u3001\u76ee\u6a19\u3001\u5047\u8a2d\u6216\u9810\u6e2c\u3002 \u9019\u4e9b\u524d\u77bb\u6027\u9673\u8ff0\u53d7\u5230\u8af8\u591a\u98a8\u96aa\u548c\u4e0d\u78ba\u5b9a\u6027\u7684\u5f71\u97ff\uff0c\u5177\u9ad4\u5167\u5bb9\u5df2\u5728\u4e9e\u76db\u91ab\u85e5\u5411\u7f8e\u570b\u8b49\u5238\u4ea4\u6613\u59d4\u54e1\u6703\uff08SEC\uff09\u63d0\u4ea4\u7684\u6587\u4ef6\u4e2d\u8a73\u7d30\u8aaa\u660e\uff0c\u5305\u62ec2025\u5e741\u670821\u65e5\u63d0\u4ea4\u7684\u7d93\u4fee\u8a02\u7684F-1\u8868\u683c\u8a3b\u518a\u8aaa\u660e\u66f8\u548c2025\u5e744\u670816\u65e5\u63d0\u4ea4\u768420-F\u8868\u683c\u4e2d\u7684\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u548c\u300c\u95dc\u65bc\u524d\u77bb\u6027\u9673\u8ff0\u53ca\u884c\u696d\u6578\u64da\u7684\u7279\u5225\u8aaa\u660e\u300d\u7ae0\u7bc0\u30012019\u5e7410\u670816\u65e5\u63d0\u4ea4\u7684\u9996\u6b21\u767c\u884c\u4e0a\u5e02\u62db\u80a1\u66f8\u4e2d\u7684\u300c\u524d\u77bb\u6027\u8072\u660e\u300d\u3001\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u7ae0\u7bc0\uff0c\u4ee5\u53ca\u6211\u5011\u4e0d\u6642\u5411SEC\u6216HKEX\u63d0\u4ea4\u7684\u5176\u4ed6\u6587\u4ef6\u3002\u9019\u4e9b\u56e0\u7d20\u53ef\u80fd\u5c0e\u81f4\u5be6\u969b\u696d\u7e3e\u3001\u904b\u71df\u6c34\u5e73\u3001\u7d93\u71df\u6210\u679c\u6216\u6210\u5c31\u8207\u524d\u77bb\u6027\u9673\u8ff0\u4e2d\u660e\u793a\u6216\u6697\u793a\u7684\u4fe1\u606f\u5b58\u5728\u91cd\u5927\u5dee\u7570\u3002\u672c\u524d\u77bb\u6027\u8072\u660e\u4e2d\u7684\u9673\u8ff0\u4e0d\u69cb\u6210\u516c\u53f8\u7ba1\u7406\u5c64\u7684\u5229\u6f64\u9810\u6e2c\u3002 \u56e0\u6b64\uff0c\u8a72\u7b49\u524d\u77bb\u6027\u9673\u8ff0\u4e0d\u61c9\u88ab\u8996\u70ba\u5c0d\u672a\u4f86\u4e8b\u4ef6\u7684\u9810\u6e2c\u3002\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u524d\u77bb\u6027\u9673\u8ff0\u50c5\u57fa\u65bc\u4e9e\u76db\u91ab\u85e5\u7576\u524d\u5c0d\u672a\u4f86\u767c\u5c55\u53ca\u5176\u6f5b\u5728\u5f71\u97ff\u7684\u9810\u671f\u548c\u5224\u65b7\uff0c\u4e14\u50c5\u4ee3\u8868\u622a\u81f3\u9673\u8ff0\u767c\u8868\u4e4b\u65e5\u7684\u89c0\u9ede\u3002\u7121\u8ad6\u51fa\u73fe\u65b0\u4fe1\u606f\u3001\u672a\u4f86\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u6cc1\uff0c\u4e9e\u76db\u91ab\u85e5\u5747\u7121\u7fa9\u52d9\u66f4\u65b0\u6216\u4fee\u8a02\u4efb\u4f55\u524d\u77bb\u6027\u9673\u8ff0\u3002\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=334269#breadcrumb\"},\"inLanguage\":\"zh-TW\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=334269\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-TW\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=334269#primaryimage\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/Ascentage_APAC_Logo-7.jpg\",\"contentUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/Ascentage_APAC_Logo-7.jpg\",\"width\":400,\"height\":150},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=334269#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u9996\u9801\",\"item\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u30102025 EHA\u3011\u4e9e\u76db\u91ab\u85e5\u6838\u5fc3\u7522\u54c1\u8010\u7acb\u514b\u00ae\u548cAPG-2575\u7b4913\u9805\u9032\u5c55\u5165\u90782025\u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703\u5e74\u6703\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#website\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/\",\"name\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\",\"description\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831PingtungTimes\uff0c\u6700\u95dc\u5fc3\u5728\u5730\u7684\u5a92\u9ad4\",\"publisher\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-TW\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#organization\",\"name\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-TW\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo-150.png\",\"contentUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo-150.png\",\"width\":150,\"height\":150,\"caption\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\"},\"image\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/pingtungnews\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/person\\\/683b937f29ec1537972f6c41e22a2cf3\",\"name\":\"\u7f8e\u901a\u793e\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-TW\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g\",\"caption\":\"\u7f8e\u901a\u793e\"},\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?author=16\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u30102025 EHA\u3011\u4e9e\u76db\u91ab\u85e5\u6838\u5fc3\u7522\u54c1\u8010\u7acb\u514b\u00ae\u548cAPG-2575\u7b4913\u9805\u9032\u5c55\u5165\u90782025\u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703\u5e74\u6703 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","description":"\u7f8e\u570b\u99ac\u91cc\u862d\u5dde\u7f85\u514b\u7dad\u723e\u5e02\u548c\u4e2d\u570b\u8607\u5dde 2025\u5e746\u670810\u65e5 \u00a0\/\u7f8e\u901a\u793e\/ -- \u81f4\u529b\u65bc\u5728\u816b\u7624\u7b49\u9818\u57df\u958b\u767c\u5275\u65b0\u85e5\u7269\u7684\u9818\u5148\u7684\u751f\u7269\u91ab\u85e5\u4f01\u696d\u2014\u2014\u4e9e\u76db\u91ab\u85e5\uff08\u7d0d\u65af\u9054\u514b\u4ee3\u78bc\uff1aAAPG\uff1b\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a6855\uff09\u5ba3\u5e03\uff0c\u6d89\u53ca\u516c\u53f8\u539f\u52751\u985e\u65b0\u85e5\u5967\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff09\u3001Bcl-2\u6291\u5236\u5291APG-2575\u3001EED\u6291\u5236\u5291APG-5918\u7b49\u91cd\u78c5\u54c1\u7a2e\u768413\u9805\u7814\u7a76\u9032\u5c55\u5c07\u57282025\u5e746\u670812\u65e5\u81f315\u65e5\u65bc\u610f\u5927\u5229\u7c73\u862d\u8209\u884c\u76842025\u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703\uff08EHA\uff09\u5e74\u6703\u4e0a\u516c\u5e03\uff0c\u5176\u4e2d\u5305\u62ec1\u9805\u53e3\u982d\u5831\u544a\uff0c\u53ca\u591a\u9805\u58c1\u5831\u5c55\u793a\u548c\u7dda\u4e0a\u767c\u8868\u3002 EHA\u5e74\u6703\u4f5c\u70ba\u6b50\u6d32\u8840\u6db2\u5b78\u9818\u57df\u898f\u6a21\u6700\u5927\u7684\u570b\u969b\u6703\u8b70\uff0c\u6bcf\u5e74\u5438\u5f15\u4f86\u81ea\u5168\u7403100\u591a\u500b\u570b\u5bb6\u76841\u842c\u591a\u540d\u5c08\u696d\u4eba\u58eb\u8207\u6703\uff0c\u5206\u4eab\u5168\u7403\u6700\u524d\u6cbf\u7684\u7814\u7a76\u9032\u5c55\u548c\u7a81\u7834\u6027\u81e8\u5e8a\u6578\u64da\u3002 \u53e3\u982d\u5831\u544a Integrating Genomic and Transcriptomic Insights for Predicting Responses and Outcomes in Patients with CML Receiving 3rd-Generation TKI Therapy\u6574\u5408\u57fa\u56e0\u7d44\u548c\u8f49\u9304\u7d44\u5b78\u898b\u89e3\u4ee5\u9810\u6e2c\u63a5\u53d7\u4e09\u4ee3TKI\u6cbb\u7642\u7684CML\u60a3\u8005\u7684\u7642\u6548\u548c\u7d50\u5c40 \u6458\u8981\u7de8\u865f\uff1aS162 \u5206\u6703\u5834\uff1aCML\u6cbb\u7642\u7642\u6548\u53ca\u8010\u85e5\u7684\u751f\u7269\u5b78\uff08Biology of CML treatment response and resistance\uff09 \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u665a\u4e0a23:30-23:45\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u4e0b\u534817:30-17:45\uff09 \u4e3b\u8981\u4f5c\u8005\uff1a\u5317\u4eac\u5927\u5b78\u4eba\u6c11\u91ab\u9662\u6c5f\u5029\u6559\u6388\uff0c\u5317\u4eac\u5927\u5b78\u4eba\u6c11\u91ab\u9662\u5f35\u5c0f\u5e25 \u58c1\u5831\u5c55\u793a Frontline Chemotherapy-Free Combination of Olverembatinib with Venetoclax and Azacitidine in Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia: Preliminary Outcomes of a Prospective Study\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u7dad\u5948\u514b\u62c9\u8207\u963f\u624e\u80de\u7518\u7528\u65bc\u7121\u5316\u7642\u4e00\u7dda\u6cbb\u7642\u65b0\u8a3a\u65b7\u7684Ph+\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff1a\u4e00\u9805\u524d\u77bb\u6027\u7814\u7a76\u7684\u521d\u6b65\u7d50\u679c \u6458\u8981\u7de8\u865f\uff1aPF384 \u5206\u6703\u5834\uff1a\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76\uff08Acute lymphoblastic leukemia - Clinical\uff09 \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u51cc\u666800:30-01:30\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670813\u65e5\uff0c\u5468\u4e94\uff0c\u665a\u4e0a18:30-19:30\uff09 \u4e3b\u8981\u4f5c\u8005\uff1a\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662\u5510\u66c9\u6587\u6559\u6388\uff0c\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662\u5f35\u6b23 A Phase 2 Study of Olverembatinib for the Treatment of Myeloid\/Lymphoid Neoplasms with FGFR1 Rearrangement\u4e00\u9805\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u7528\u65bc\u6cbb\u7642\u4f34FGFR1\u91cd\u6392\u7684\u9ad3\u7cfb\/\u6dcb\u5df4\u7cfb\u816b\u7624\u7684II\u671f\u7814\u7a76 \u6458\u8981\u7de8\u865f\uff1aPF390 \u5206\u6703\u5834\uff1a\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76\uff08Acute lymphoblastic leukemia - Clinical\uff09 \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u51cc\u666800:30-01:30\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670813\u65e5\uff0c\u5468\u4e94\uff0c\u665a\u4e0a18:30-19:30\uff09 \u4e3b\u8981\u4f5c\u8005\uff1a\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662\u9673\u8607\u5be7\u6559\u6388\uff0c\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662\u8521\u6587\u6cbb Efficacy and Safety of Regimen with Olverembatinib and Blinatumomab for the Frontline Treatment of Ph-Positive or Ph-Like Acute Lymphoblastic Leukemia\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u8c9d\u6797\u59a5\u6b50\u55ae\u6297\u4e00\u7dda\u6cbb\u7642\u8cbb\u57ce\u67d3\u8272\u9ad4\uff08Ph\uff09\u967d\u6027\u6216Ph\u6a23\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\u7684\u7642\u6548\u548c\u5b89\u5168\u6027 \u6458\u8981\u7de8\u865f\uff1aPS1367 \u5206\u6703\u5834\uff1a\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76\uff08Acute lymphoblastic leukemia - Clinical\uff09 \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670815\u65e5\uff0c\u5468\u65e5\uff0c\u51cc\u666800:30-01:30\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u665a\u4e0a18:30-19:30 \uff09 \u4e3b\u8981\u4f5c\u8005\uff1a\u5357\u65b9\u91ab\u79d1\u5927\u5b78\u5357\u65b9\u91ab\u9662\u5468\u7d05\u5347\u6559\u6388\uff0c\u5357\u65b9\u91ab\u79d1\u5927\u5b78\u5357\u65b9\u91ab\u9662\u8a31\u79c0\u9e97 Combination of Olverembatinib and VP Regimen as First-Line Therapy for Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Single-Arm, Multicentre, Phase 2 Trial\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408VP\u65b9\u6848\u4e00\u7dda\u6cbb\u7642\u6210\u4eba\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff1a\u4e00\u9805\u55ae\u81c2\u3001\u591a\u4e2d\u5fc3II\u671f\u7814\u7a76 \u6458\u8981\u7de8\u865f\uff1aPS1372 \u5206\u6703\u5834\uff1a\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76\uff08Acute lymphoblastic leukemia - Clinical\uff09 \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670815\u65e5\uff0c\u5468\u65e5\uff0c\u51cc\u666800:30-01:30\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u665a\u4e0a18:30-19:30\uff09 \u4e3b\u8981\u4f5c\u8005\uff1a\u6d59\u6c5f\u5927\u5b78\u91ab\u5b78\u9662\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662\u91d1\u6f54\u6559\u6388\uff0c\u6d59\u6c5f\u5927\u5b78\u91ab\u5b78\u9662\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662\u8a31\u6539\u9999 Efficacy and Safety of The Third-Generation Tyrosine Kinase Inhibitor Olverembatinib in Combination with Inotuzumab Ozogamicin for the Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients With Relapsed Disease or Persistent Minimal Residual Disease Bridging to Hematopoietic Stem Cell Transplantation: A Phase II Study\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u5967\u52a0\u4f0a\u59a5\u73e0\u55ae\u6297\u6cbb\u7642\u5fa9\u767c\u6216\u9020\u8840\u5e72\u7d30\u80de\u79fb\u690d\u524d\u6301\u7e8cMRD\u967d\u6027\u6210\u4ebaPh+ ALL\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\uff1a\u4e00\u9805\u2161\u671f\u7814\u7a76 \u6458\u8981\u7de8\u865f\uff1aPS1387 \u5206\u6703\u5834\uff1a\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76\uff08Acute lymphoblastic leukemia - Clinical\uff09 \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670815\u65e5\uff0c\u5468\u65e5\uff0c\u51cc\u666800:30-01:30\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u665a\u4e0a18:30-19:30\uff09 \u4e3b\u8981\u4f5c\u8005\uff1a\u4e2d\u570b\u91ab\u5b78\u79d1\u5b78\u9662\u5317\u4eac\u5354\u548c\u91ab\u5b78\u9662\u8840\u6db2\u75c5\u91ab\u9662\u59dc\u723e\u70c8\u6559\u6388\uff0c\u4e2d\u570b\u91ab\u5b78\u79d1\u5b78\u9662\u5317\u4eac\u5354\u548c\u91ab\u5b78\u9662\u8840\u6db2\u75c5\u91ab\u9662\u5f35\u701f\u4e88 Embryonic Ectoderm Development (EED) Inhibitor APG-5918 Exhibits Potent Antitumor Activity and Synergizes with Histone Deacetylase Inhibitor Tucidinostat in PreclinicalT-Cell Lymphoma (TCL) Models\u80da\u80ce\u5916\u80da\u5c64\u767c\u80b2\u86cb\u767d\uff08EED\uff09\u6291\u5236\u5291APG-5918\u5728T\u7d30\u80de\u6dcb\u5df4\u7624\uff08TCL\uff09\u81e8\u5e8a\u524d\u6a21\u578b\u4e2d\u5c55\u73fe\u5f37\u6548\u6297\u816b\u7624\u6d3b\u6027\uff0c\u4e26\u8207\u7d44\u86cb\u767d\u53bb\u4e59\u9170\u5316\u9176\u6291\u5236\u5291\u897f\u9054\u672c\u80fa\u5354\u540c\u589e\u6548 \u6458\u8981\u7de8\u865f\uff1aPS1993 \u5206\u6703\u5834\uff1a\u6dcb\u5df4\u7624\u751f\u7269\u5b78\u8207\u8f49\u5316\u7814\u7a76\uff08Lymphoma biology & translational research\uff09 \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670815\u65e5\uff0c\u5468\u65e5\uff0c\u51cc\u666800:30-01:30\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u665a\u4e0a18:30-19:30\uff09 \u4e3b\u8981\u4f5c\u8005\uff1a\u4e9e\u76db\u91ab\u85e5Eric Liang\u535a\u58eb \u5728\u7dda\u767c\u5e03 Alternating Low-Dose Inotuzumab Ozogamicin and Blinatumomab in Maintenance Therapy for Ph+ ALL: A Single-Center Retrospective Analysis\u4f4e\u5291\u91cf\u5967\u52a0\u4f0a\u59a5\u73e0\u55ae\u6297\u548c\u8c9d\u6797\u59a5\u6b50\u55ae\u6297\u4ea4\u66ff\u7dad\u6301\u6cbb\u7642\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\uff08Ph+\uff09\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08ALL\uff09\uff1a\u4e00\u9805\u55ae\u4e2d\u5fc3\u56de\u9867\u6027\u5206\u6790 \u6458\u8981\u7de8\u865f\uff1aPB2384 \u4e3b\u8981\u4f5c\u8005\uff1a\u6cb3\u5317\u91ab\u79d1\u5927\u5b78\u7b2c\u4e8c\u91ab\u9662\u8076\u5b50\u5143\u6559\u6388 Efficacy and Safety of Blinatumomab in Newly-Diagnosed Patients with Ph-Positive\/Negative B-Cell Acute Lymphoblastic Leukemia\u8c9d\u6797\u59a5\u6b50\u55ae\u6297\u6cbb\u7642\u65b0\u78ba\u8a3a\u7684 Ph \u967d\u6027\/\u9670\u6027 B \u7d30\u80de\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\u60a3\u8005\u7684\u7642\u6548\u548c\u5b89\u5168\u6027 \u6458\u8981\u7de8\u865f\uff1aPB2363 \u4e3b\u8981\u4f5c\u8005\uff1a\u83ef\u4e2d\u79d1\u6280\u5927\u5b78\u540c\u6fdf\u91ab\u5b78\u9662\u9644\u5c6c\u5354\u548c\u91ab\u9662\u5f35\u5bc5\u5b19 Efficacy and Safety of the Third-Generation TKI Olverembatinib in Relapsed and Persistent MRD Positive Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients\u7b2c\u4e09\u4ee3TKI\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u5fa9\u767c\u548c\u6301\u7e8cMRD\u967d\u6027\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\u60a3\u8005\u7684\u7642\u6548\u8207\u5b89\u5168\u6027 \u6458\u8981\u7de8\u865f\uff1aPB2360 \u4e3b\u8981\u4f5c\u8005\uff1a\u6cb3\u5317\u91ab\u79d1\u5927\u5b78\u7b2c\u4e8c\u91ab\u9662\u8523\u854a\u6eab Clinical Features and Genetic Abnormalities Predict Outcomes in Patients with Chronic Myeloid Leukemia in the Accelerated-Phase Receiving Olverembatinib Therapy: A Retrospective Multicenter Study\u81e8\u5e8a\u7279\u5fb5\u548c\u57fa\u56e0\u7570\u5e38\u7528\u65bc\u9810\u6e2c\u63a5\u53d7\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7684\u52a0\u901f\u671f\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u60a3\u8005\u7684\u6cbb\u7642\u7d50\u5c40\uff1a\u4e00\u9805\u56de\u9867\u6027\u591a\u4e2d\u5fc3\u7814\u7a76 \u6458\u8981\u7de8\u865f\uff1aPB2701 \u4e3b\u8981\u4f5c\u8005\uff1a\u5317\u4eac\u5927\u5b78\u4eba\u6c11\u91ab\u9662\u539f\u5922\u7464 A Real-World Study of Olverembatinib in the Treatment of Chronic Myeloid Leukemia from China: A Single-Center Retrospective Study\u4e00\u9805\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u7528\u65bc\u6cbb\u7642\u4e2d\u570b\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u60a3\u8005\u7684\u771f\u5be6\u4e16\u754c\u7814\u7a76\uff1a\u4e00\u9805\u55ae\u4e2d\u5fc3\u56de\u9867\u6027\u7814\u7a76 \u6458\u8981\u7de8\u865f\uff1aPB2714 \u4e3b\u8981\u4f5c\u8005\uff1a\u56db\u5ddd\u5927\u5b78\u83ef\u897f\u91ab\u9662\u8463\u5929 Synergistic Effects of Olverembatinib (HQP1351) Combined with Bcl-2 Inhibitor Lisaftoclax (APG-2575) and Bcl-2\/Bcl-xL Inhibitor Pelcitoclax (APG-1252) in T-Cell Acute Lymphoblastic Leukemia (T-ALL)\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u806f\u5408Bcl-2\u6291\u5236\u5291lisaftoclax\uff08APG-2575\uff09\u548cBcl-2\/Bcl-xL\u6291\u5236\u5291pelcitoclax\uff08APG-1252\uff09\u5728T\u7d30\u80de\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08T-ALL\uff09\u4e2d\u7684\u5354\u540c\u4f5c\u7528 \u6458\u8981\u7de8\u865f\uff1aPB2341 \u4e3b\u8981\u4f5c\u8005\uff1a\u4e9e\u76db\u91ab\u85e5\u5f6d\u6ce2 \u95dc\u65bc\u4e9e\u76db\u91ab\u85e5 \u4e9e\u76db\u91ab\u85e5\u662f\u4e00\u5bb6\u7d9c\u5408\u6027\u7684\u5168\u7403\u751f\u7269\u91ab\u85e5\u4f01\u696d\uff0c\u81f4\u529b\u65bc\u7814\u767c\u5275\u65b0\u85e5\uff0c\u4ee5\u89e3\u6c7a\u816b\u7624\u7b49\u9818\u57df\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u30022019\u5e7410\u670828\u65e5\uff0c\u516c\u53f8\u5728\u9999\u6e2f\u806f\u4ea4\u6240\u4e3b\u677f\u639b\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u78bc\uff1a6855.HK\uff1b2025\u5e741\u670824\u65e5\uff0c\u516c\u53f8\u5728\u7f8e\u570b\u7d0d\u65af\u9054\u514b\u8b49\u5238\u4ea4\u6613\u6240\u639b\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u78bc\uff1aAAPG\u3002 \u4e9e\u76db\u91ab\u85e5\u5df2\u5efa\u7acb\u8c50\u5bcc\u7684\u5275\u65b0\u85e5\u7522\u54c1\u7ba1\u7dda\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u548c MDM2-p53 \u7b49\u7d30\u80de\u51cb\u4ea1\u901a\u8def\u95dc\u9375\u86cb\u767d\u7684\u6291\u5236\u5291\uff1b\u65b0\u4e00\u4ee3\u91dd\u5c0d\u764c\u75c7\u6cbb\u7642\u4e2d\u51fa\u73fe\u7684\u6fc0\u9176\u7a81\u8b8a\u9ad4\u7684\u6291\u5236\u5291\u7b49\u3002 \u516c\u53f8\u6838\u5fc3\u54c1\u7a2e\u8010\u7acb\u514b\u00ae\u662f\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\uff0c\u4e14\u7372\u6279\u9069\u61c9\u75c7\u5747\u88ab\u6210\u529f\u7d0d\u5165\u570b\u5bb6\u91ab\u4fdd\u85e5\u54c1\u76ee\u9304\uff0c\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u8010\u7acb\u514b\u00ae\u4e00\u9805\u7372\u7f8e\u570bFDA\u8a31\u53ef\u7684\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff08POLARIS-2\uff09\uff0c\u7528\u65bc\u6cbb\u7642\u65e2\u5f80\u63a5\u53d7\u904e\u6cbb\u7642\u7684\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CML-CP\uff09\u6210\u5e74\u60a3\u8005\u3002\u6b64\u5916\uff0c\u8010\u7acb\u514b\u00ae\u806f\u5408\u6cbb\u7642\u65b0\u8a3a\u65b7\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u60a3\u8005\u548c\u6cbb\u7642\u7425\u73c0\u9178\u812b\u6c2b\u9176\uff08SDH\uff09\u7f3a\u9677\u578b\u80c3\u8178\u9053\u9593\u8cea\u7624\uff08GIST\uff09\u60a3\u8005\u7684\u5168\u7403\u8a3b\u518aIII\u671f\u7814\u7a76\u6b63\u5728\u958b\u5c55\u4e2d\u3002 \u516c\u53f8\u53e6\u4e00\u91cd\u78c5\u54c1\u7a2e\uff0c\u65b0\u578bBcl-2\u9078\u64c7\u6027\u6291\u5236\u5291APG-2575\uff08Lisaftoclax\uff09\u7684\u65b0\u85e5\u4e0a\u5e02\u7533\u8acb\uff08NDA\uff09\u5df2\u7372CDE\u53d7\u7406\uff0c\u4e26\u88ab\u7d0d\u5165\u512a\u5148\u5be9\u8a55\u3002\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55APG-2575\uff08Lisaftoclax\uff09\u56db\u9805\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u5206\u5225\u70ba\u7372\u7f8e\u570bFDA\u8a31\u53ef\u7684\u6cbb\u7642\u7d93\u6cbb\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u7684\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff08GLORA\uff09\uff1b\u6cbb\u7642\u521d\u6cbbCLL\/SLL\u60a3\u8005\u7684\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff1b\u4e00\u7dda\u6cbb\u7642\u65b0\u8a3a\u65b7\u8001\u5e74\u6216\u9ad4\u5f31\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08AML\uff09\u7684\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff1b\u4ee5\u53ca\u6cbb\u7642\u65b0\u8a3a\u65b7\u4e2d\u9ad8\u5371\u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u75c7\uff08MDS\uff09\u60a3\u8005\u7684\u8a3b\u518aIII\u671f\u7814\u7a76\u3002 \u622a\u81f3\u76ee\u524d\uff0c\u516c\u53f84\u500b\u5728\u7814\u65b0\u85e5\u5171\u737216\u9805FDA\u548c1\u9805\u6b50\u76df\u5b64\u5152\u85e5\u8cc7\u683c\u8a8d\u5b9a\uff0c2\u9805FDA\u5feb\u901f\u901a\u9053\u8cc7\u683c\u4ee5\u53ca2\u9805FDA\u5152\u7ae5\u7f55\u898b\u75c5\u8cc7\u683c\u8a8d\u8b49\u3002\u6191\u501f\u5f37\u5927\u7684\u7814\u767c\u80fd\u529b\uff0c\u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u5168\u7403\u7bc4\u570d\u5167\u9032\u884c\u77e5\u8b58\u7522\u6b0a\u5e03\u5c40\uff0c\u4e26\u8207\u6b66\u7530\u3001\u9ed8\u6c99\u6771\u3001\u963f\u65af\u5229\u5eb7\u3001\u8f1d\u745e\u3001\u4fe1\u9054\u7b49\u9818\u5148\u7684\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u4ee5\u53ca\u6885\u5967\u91ab\u5b78\u4e2d\u5fc3\uff08Mayo Clinic\uff09\u3001\u4e39\u5a1c\u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662\uff08Dana-Farber Cancer Institute\uff09\u3001\u7f8e\u570b\u570b\u5bb6\u764c\u75c7\u7814\u7a76\u6240\uff08NCI\uff09\u548c\u5bc6\u897f\u6839\u5927\u5b78\u7b49\u5b78\u8853\u6a5f\u69cb\u9054\u6210\u5168\u7403\u5408\u4f5c\u95dc\u4fc2\u3002 \u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u539f\u5275\u65b0\u85e5\u7814\u767c\u8207\u81e8\u5e8a\u958b\u767c\u9818\u57df\u5efa\u7acb\u7d93\u9a57\u8c50\u5bcc\u7684\u570b\u969b\u5316\u4eba\u624d\u5718\u968a\uff0c\u4ee5\u53ca\u6210\u719f\u7684\u5546\u696d\u5316\u751f\u7522\u8207\u5e02\u5834\u71df\u92b7\u5718\u968a\u3002\u4e9e\u76db\u91ab\u85e5\u5c07\u4e0d\u65b7\u63d0\u9ad8\u7814\u767c\u80fd\u529b\uff0c\u52a0\u901f\u63a8\u9032\u516c\u53f8\u7522\u54c1\u7ba1\u7dda\u7684\u81e8\u5e8a\u958b\u767c\u9032\u5ea6\uff0c\u771f\u6b63\u8e10\u884c\u300c\u89e3\u6c7a\u4e2d\u570b\u4e43\u81f3\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u300d\u7684\u4f7f\u547d\uff0c\u4ee5\u9020\u798f\u66f4\u591a\u60a3\u8005\u3002 \u524d\u77bb\u6027\u8072\u660e \u672c\u65b0\u805e\u7a3f\u5305\u542b\u6839\u64da\u7f8e\u570b\u300a1995\u5e74\u79c1\u4eba\u8b49\u5238\u8a34\u8a1f\u6539\u9769\u6cd5\u6848\u300b\uff0c\u4ee5\u53ca\u7d93\u4fee\u8a02\u7684\u300a1933\u5e74\u8b49\u5238\u6cd5\u300b\u7b2c27A\u689d\u548c\u300a1934\u5e74\u8b49\u5238\u4ea4\u6613\u6cd5\u300b\u7b2c21E\u689d\u6240\u754c\u5b9a\u7684\u524d\u77bb\u6027\u9673\u8ff0\u3002\u9664\u6b77\u53f2\u4e8b\u5be6\u9673\u8ff0\u5916\uff0c\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u6240\u6709\u5167\u5bb9\u5747\u53ef\u80fd\u69cb\u6210\u524d\u77bb\u6027\u9673\u8ff0\uff0c\u5305\u62ec\u4e9e\u76db\u91ab\u85e5\u5c0d\u672a\u4f86\u4e8b\u4ef6\u3001\u7d93\u71df\u6210\u679c\u6216\u8ca1\u52d9\u72c0\u6cc1\u6240\u767c\u8868\u7684\u610f\u898b\u3001\u9810\u671f\u3001\u4fe1\u5ff5\u3001\u8a08\u5283\u3001\u76ee\u6a19\u3001\u5047\u8a2d\u6216\u9810\u6e2c\u3002 \u9019\u4e9b\u524d\u77bb\u6027\u9673\u8ff0\u53d7\u5230\u8af8\u591a\u98a8\u96aa\u548c\u4e0d\u78ba\u5b9a\u6027\u7684\u5f71\u97ff\uff0c\u5177\u9ad4\u5167\u5bb9\u5df2\u5728\u4e9e\u76db\u91ab\u85e5\u5411\u7f8e\u570b\u8b49\u5238\u4ea4\u6613\u59d4\u54e1\u6703\uff08SEC\uff09\u63d0\u4ea4\u7684\u6587\u4ef6\u4e2d\u8a73\u7d30\u8aaa\u660e\uff0c\u5305\u62ec2025\u5e741\u670821\u65e5\u63d0\u4ea4\u7684\u7d93\u4fee\u8a02\u7684F-1\u8868\u683c\u8a3b\u518a\u8aaa\u660e\u66f8\u548c2025\u5e744\u670816\u65e5\u63d0\u4ea4\u768420-F\u8868\u683c\u4e2d\u7684\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u548c\u300c\u95dc\u65bc\u524d\u77bb\u6027\u9673\u8ff0\u53ca\u884c\u696d\u6578\u64da\u7684\u7279\u5225\u8aaa\u660e\u300d\u7ae0\u7bc0\u30012019\u5e7410\u670816\u65e5\u63d0\u4ea4\u7684\u9996\u6b21\u767c\u884c\u4e0a\u5e02\u62db\u80a1\u66f8\u4e2d\u7684\u300c\u524d\u77bb\u6027\u8072\u660e\u300d\u3001\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u7ae0\u7bc0\uff0c\u4ee5\u53ca\u6211\u5011\u4e0d\u6642\u5411SEC\u6216HKEX\u63d0\u4ea4\u7684\u5176\u4ed6\u6587\u4ef6\u3002\u9019\u4e9b\u56e0\u7d20\u53ef\u80fd\u5c0e\u81f4\u5be6\u969b\u696d\u7e3e\u3001\u904b\u71df\u6c34\u5e73\u3001\u7d93\u71df\u6210\u679c\u6216\u6210\u5c31\u8207\u524d\u77bb\u6027\u9673\u8ff0\u4e2d\u660e\u793a\u6216\u6697\u793a\u7684\u4fe1\u606f\u5b58\u5728\u91cd\u5927\u5dee\u7570\u3002\u672c\u524d\u77bb\u6027\u8072\u660e\u4e2d\u7684\u9673\u8ff0\u4e0d\u69cb\u6210\u516c\u53f8\u7ba1\u7406\u5c64\u7684\u5229\u6f64\u9810\u6e2c\u3002 \u56e0\u6b64\uff0c\u8a72\u7b49\u524d\u77bb\u6027\u9673\u8ff0\u4e0d\u61c9\u88ab\u8996\u70ba\u5c0d\u672a\u4f86\u4e8b\u4ef6\u7684\u9810\u6e2c\u3002\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u524d\u77bb\u6027\u9673\u8ff0\u50c5\u57fa\u65bc\u4e9e\u76db\u91ab\u85e5\u7576\u524d\u5c0d\u672a\u4f86\u767c\u5c55\u53ca\u5176\u6f5b\u5728\u5f71\u97ff\u7684\u9810\u671f\u548c\u5224\u65b7\uff0c\u4e14\u50c5\u4ee3\u8868\u622a\u81f3\u9673\u8ff0\u767c\u8868\u4e4b\u65e5\u7684\u89c0\u9ede\u3002\u7121\u8ad6\u51fa\u73fe\u65b0\u4fe1\u606f\u3001\u672a\u4f86\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u6cc1\uff0c\u4e9e\u76db\u91ab\u85e5\u5747\u7121\u7fa9\u52d9\u66f4\u65b0\u6216\u4fee\u8a02\u4efb\u4f55\u524d\u77bb\u6027\u9673\u8ff0\u3002","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pingtungtimes.com.tw\/?p=334269","og_locale":"zh_TW","og_type":"article","og_title":"\u30102025 EHA\u3011\u4e9e\u76db\u91ab\u85e5\u6838\u5fc3\u7522\u54c1\u8010\u7acb\u514b\u00ae\u548cAPG-2575\u7b4913\u9805\u9032\u5c55\u5165\u90782025\u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703\u5e74\u6703 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","og_description":"\u7f8e\u570b\u99ac\u91cc\u862d\u5dde\u7f85\u514b\u7dad\u723e\u5e02\u548c\u4e2d\u570b\u8607\u5dde 2025\u5e746\u670810\u65e5 \u00a0\/\u7f8e\u901a\u793e\/ -- \u81f4\u529b\u65bc\u5728\u816b\u7624\u7b49\u9818\u57df\u958b\u767c\u5275\u65b0\u85e5\u7269\u7684\u9818\u5148\u7684\u751f\u7269\u91ab\u85e5\u4f01\u696d\u2014\u2014\u4e9e\u76db\u91ab\u85e5\uff08\u7d0d\u65af\u9054\u514b\u4ee3\u78bc\uff1aAAPG\uff1b\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a6855\uff09\u5ba3\u5e03\uff0c\u6d89\u53ca\u516c\u53f8\u539f\u52751\u985e\u65b0\u85e5\u5967\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff09\u3001Bcl-2\u6291\u5236\u5291APG-2575\u3001EED\u6291\u5236\u5291APG-5918\u7b49\u91cd\u78c5\u54c1\u7a2e\u768413\u9805\u7814\u7a76\u9032\u5c55\u5c07\u57282025\u5e746\u670812\u65e5\u81f315\u65e5\u65bc\u610f\u5927\u5229\u7c73\u862d\u8209\u884c\u76842025\u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703\uff08EHA\uff09\u5e74\u6703\u4e0a\u516c\u5e03\uff0c\u5176\u4e2d\u5305\u62ec1\u9805\u53e3\u982d\u5831\u544a\uff0c\u53ca\u591a\u9805\u58c1\u5831\u5c55\u793a\u548c\u7dda\u4e0a\u767c\u8868\u3002 EHA\u5e74\u6703\u4f5c\u70ba\u6b50\u6d32\u8840\u6db2\u5b78\u9818\u57df\u898f\u6a21\u6700\u5927\u7684\u570b\u969b\u6703\u8b70\uff0c\u6bcf\u5e74\u5438\u5f15\u4f86\u81ea\u5168\u7403100\u591a\u500b\u570b\u5bb6\u76841\u842c\u591a\u540d\u5c08\u696d\u4eba\u58eb\u8207\u6703\uff0c\u5206\u4eab\u5168\u7403\u6700\u524d\u6cbf\u7684\u7814\u7a76\u9032\u5c55\u548c\u7a81\u7834\u6027\u81e8\u5e8a\u6578\u64da\u3002 \u53e3\u982d\u5831\u544a Integrating Genomic and Transcriptomic Insights for Predicting Responses and Outcomes in Patients with CML Receiving 3rd-Generation TKI Therapy\u6574\u5408\u57fa\u56e0\u7d44\u548c\u8f49\u9304\u7d44\u5b78\u898b\u89e3\u4ee5\u9810\u6e2c\u63a5\u53d7\u4e09\u4ee3TKI\u6cbb\u7642\u7684CML\u60a3\u8005\u7684\u7642\u6548\u548c\u7d50\u5c40 \u6458\u8981\u7de8\u865f\uff1aS162 \u5206\u6703\u5834\uff1aCML\u6cbb\u7642\u7642\u6548\u53ca\u8010\u85e5\u7684\u751f\u7269\u5b78\uff08Biology of CML treatment response and resistance\uff09 \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u665a\u4e0a23:30-23:45\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u4e0b\u534817:30-17:45\uff09 \u4e3b\u8981\u4f5c\u8005\uff1a\u5317\u4eac\u5927\u5b78\u4eba\u6c11\u91ab\u9662\u6c5f\u5029\u6559\u6388\uff0c\u5317\u4eac\u5927\u5b78\u4eba\u6c11\u91ab\u9662\u5f35\u5c0f\u5e25 \u58c1\u5831\u5c55\u793a Frontline Chemotherapy-Free Combination of Olverembatinib with Venetoclax and Azacitidine in Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia: Preliminary Outcomes of a Prospective Study\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u7dad\u5948\u514b\u62c9\u8207\u963f\u624e\u80de\u7518\u7528\u65bc\u7121\u5316\u7642\u4e00\u7dda\u6cbb\u7642\u65b0\u8a3a\u65b7\u7684Ph+\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff1a\u4e00\u9805\u524d\u77bb\u6027\u7814\u7a76\u7684\u521d\u6b65\u7d50\u679c \u6458\u8981\u7de8\u865f\uff1aPF384 \u5206\u6703\u5834\uff1a\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76\uff08Acute lymphoblastic leukemia - Clinical\uff09 \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u51cc\u666800:30-01:30\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670813\u65e5\uff0c\u5468\u4e94\uff0c\u665a\u4e0a18:30-19:30\uff09 \u4e3b\u8981\u4f5c\u8005\uff1a\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662\u5510\u66c9\u6587\u6559\u6388\uff0c\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662\u5f35\u6b23 A Phase 2 Study of Olverembatinib for the Treatment of Myeloid\/Lymphoid Neoplasms with FGFR1 Rearrangement\u4e00\u9805\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u7528\u65bc\u6cbb\u7642\u4f34FGFR1\u91cd\u6392\u7684\u9ad3\u7cfb\/\u6dcb\u5df4\u7cfb\u816b\u7624\u7684II\u671f\u7814\u7a76 \u6458\u8981\u7de8\u865f\uff1aPF390 \u5206\u6703\u5834\uff1a\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76\uff08Acute lymphoblastic leukemia - Clinical\uff09 \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u51cc\u666800:30-01:30\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670813\u65e5\uff0c\u5468\u4e94\uff0c\u665a\u4e0a18:30-19:30\uff09 \u4e3b\u8981\u4f5c\u8005\uff1a\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662\u9673\u8607\u5be7\u6559\u6388\uff0c\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662\u8521\u6587\u6cbb Efficacy and Safety of Regimen with Olverembatinib and Blinatumomab for the Frontline Treatment of Ph-Positive or Ph-Like Acute Lymphoblastic Leukemia\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u8c9d\u6797\u59a5\u6b50\u55ae\u6297\u4e00\u7dda\u6cbb\u7642\u8cbb\u57ce\u67d3\u8272\u9ad4\uff08Ph\uff09\u967d\u6027\u6216Ph\u6a23\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\u7684\u7642\u6548\u548c\u5b89\u5168\u6027 \u6458\u8981\u7de8\u865f\uff1aPS1367 \u5206\u6703\u5834\uff1a\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76\uff08Acute lymphoblastic leukemia - Clinical\uff09 \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670815\u65e5\uff0c\u5468\u65e5\uff0c\u51cc\u666800:30-01:30\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u665a\u4e0a18:30-19:30 \uff09 \u4e3b\u8981\u4f5c\u8005\uff1a\u5357\u65b9\u91ab\u79d1\u5927\u5b78\u5357\u65b9\u91ab\u9662\u5468\u7d05\u5347\u6559\u6388\uff0c\u5357\u65b9\u91ab\u79d1\u5927\u5b78\u5357\u65b9\u91ab\u9662\u8a31\u79c0\u9e97 Combination of Olverembatinib and VP Regimen as First-Line Therapy for Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Single-Arm, Multicentre, Phase 2 Trial\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408VP\u65b9\u6848\u4e00\u7dda\u6cbb\u7642\u6210\u4eba\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff1a\u4e00\u9805\u55ae\u81c2\u3001\u591a\u4e2d\u5fc3II\u671f\u7814\u7a76 \u6458\u8981\u7de8\u865f\uff1aPS1372 \u5206\u6703\u5834\uff1a\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76\uff08Acute lymphoblastic leukemia - Clinical\uff09 \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670815\u65e5\uff0c\u5468\u65e5\uff0c\u51cc\u666800:30-01:30\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u665a\u4e0a18:30-19:30\uff09 \u4e3b\u8981\u4f5c\u8005\uff1a\u6d59\u6c5f\u5927\u5b78\u91ab\u5b78\u9662\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662\u91d1\u6f54\u6559\u6388\uff0c\u6d59\u6c5f\u5927\u5b78\u91ab\u5b78\u9662\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662\u8a31\u6539\u9999 Efficacy and Safety of The Third-Generation Tyrosine Kinase Inhibitor Olverembatinib in Combination with Inotuzumab Ozogamicin for the Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients With Relapsed Disease or Persistent Minimal Residual Disease Bridging to Hematopoietic Stem Cell Transplantation: A Phase II Study\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u5967\u52a0\u4f0a\u59a5\u73e0\u55ae\u6297\u6cbb\u7642\u5fa9\u767c\u6216\u9020\u8840\u5e72\u7d30\u80de\u79fb\u690d\u524d\u6301\u7e8cMRD\u967d\u6027\u6210\u4ebaPh+ ALL\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\uff1a\u4e00\u9805\u2161\u671f\u7814\u7a76 \u6458\u8981\u7de8\u865f\uff1aPS1387 \u5206\u6703\u5834\uff1a\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76\uff08Acute lymphoblastic leukemia - Clinical\uff09 \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670815\u65e5\uff0c\u5468\u65e5\uff0c\u51cc\u666800:30-01:30\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u665a\u4e0a18:30-19:30\uff09 \u4e3b\u8981\u4f5c\u8005\uff1a\u4e2d\u570b\u91ab\u5b78\u79d1\u5b78\u9662\u5317\u4eac\u5354\u548c\u91ab\u5b78\u9662\u8840\u6db2\u75c5\u91ab\u9662\u59dc\u723e\u70c8\u6559\u6388\uff0c\u4e2d\u570b\u91ab\u5b78\u79d1\u5b78\u9662\u5317\u4eac\u5354\u548c\u91ab\u5b78\u9662\u8840\u6db2\u75c5\u91ab\u9662\u5f35\u701f\u4e88 Embryonic Ectoderm Development (EED) Inhibitor APG-5918 Exhibits Potent Antitumor Activity and Synergizes with Histone Deacetylase Inhibitor Tucidinostat in PreclinicalT-Cell Lymphoma (TCL) Models\u80da\u80ce\u5916\u80da\u5c64\u767c\u80b2\u86cb\u767d\uff08EED\uff09\u6291\u5236\u5291APG-5918\u5728T\u7d30\u80de\u6dcb\u5df4\u7624\uff08TCL\uff09\u81e8\u5e8a\u524d\u6a21\u578b\u4e2d\u5c55\u73fe\u5f37\u6548\u6297\u816b\u7624\u6d3b\u6027\uff0c\u4e26\u8207\u7d44\u86cb\u767d\u53bb\u4e59\u9170\u5316\u9176\u6291\u5236\u5291\u897f\u9054\u672c\u80fa\u5354\u540c\u589e\u6548 \u6458\u8981\u7de8\u865f\uff1aPS1993 \u5206\u6703\u5834\uff1a\u6dcb\u5df4\u7624\u751f\u7269\u5b78\u8207\u8f49\u5316\u7814\u7a76\uff08Lymphoma biology & translational research\uff09 \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670815\u65e5\uff0c\u5468\u65e5\uff0c\u51cc\u666800:30-01:30\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u665a\u4e0a18:30-19:30\uff09 \u4e3b\u8981\u4f5c\u8005\uff1a\u4e9e\u76db\u91ab\u85e5Eric Liang\u535a\u58eb \u5728\u7dda\u767c\u5e03 Alternating Low-Dose Inotuzumab Ozogamicin and Blinatumomab in Maintenance Therapy for Ph+ ALL: A Single-Center Retrospective Analysis\u4f4e\u5291\u91cf\u5967\u52a0\u4f0a\u59a5\u73e0\u55ae\u6297\u548c\u8c9d\u6797\u59a5\u6b50\u55ae\u6297\u4ea4\u66ff\u7dad\u6301\u6cbb\u7642\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\uff08Ph+\uff09\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08ALL\uff09\uff1a\u4e00\u9805\u55ae\u4e2d\u5fc3\u56de\u9867\u6027\u5206\u6790 \u6458\u8981\u7de8\u865f\uff1aPB2384 \u4e3b\u8981\u4f5c\u8005\uff1a\u6cb3\u5317\u91ab\u79d1\u5927\u5b78\u7b2c\u4e8c\u91ab\u9662\u8076\u5b50\u5143\u6559\u6388 Efficacy and Safety of Blinatumomab in Newly-Diagnosed Patients with Ph-Positive\/Negative B-Cell Acute Lymphoblastic Leukemia\u8c9d\u6797\u59a5\u6b50\u55ae\u6297\u6cbb\u7642\u65b0\u78ba\u8a3a\u7684 Ph \u967d\u6027\/\u9670\u6027 B \u7d30\u80de\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\u60a3\u8005\u7684\u7642\u6548\u548c\u5b89\u5168\u6027 \u6458\u8981\u7de8\u865f\uff1aPB2363 \u4e3b\u8981\u4f5c\u8005\uff1a\u83ef\u4e2d\u79d1\u6280\u5927\u5b78\u540c\u6fdf\u91ab\u5b78\u9662\u9644\u5c6c\u5354\u548c\u91ab\u9662\u5f35\u5bc5\u5b19 Efficacy and Safety of the Third-Generation TKI Olverembatinib in Relapsed and Persistent MRD Positive Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients\u7b2c\u4e09\u4ee3TKI\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u5fa9\u767c\u548c\u6301\u7e8cMRD\u967d\u6027\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\u60a3\u8005\u7684\u7642\u6548\u8207\u5b89\u5168\u6027 \u6458\u8981\u7de8\u865f\uff1aPB2360 \u4e3b\u8981\u4f5c\u8005\uff1a\u6cb3\u5317\u91ab\u79d1\u5927\u5b78\u7b2c\u4e8c\u91ab\u9662\u8523\u854a\u6eab Clinical Features and Genetic Abnormalities Predict Outcomes in Patients with Chronic Myeloid Leukemia in the Accelerated-Phase Receiving Olverembatinib Therapy: A Retrospective Multicenter Study\u81e8\u5e8a\u7279\u5fb5\u548c\u57fa\u56e0\u7570\u5e38\u7528\u65bc\u9810\u6e2c\u63a5\u53d7\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7684\u52a0\u901f\u671f\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u60a3\u8005\u7684\u6cbb\u7642\u7d50\u5c40\uff1a\u4e00\u9805\u56de\u9867\u6027\u591a\u4e2d\u5fc3\u7814\u7a76 \u6458\u8981\u7de8\u865f\uff1aPB2701 \u4e3b\u8981\u4f5c\u8005\uff1a\u5317\u4eac\u5927\u5b78\u4eba\u6c11\u91ab\u9662\u539f\u5922\u7464 A Real-World Study of Olverembatinib in the Treatment of Chronic Myeloid Leukemia from China: A Single-Center Retrospective Study\u4e00\u9805\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u7528\u65bc\u6cbb\u7642\u4e2d\u570b\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u60a3\u8005\u7684\u771f\u5be6\u4e16\u754c\u7814\u7a76\uff1a\u4e00\u9805\u55ae\u4e2d\u5fc3\u56de\u9867\u6027\u7814\u7a76 \u6458\u8981\u7de8\u865f\uff1aPB2714 \u4e3b\u8981\u4f5c\u8005\uff1a\u56db\u5ddd\u5927\u5b78\u83ef\u897f\u91ab\u9662\u8463\u5929 Synergistic Effects of Olverembatinib (HQP1351) Combined with Bcl-2 Inhibitor Lisaftoclax (APG-2575) and Bcl-2\/Bcl-xL Inhibitor Pelcitoclax (APG-1252) in T-Cell Acute Lymphoblastic Leukemia (T-ALL)\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u806f\u5408Bcl-2\u6291\u5236\u5291lisaftoclax\uff08APG-2575\uff09\u548cBcl-2\/Bcl-xL\u6291\u5236\u5291pelcitoclax\uff08APG-1252\uff09\u5728T\u7d30\u80de\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08T-ALL\uff09\u4e2d\u7684\u5354\u540c\u4f5c\u7528 \u6458\u8981\u7de8\u865f\uff1aPB2341 \u4e3b\u8981\u4f5c\u8005\uff1a\u4e9e\u76db\u91ab\u85e5\u5f6d\u6ce2 \u95dc\u65bc\u4e9e\u76db\u91ab\u85e5 \u4e9e\u76db\u91ab\u85e5\u662f\u4e00\u5bb6\u7d9c\u5408\u6027\u7684\u5168\u7403\u751f\u7269\u91ab\u85e5\u4f01\u696d\uff0c\u81f4\u529b\u65bc\u7814\u767c\u5275\u65b0\u85e5\uff0c\u4ee5\u89e3\u6c7a\u816b\u7624\u7b49\u9818\u57df\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u30022019\u5e7410\u670828\u65e5\uff0c\u516c\u53f8\u5728\u9999\u6e2f\u806f\u4ea4\u6240\u4e3b\u677f\u639b\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u78bc\uff1a6855.HK\uff1b2025\u5e741\u670824\u65e5\uff0c\u516c\u53f8\u5728\u7f8e\u570b\u7d0d\u65af\u9054\u514b\u8b49\u5238\u4ea4\u6613\u6240\u639b\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u78bc\uff1aAAPG\u3002 \u4e9e\u76db\u91ab\u85e5\u5df2\u5efa\u7acb\u8c50\u5bcc\u7684\u5275\u65b0\u85e5\u7522\u54c1\u7ba1\u7dda\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u548c MDM2-p53 \u7b49\u7d30\u80de\u51cb\u4ea1\u901a\u8def\u95dc\u9375\u86cb\u767d\u7684\u6291\u5236\u5291\uff1b\u65b0\u4e00\u4ee3\u91dd\u5c0d\u764c\u75c7\u6cbb\u7642\u4e2d\u51fa\u73fe\u7684\u6fc0\u9176\u7a81\u8b8a\u9ad4\u7684\u6291\u5236\u5291\u7b49\u3002 \u516c\u53f8\u6838\u5fc3\u54c1\u7a2e\u8010\u7acb\u514b\u00ae\u662f\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\uff0c\u4e14\u7372\u6279\u9069\u61c9\u75c7\u5747\u88ab\u6210\u529f\u7d0d\u5165\u570b\u5bb6\u91ab\u4fdd\u85e5\u54c1\u76ee\u9304\uff0c\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u8010\u7acb\u514b\u00ae\u4e00\u9805\u7372\u7f8e\u570bFDA\u8a31\u53ef\u7684\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff08POLARIS-2\uff09\uff0c\u7528\u65bc\u6cbb\u7642\u65e2\u5f80\u63a5\u53d7\u904e\u6cbb\u7642\u7684\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CML-CP\uff09\u6210\u5e74\u60a3\u8005\u3002\u6b64\u5916\uff0c\u8010\u7acb\u514b\u00ae\u806f\u5408\u6cbb\u7642\u65b0\u8a3a\u65b7\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u60a3\u8005\u548c\u6cbb\u7642\u7425\u73c0\u9178\u812b\u6c2b\u9176\uff08SDH\uff09\u7f3a\u9677\u578b\u80c3\u8178\u9053\u9593\u8cea\u7624\uff08GIST\uff09\u60a3\u8005\u7684\u5168\u7403\u8a3b\u518aIII\u671f\u7814\u7a76\u6b63\u5728\u958b\u5c55\u4e2d\u3002 \u516c\u53f8\u53e6\u4e00\u91cd\u78c5\u54c1\u7a2e\uff0c\u65b0\u578bBcl-2\u9078\u64c7\u6027\u6291\u5236\u5291APG-2575\uff08Lisaftoclax\uff09\u7684\u65b0\u85e5\u4e0a\u5e02\u7533\u8acb\uff08NDA\uff09\u5df2\u7372CDE\u53d7\u7406\uff0c\u4e26\u88ab\u7d0d\u5165\u512a\u5148\u5be9\u8a55\u3002\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55APG-2575\uff08Lisaftoclax\uff09\u56db\u9805\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u5206\u5225\u70ba\u7372\u7f8e\u570bFDA\u8a31\u53ef\u7684\u6cbb\u7642\u7d93\u6cbb\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u7684\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff08GLORA\uff09\uff1b\u6cbb\u7642\u521d\u6cbbCLL\/SLL\u60a3\u8005\u7684\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff1b\u4e00\u7dda\u6cbb\u7642\u65b0\u8a3a\u65b7\u8001\u5e74\u6216\u9ad4\u5f31\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08AML\uff09\u7684\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff1b\u4ee5\u53ca\u6cbb\u7642\u65b0\u8a3a\u65b7\u4e2d\u9ad8\u5371\u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u75c7\uff08MDS\uff09\u60a3\u8005\u7684\u8a3b\u518aIII\u671f\u7814\u7a76\u3002 \u622a\u81f3\u76ee\u524d\uff0c\u516c\u53f84\u500b\u5728\u7814\u65b0\u85e5\u5171\u737216\u9805FDA\u548c1\u9805\u6b50\u76df\u5b64\u5152\u85e5\u8cc7\u683c\u8a8d\u5b9a\uff0c2\u9805FDA\u5feb\u901f\u901a\u9053\u8cc7\u683c\u4ee5\u53ca2\u9805FDA\u5152\u7ae5\u7f55\u898b\u75c5\u8cc7\u683c\u8a8d\u8b49\u3002\u6191\u501f\u5f37\u5927\u7684\u7814\u767c\u80fd\u529b\uff0c\u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u5168\u7403\u7bc4\u570d\u5167\u9032\u884c\u77e5\u8b58\u7522\u6b0a\u5e03\u5c40\uff0c\u4e26\u8207\u6b66\u7530\u3001\u9ed8\u6c99\u6771\u3001\u963f\u65af\u5229\u5eb7\u3001\u8f1d\u745e\u3001\u4fe1\u9054\u7b49\u9818\u5148\u7684\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u4ee5\u53ca\u6885\u5967\u91ab\u5b78\u4e2d\u5fc3\uff08Mayo Clinic\uff09\u3001\u4e39\u5a1c\u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662\uff08Dana-Farber Cancer Institute\uff09\u3001\u7f8e\u570b\u570b\u5bb6\u764c\u75c7\u7814\u7a76\u6240\uff08NCI\uff09\u548c\u5bc6\u897f\u6839\u5927\u5b78\u7b49\u5b78\u8853\u6a5f\u69cb\u9054\u6210\u5168\u7403\u5408\u4f5c\u95dc\u4fc2\u3002 \u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u539f\u5275\u65b0\u85e5\u7814\u767c\u8207\u81e8\u5e8a\u958b\u767c\u9818\u57df\u5efa\u7acb\u7d93\u9a57\u8c50\u5bcc\u7684\u570b\u969b\u5316\u4eba\u624d\u5718\u968a\uff0c\u4ee5\u53ca\u6210\u719f\u7684\u5546\u696d\u5316\u751f\u7522\u8207\u5e02\u5834\u71df\u92b7\u5718\u968a\u3002\u4e9e\u76db\u91ab\u85e5\u5c07\u4e0d\u65b7\u63d0\u9ad8\u7814\u767c\u80fd\u529b\uff0c\u52a0\u901f\u63a8\u9032\u516c\u53f8\u7522\u54c1\u7ba1\u7dda\u7684\u81e8\u5e8a\u958b\u767c\u9032\u5ea6\uff0c\u771f\u6b63\u8e10\u884c\u300c\u89e3\u6c7a\u4e2d\u570b\u4e43\u81f3\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u300d\u7684\u4f7f\u547d\uff0c\u4ee5\u9020\u798f\u66f4\u591a\u60a3\u8005\u3002 \u524d\u77bb\u6027\u8072\u660e \u672c\u65b0\u805e\u7a3f\u5305\u542b\u6839\u64da\u7f8e\u570b\u300a1995\u5e74\u79c1\u4eba\u8b49\u5238\u8a34\u8a1f\u6539\u9769\u6cd5\u6848\u300b\uff0c\u4ee5\u53ca\u7d93\u4fee\u8a02\u7684\u300a1933\u5e74\u8b49\u5238\u6cd5\u300b\u7b2c27A\u689d\u548c\u300a1934\u5e74\u8b49\u5238\u4ea4\u6613\u6cd5\u300b\u7b2c21E\u689d\u6240\u754c\u5b9a\u7684\u524d\u77bb\u6027\u9673\u8ff0\u3002\u9664\u6b77\u53f2\u4e8b\u5be6\u9673\u8ff0\u5916\uff0c\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u6240\u6709\u5167\u5bb9\u5747\u53ef\u80fd\u69cb\u6210\u524d\u77bb\u6027\u9673\u8ff0\uff0c\u5305\u62ec\u4e9e\u76db\u91ab\u85e5\u5c0d\u672a\u4f86\u4e8b\u4ef6\u3001\u7d93\u71df\u6210\u679c\u6216\u8ca1\u52d9\u72c0\u6cc1\u6240\u767c\u8868\u7684\u610f\u898b\u3001\u9810\u671f\u3001\u4fe1\u5ff5\u3001\u8a08\u5283\u3001\u76ee\u6a19\u3001\u5047\u8a2d\u6216\u9810\u6e2c\u3002 \u9019\u4e9b\u524d\u77bb\u6027\u9673\u8ff0\u53d7\u5230\u8af8\u591a\u98a8\u96aa\u548c\u4e0d\u78ba\u5b9a\u6027\u7684\u5f71\u97ff\uff0c\u5177\u9ad4\u5167\u5bb9\u5df2\u5728\u4e9e\u76db\u91ab\u85e5\u5411\u7f8e\u570b\u8b49\u5238\u4ea4\u6613\u59d4\u54e1\u6703\uff08SEC\uff09\u63d0\u4ea4\u7684\u6587\u4ef6\u4e2d\u8a73\u7d30\u8aaa\u660e\uff0c\u5305\u62ec2025\u5e741\u670821\u65e5\u63d0\u4ea4\u7684\u7d93\u4fee\u8a02\u7684F-1\u8868\u683c\u8a3b\u518a\u8aaa\u660e\u66f8\u548c2025\u5e744\u670816\u65e5\u63d0\u4ea4\u768420-F\u8868\u683c\u4e2d\u7684\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u548c\u300c\u95dc\u65bc\u524d\u77bb\u6027\u9673\u8ff0\u53ca\u884c\u696d\u6578\u64da\u7684\u7279\u5225\u8aaa\u660e\u300d\u7ae0\u7bc0\u30012019\u5e7410\u670816\u65e5\u63d0\u4ea4\u7684\u9996\u6b21\u767c\u884c\u4e0a\u5e02\u62db\u80a1\u66f8\u4e2d\u7684\u300c\u524d\u77bb\u6027\u8072\u660e\u300d\u3001\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u7ae0\u7bc0\uff0c\u4ee5\u53ca\u6211\u5011\u4e0d\u6642\u5411SEC\u6216HKEX\u63d0\u4ea4\u7684\u5176\u4ed6\u6587\u4ef6\u3002\u9019\u4e9b\u56e0\u7d20\u53ef\u80fd\u5c0e\u81f4\u5be6\u969b\u696d\u7e3e\u3001\u904b\u71df\u6c34\u5e73\u3001\u7d93\u71df\u6210\u679c\u6216\u6210\u5c31\u8207\u524d\u77bb\u6027\u9673\u8ff0\u4e2d\u660e\u793a\u6216\u6697\u793a\u7684\u4fe1\u606f\u5b58\u5728\u91cd\u5927\u5dee\u7570\u3002\u672c\u524d\u77bb\u6027\u8072\u660e\u4e2d\u7684\u9673\u8ff0\u4e0d\u69cb\u6210\u516c\u53f8\u7ba1\u7406\u5c64\u7684\u5229\u6f64\u9810\u6e2c\u3002 \u56e0\u6b64\uff0c\u8a72\u7b49\u524d\u77bb\u6027\u9673\u8ff0\u4e0d\u61c9\u88ab\u8996\u70ba\u5c0d\u672a\u4f86\u4e8b\u4ef6\u7684\u9810\u6e2c\u3002\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u524d\u77bb\u6027\u9673\u8ff0\u50c5\u57fa\u65bc\u4e9e\u76db\u91ab\u85e5\u7576\u524d\u5c0d\u672a\u4f86\u767c\u5c55\u53ca\u5176\u6f5b\u5728\u5f71\u97ff\u7684\u9810\u671f\u548c\u5224\u65b7\uff0c\u4e14\u50c5\u4ee3\u8868\u622a\u81f3\u9673\u8ff0\u767c\u8868\u4e4b\u65e5\u7684\u89c0\u9ede\u3002\u7121\u8ad6\u51fa\u73fe\u65b0\u4fe1\u606f\u3001\u672a\u4f86\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u6cc1\uff0c\u4e9e\u76db\u91ab\u85e5\u5747\u7121\u7fa9\u52d9\u66f4\u65b0\u6216\u4fee\u8a02\u4efb\u4f55\u524d\u77bb\u6027\u9673\u8ff0\u3002","og_url":"https:\/\/pingtungtimes.com.tw\/?p=334269","og_site_name":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","article_publisher":"https:\/\/www.facebook.com\/pingtungnews","article_published_time":"2025-06-10T01:18:00+00:00","og_image":[{"url":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","width":1,"height":1,"type":"image\/jpeg"}],"author":"\u7f8e\u901a\u793e","twitter_card":"summary_large_image","twitter_misc":{"\u4f5c\u8005:":"\u7f8e\u901a\u793e","\u9810\u4f30\u95b1\u8b80\u6642\u9593":"2 \u5206\u9418"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/pingtungtimes.com.tw\/?p=334269#article","isPartOf":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=334269"},"author":{"name":"\u7f8e\u901a\u793e","@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/person\/683b937f29ec1537972f6c41e22a2cf3"},"headline":"\u30102025 EHA\u3011\u4e9e\u76db\u91ab\u85e5\u6838\u5fc3\u7522\u54c1\u8010\u7acb\u514b\u00ae\u548cAPG-2575\u7b4913\u9805\u9032\u5c55\u5165\u90782025\u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703\u5e74\u6703","datePublished":"2025-06-10T01:18:00+00:00","mainEntityOfPage":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=334269"},"wordCount":439,"publisher":{"@id":"https:\/\/pingtungtimes.com.tw\/#organization"},"image":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=334269#primaryimage"},"thumbnailUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/Ascentage_APAC_Logo-7.jpg","articleSection":["\u7f8e\u901a\u793e"],"inLanguage":"zh-TW"},{"@type":"WebPage","@id":"https:\/\/pingtungtimes.com.tw\/?p=334269","url":"https:\/\/pingtungtimes.com.tw\/?p=334269","name":"\u30102025 EHA\u3011\u4e9e\u76db\u91ab\u85e5\u6838\u5fc3\u7522\u54c1\u8010\u7acb\u514b\u00ae\u548cAPG-2575\u7b4913\u9805\u9032\u5c55\u5165\u90782025\u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703\u5e74\u6703 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","isPartOf":{"@id":"https:\/\/pingtungtimes.com.tw\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=334269#primaryimage"},"image":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=334269#primaryimage"},"thumbnailUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/Ascentage_APAC_Logo-7.jpg","datePublished":"2025-06-10T01:18:00+00:00","description":"\u7f8e\u570b\u99ac\u91cc\u862d\u5dde\u7f85\u514b\u7dad\u723e\u5e02\u548c\u4e2d\u570b\u8607\u5dde 2025\u5e746\u670810\u65e5 \u00a0\/\u7f8e\u901a\u793e\/ -- \u81f4\u529b\u65bc\u5728\u816b\u7624\u7b49\u9818\u57df\u958b\u767c\u5275\u65b0\u85e5\u7269\u7684\u9818\u5148\u7684\u751f\u7269\u91ab\u85e5\u4f01\u696d\u2014\u2014\u4e9e\u76db\u91ab\u85e5\uff08\u7d0d\u65af\u9054\u514b\u4ee3\u78bc\uff1aAAPG\uff1b\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a6855\uff09\u5ba3\u5e03\uff0c\u6d89\u53ca\u516c\u53f8\u539f\u52751\u985e\u65b0\u85e5\u5967\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff09\u3001Bcl-2\u6291\u5236\u5291APG-2575\u3001EED\u6291\u5236\u5291APG-5918\u7b49\u91cd\u78c5\u54c1\u7a2e\u768413\u9805\u7814\u7a76\u9032\u5c55\u5c07\u57282025\u5e746\u670812\u65e5\u81f315\u65e5\u65bc\u610f\u5927\u5229\u7c73\u862d\u8209\u884c\u76842025\u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703\uff08EHA\uff09\u5e74\u6703\u4e0a\u516c\u5e03\uff0c\u5176\u4e2d\u5305\u62ec1\u9805\u53e3\u982d\u5831\u544a\uff0c\u53ca\u591a\u9805\u58c1\u5831\u5c55\u793a\u548c\u7dda\u4e0a\u767c\u8868\u3002 EHA\u5e74\u6703\u4f5c\u70ba\u6b50\u6d32\u8840\u6db2\u5b78\u9818\u57df\u898f\u6a21\u6700\u5927\u7684\u570b\u969b\u6703\u8b70\uff0c\u6bcf\u5e74\u5438\u5f15\u4f86\u81ea\u5168\u7403100\u591a\u500b\u570b\u5bb6\u76841\u842c\u591a\u540d\u5c08\u696d\u4eba\u58eb\u8207\u6703\uff0c\u5206\u4eab\u5168\u7403\u6700\u524d\u6cbf\u7684\u7814\u7a76\u9032\u5c55\u548c\u7a81\u7834\u6027\u81e8\u5e8a\u6578\u64da\u3002 \u53e3\u982d\u5831\u544a Integrating Genomic and Transcriptomic Insights for Predicting Responses and Outcomes in Patients with CML Receiving 3rd-Generation TKI Therapy\u6574\u5408\u57fa\u56e0\u7d44\u548c\u8f49\u9304\u7d44\u5b78\u898b\u89e3\u4ee5\u9810\u6e2c\u63a5\u53d7\u4e09\u4ee3TKI\u6cbb\u7642\u7684CML\u60a3\u8005\u7684\u7642\u6548\u548c\u7d50\u5c40 \u6458\u8981\u7de8\u865f\uff1aS162 \u5206\u6703\u5834\uff1aCML\u6cbb\u7642\u7642\u6548\u53ca\u8010\u85e5\u7684\u751f\u7269\u5b78\uff08Biology of CML treatment response and resistance\uff09 \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u665a\u4e0a23:30-23:45\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u4e0b\u534817:30-17:45\uff09 \u4e3b\u8981\u4f5c\u8005\uff1a\u5317\u4eac\u5927\u5b78\u4eba\u6c11\u91ab\u9662\u6c5f\u5029\u6559\u6388\uff0c\u5317\u4eac\u5927\u5b78\u4eba\u6c11\u91ab\u9662\u5f35\u5c0f\u5e25 \u58c1\u5831\u5c55\u793a Frontline Chemotherapy-Free Combination of Olverembatinib with Venetoclax and Azacitidine in Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia: Preliminary Outcomes of a Prospective Study\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u7dad\u5948\u514b\u62c9\u8207\u963f\u624e\u80de\u7518\u7528\u65bc\u7121\u5316\u7642\u4e00\u7dda\u6cbb\u7642\u65b0\u8a3a\u65b7\u7684Ph+\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff1a\u4e00\u9805\u524d\u77bb\u6027\u7814\u7a76\u7684\u521d\u6b65\u7d50\u679c \u6458\u8981\u7de8\u865f\uff1aPF384 \u5206\u6703\u5834\uff1a\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76\uff08Acute lymphoblastic leukemia - Clinical\uff09 \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u51cc\u666800:30-01:30\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670813\u65e5\uff0c\u5468\u4e94\uff0c\u665a\u4e0a18:30-19:30\uff09 \u4e3b\u8981\u4f5c\u8005\uff1a\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662\u5510\u66c9\u6587\u6559\u6388\uff0c\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662\u5f35\u6b23 A Phase 2 Study of Olverembatinib for the Treatment of Myeloid\/Lymphoid Neoplasms with FGFR1 Rearrangement\u4e00\u9805\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u7528\u65bc\u6cbb\u7642\u4f34FGFR1\u91cd\u6392\u7684\u9ad3\u7cfb\/\u6dcb\u5df4\u7cfb\u816b\u7624\u7684II\u671f\u7814\u7a76 \u6458\u8981\u7de8\u865f\uff1aPF390 \u5206\u6703\u5834\uff1a\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76\uff08Acute lymphoblastic leukemia - Clinical\uff09 \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u51cc\u666800:30-01:30\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670813\u65e5\uff0c\u5468\u4e94\uff0c\u665a\u4e0a18:30-19:30\uff09 \u4e3b\u8981\u4f5c\u8005\uff1a\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662\u9673\u8607\u5be7\u6559\u6388\uff0c\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662\u8521\u6587\u6cbb Efficacy and Safety of Regimen with Olverembatinib and Blinatumomab for the Frontline Treatment of Ph-Positive or Ph-Like Acute Lymphoblastic Leukemia\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u8c9d\u6797\u59a5\u6b50\u55ae\u6297\u4e00\u7dda\u6cbb\u7642\u8cbb\u57ce\u67d3\u8272\u9ad4\uff08Ph\uff09\u967d\u6027\u6216Ph\u6a23\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\u7684\u7642\u6548\u548c\u5b89\u5168\u6027 \u6458\u8981\u7de8\u865f\uff1aPS1367 \u5206\u6703\u5834\uff1a\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76\uff08Acute lymphoblastic leukemia - Clinical\uff09 \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670815\u65e5\uff0c\u5468\u65e5\uff0c\u51cc\u666800:30-01:30\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u665a\u4e0a18:30-19:30 \uff09 \u4e3b\u8981\u4f5c\u8005\uff1a\u5357\u65b9\u91ab\u79d1\u5927\u5b78\u5357\u65b9\u91ab\u9662\u5468\u7d05\u5347\u6559\u6388\uff0c\u5357\u65b9\u91ab\u79d1\u5927\u5b78\u5357\u65b9\u91ab\u9662\u8a31\u79c0\u9e97 Combination of Olverembatinib and VP Regimen as First-Line Therapy for Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Single-Arm, Multicentre, Phase 2 Trial\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408VP\u65b9\u6848\u4e00\u7dda\u6cbb\u7642\u6210\u4eba\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff1a\u4e00\u9805\u55ae\u81c2\u3001\u591a\u4e2d\u5fc3II\u671f\u7814\u7a76 \u6458\u8981\u7de8\u865f\uff1aPS1372 \u5206\u6703\u5834\uff1a\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76\uff08Acute lymphoblastic leukemia - Clinical\uff09 \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670815\u65e5\uff0c\u5468\u65e5\uff0c\u51cc\u666800:30-01:30\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u665a\u4e0a18:30-19:30\uff09 \u4e3b\u8981\u4f5c\u8005\uff1a\u6d59\u6c5f\u5927\u5b78\u91ab\u5b78\u9662\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662\u91d1\u6f54\u6559\u6388\uff0c\u6d59\u6c5f\u5927\u5b78\u91ab\u5b78\u9662\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662\u8a31\u6539\u9999 Efficacy and Safety of The Third-Generation Tyrosine Kinase Inhibitor Olverembatinib in Combination with Inotuzumab Ozogamicin for the Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients With Relapsed Disease or Persistent Minimal Residual Disease Bridging to Hematopoietic Stem Cell Transplantation: A Phase II Study\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u5967\u52a0\u4f0a\u59a5\u73e0\u55ae\u6297\u6cbb\u7642\u5fa9\u767c\u6216\u9020\u8840\u5e72\u7d30\u80de\u79fb\u690d\u524d\u6301\u7e8cMRD\u967d\u6027\u6210\u4ebaPh+ ALL\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\uff1a\u4e00\u9805\u2161\u671f\u7814\u7a76 \u6458\u8981\u7de8\u865f\uff1aPS1387 \u5206\u6703\u5834\uff1a\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76\uff08Acute lymphoblastic leukemia - Clinical\uff09 \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670815\u65e5\uff0c\u5468\u65e5\uff0c\u51cc\u666800:30-01:30\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u665a\u4e0a18:30-19:30\uff09 \u4e3b\u8981\u4f5c\u8005\uff1a\u4e2d\u570b\u91ab\u5b78\u79d1\u5b78\u9662\u5317\u4eac\u5354\u548c\u91ab\u5b78\u9662\u8840\u6db2\u75c5\u91ab\u9662\u59dc\u723e\u70c8\u6559\u6388\uff0c\u4e2d\u570b\u91ab\u5b78\u79d1\u5b78\u9662\u5317\u4eac\u5354\u548c\u91ab\u5b78\u9662\u8840\u6db2\u75c5\u91ab\u9662\u5f35\u701f\u4e88 Embryonic Ectoderm Development (EED) Inhibitor APG-5918 Exhibits Potent Antitumor Activity and Synergizes with Histone Deacetylase Inhibitor Tucidinostat in PreclinicalT-Cell Lymphoma (TCL) Models\u80da\u80ce\u5916\u80da\u5c64\u767c\u80b2\u86cb\u767d\uff08EED\uff09\u6291\u5236\u5291APG-5918\u5728T\u7d30\u80de\u6dcb\u5df4\u7624\uff08TCL\uff09\u81e8\u5e8a\u524d\u6a21\u578b\u4e2d\u5c55\u73fe\u5f37\u6548\u6297\u816b\u7624\u6d3b\u6027\uff0c\u4e26\u8207\u7d44\u86cb\u767d\u53bb\u4e59\u9170\u5316\u9176\u6291\u5236\u5291\u897f\u9054\u672c\u80fa\u5354\u540c\u589e\u6548 \u6458\u8981\u7de8\u865f\uff1aPS1993 \u5206\u6703\u5834\uff1a\u6dcb\u5df4\u7624\u751f\u7269\u5b78\u8207\u8f49\u5316\u7814\u7a76\uff08Lymphoma biology & translational research\uff09 \u5831\u544a\u6642\u9593\uff1a\u5317\u4eac\u6642\u95936\u670815\u65e5\uff0c\u5468\u65e5\uff0c\u51cc\u666800:30-01:30\uff08\u6b50\u6d32\u4e2d\u90e8\u6642\u95936\u670814\u65e5\uff0c\u5468\u516d\uff0c\u665a\u4e0a18:30-19:30\uff09 \u4e3b\u8981\u4f5c\u8005\uff1a\u4e9e\u76db\u91ab\u85e5Eric Liang\u535a\u58eb \u5728\u7dda\u767c\u5e03 Alternating Low-Dose Inotuzumab Ozogamicin and Blinatumomab in Maintenance Therapy for Ph+ ALL: A Single-Center Retrospective Analysis\u4f4e\u5291\u91cf\u5967\u52a0\u4f0a\u59a5\u73e0\u55ae\u6297\u548c\u8c9d\u6797\u59a5\u6b50\u55ae\u6297\u4ea4\u66ff\u7dad\u6301\u6cbb\u7642\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\uff08Ph+\uff09\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08ALL\uff09\uff1a\u4e00\u9805\u55ae\u4e2d\u5fc3\u56de\u9867\u6027\u5206\u6790 \u6458\u8981\u7de8\u865f\uff1aPB2384 \u4e3b\u8981\u4f5c\u8005\uff1a\u6cb3\u5317\u91ab\u79d1\u5927\u5b78\u7b2c\u4e8c\u91ab\u9662\u8076\u5b50\u5143\u6559\u6388 Efficacy and Safety of Blinatumomab in Newly-Diagnosed Patients with Ph-Positive\/Negative B-Cell Acute Lymphoblastic Leukemia\u8c9d\u6797\u59a5\u6b50\u55ae\u6297\u6cbb\u7642\u65b0\u78ba\u8a3a\u7684 Ph \u967d\u6027\/\u9670\u6027 B \u7d30\u80de\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\u60a3\u8005\u7684\u7642\u6548\u548c\u5b89\u5168\u6027 \u6458\u8981\u7de8\u865f\uff1aPB2363 \u4e3b\u8981\u4f5c\u8005\uff1a\u83ef\u4e2d\u79d1\u6280\u5927\u5b78\u540c\u6fdf\u91ab\u5b78\u9662\u9644\u5c6c\u5354\u548c\u91ab\u9662\u5f35\u5bc5\u5b19 Efficacy and Safety of the Third-Generation TKI Olverembatinib in Relapsed and Persistent MRD Positive Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients\u7b2c\u4e09\u4ee3TKI\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u5fa9\u767c\u548c\u6301\u7e8cMRD\u967d\u6027\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\u60a3\u8005\u7684\u7642\u6548\u8207\u5b89\u5168\u6027 \u6458\u8981\u7de8\u865f\uff1aPB2360 \u4e3b\u8981\u4f5c\u8005\uff1a\u6cb3\u5317\u91ab\u79d1\u5927\u5b78\u7b2c\u4e8c\u91ab\u9662\u8523\u854a\u6eab Clinical Features and Genetic Abnormalities Predict Outcomes in Patients with Chronic Myeloid Leukemia in the Accelerated-Phase Receiving Olverembatinib Therapy: A Retrospective Multicenter Study\u81e8\u5e8a\u7279\u5fb5\u548c\u57fa\u56e0\u7570\u5e38\u7528\u65bc\u9810\u6e2c\u63a5\u53d7\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7684\u52a0\u901f\u671f\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u60a3\u8005\u7684\u6cbb\u7642\u7d50\u5c40\uff1a\u4e00\u9805\u56de\u9867\u6027\u591a\u4e2d\u5fc3\u7814\u7a76 \u6458\u8981\u7de8\u865f\uff1aPB2701 \u4e3b\u8981\u4f5c\u8005\uff1a\u5317\u4eac\u5927\u5b78\u4eba\u6c11\u91ab\u9662\u539f\u5922\u7464 A Real-World Study of Olverembatinib in the Treatment of Chronic Myeloid Leukemia from China: A Single-Center Retrospective Study\u4e00\u9805\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u7528\u65bc\u6cbb\u7642\u4e2d\u570b\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u60a3\u8005\u7684\u771f\u5be6\u4e16\u754c\u7814\u7a76\uff1a\u4e00\u9805\u55ae\u4e2d\u5fc3\u56de\u9867\u6027\u7814\u7a76 \u6458\u8981\u7de8\u865f\uff1aPB2714 \u4e3b\u8981\u4f5c\u8005\uff1a\u56db\u5ddd\u5927\u5b78\u83ef\u897f\u91ab\u9662\u8463\u5929 Synergistic Effects of Olverembatinib (HQP1351) Combined with Bcl-2 Inhibitor Lisaftoclax (APG-2575) and Bcl-2\/Bcl-xL Inhibitor Pelcitoclax (APG-1252) in T-Cell Acute Lymphoblastic Leukemia (T-ALL)\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u806f\u5408Bcl-2\u6291\u5236\u5291lisaftoclax\uff08APG-2575\uff09\u548cBcl-2\/Bcl-xL\u6291\u5236\u5291pelcitoclax\uff08APG-1252\uff09\u5728T\u7d30\u80de\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08T-ALL\uff09\u4e2d\u7684\u5354\u540c\u4f5c\u7528 \u6458\u8981\u7de8\u865f\uff1aPB2341 \u4e3b\u8981\u4f5c\u8005\uff1a\u4e9e\u76db\u91ab\u85e5\u5f6d\u6ce2 \u95dc\u65bc\u4e9e\u76db\u91ab\u85e5 \u4e9e\u76db\u91ab\u85e5\u662f\u4e00\u5bb6\u7d9c\u5408\u6027\u7684\u5168\u7403\u751f\u7269\u91ab\u85e5\u4f01\u696d\uff0c\u81f4\u529b\u65bc\u7814\u767c\u5275\u65b0\u85e5\uff0c\u4ee5\u89e3\u6c7a\u816b\u7624\u7b49\u9818\u57df\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u30022019\u5e7410\u670828\u65e5\uff0c\u516c\u53f8\u5728\u9999\u6e2f\u806f\u4ea4\u6240\u4e3b\u677f\u639b\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u78bc\uff1a6855.HK\uff1b2025\u5e741\u670824\u65e5\uff0c\u516c\u53f8\u5728\u7f8e\u570b\u7d0d\u65af\u9054\u514b\u8b49\u5238\u4ea4\u6613\u6240\u639b\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u78bc\uff1aAAPG\u3002 \u4e9e\u76db\u91ab\u85e5\u5df2\u5efa\u7acb\u8c50\u5bcc\u7684\u5275\u65b0\u85e5\u7522\u54c1\u7ba1\u7dda\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u548c MDM2-p53 \u7b49\u7d30\u80de\u51cb\u4ea1\u901a\u8def\u95dc\u9375\u86cb\u767d\u7684\u6291\u5236\u5291\uff1b\u65b0\u4e00\u4ee3\u91dd\u5c0d\u764c\u75c7\u6cbb\u7642\u4e2d\u51fa\u73fe\u7684\u6fc0\u9176\u7a81\u8b8a\u9ad4\u7684\u6291\u5236\u5291\u7b49\u3002 \u516c\u53f8\u6838\u5fc3\u54c1\u7a2e\u8010\u7acb\u514b\u00ae\u662f\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\uff0c\u4e14\u7372\u6279\u9069\u61c9\u75c7\u5747\u88ab\u6210\u529f\u7d0d\u5165\u570b\u5bb6\u91ab\u4fdd\u85e5\u54c1\u76ee\u9304\uff0c\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u8010\u7acb\u514b\u00ae\u4e00\u9805\u7372\u7f8e\u570bFDA\u8a31\u53ef\u7684\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff08POLARIS-2\uff09\uff0c\u7528\u65bc\u6cbb\u7642\u65e2\u5f80\u63a5\u53d7\u904e\u6cbb\u7642\u7684\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CML-CP\uff09\u6210\u5e74\u60a3\u8005\u3002\u6b64\u5916\uff0c\u8010\u7acb\u514b\u00ae\u806f\u5408\u6cbb\u7642\u65b0\u8a3a\u65b7\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u60a3\u8005\u548c\u6cbb\u7642\u7425\u73c0\u9178\u812b\u6c2b\u9176\uff08SDH\uff09\u7f3a\u9677\u578b\u80c3\u8178\u9053\u9593\u8cea\u7624\uff08GIST\uff09\u60a3\u8005\u7684\u5168\u7403\u8a3b\u518aIII\u671f\u7814\u7a76\u6b63\u5728\u958b\u5c55\u4e2d\u3002 \u516c\u53f8\u53e6\u4e00\u91cd\u78c5\u54c1\u7a2e\uff0c\u65b0\u578bBcl-2\u9078\u64c7\u6027\u6291\u5236\u5291APG-2575\uff08Lisaftoclax\uff09\u7684\u65b0\u85e5\u4e0a\u5e02\u7533\u8acb\uff08NDA\uff09\u5df2\u7372CDE\u53d7\u7406\uff0c\u4e26\u88ab\u7d0d\u5165\u512a\u5148\u5be9\u8a55\u3002\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55APG-2575\uff08Lisaftoclax\uff09\u56db\u9805\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u5206\u5225\u70ba\u7372\u7f8e\u570bFDA\u8a31\u53ef\u7684\u6cbb\u7642\u7d93\u6cbb\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u7684\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff08GLORA\uff09\uff1b\u6cbb\u7642\u521d\u6cbbCLL\/SLL\u60a3\u8005\u7684\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff1b\u4e00\u7dda\u6cbb\u7642\u65b0\u8a3a\u65b7\u8001\u5e74\u6216\u9ad4\u5f31\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08AML\uff09\u7684\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff1b\u4ee5\u53ca\u6cbb\u7642\u65b0\u8a3a\u65b7\u4e2d\u9ad8\u5371\u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u75c7\uff08MDS\uff09\u60a3\u8005\u7684\u8a3b\u518aIII\u671f\u7814\u7a76\u3002 \u622a\u81f3\u76ee\u524d\uff0c\u516c\u53f84\u500b\u5728\u7814\u65b0\u85e5\u5171\u737216\u9805FDA\u548c1\u9805\u6b50\u76df\u5b64\u5152\u85e5\u8cc7\u683c\u8a8d\u5b9a\uff0c2\u9805FDA\u5feb\u901f\u901a\u9053\u8cc7\u683c\u4ee5\u53ca2\u9805FDA\u5152\u7ae5\u7f55\u898b\u75c5\u8cc7\u683c\u8a8d\u8b49\u3002\u6191\u501f\u5f37\u5927\u7684\u7814\u767c\u80fd\u529b\uff0c\u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u5168\u7403\u7bc4\u570d\u5167\u9032\u884c\u77e5\u8b58\u7522\u6b0a\u5e03\u5c40\uff0c\u4e26\u8207\u6b66\u7530\u3001\u9ed8\u6c99\u6771\u3001\u963f\u65af\u5229\u5eb7\u3001\u8f1d\u745e\u3001\u4fe1\u9054\u7b49\u9818\u5148\u7684\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u4ee5\u53ca\u6885\u5967\u91ab\u5b78\u4e2d\u5fc3\uff08Mayo Clinic\uff09\u3001\u4e39\u5a1c\u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662\uff08Dana-Farber Cancer Institute\uff09\u3001\u7f8e\u570b\u570b\u5bb6\u764c\u75c7\u7814\u7a76\u6240\uff08NCI\uff09\u548c\u5bc6\u897f\u6839\u5927\u5b78\u7b49\u5b78\u8853\u6a5f\u69cb\u9054\u6210\u5168\u7403\u5408\u4f5c\u95dc\u4fc2\u3002 \u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u539f\u5275\u65b0\u85e5\u7814\u767c\u8207\u81e8\u5e8a\u958b\u767c\u9818\u57df\u5efa\u7acb\u7d93\u9a57\u8c50\u5bcc\u7684\u570b\u969b\u5316\u4eba\u624d\u5718\u968a\uff0c\u4ee5\u53ca\u6210\u719f\u7684\u5546\u696d\u5316\u751f\u7522\u8207\u5e02\u5834\u71df\u92b7\u5718\u968a\u3002\u4e9e\u76db\u91ab\u85e5\u5c07\u4e0d\u65b7\u63d0\u9ad8\u7814\u767c\u80fd\u529b\uff0c\u52a0\u901f\u63a8\u9032\u516c\u53f8\u7522\u54c1\u7ba1\u7dda\u7684\u81e8\u5e8a\u958b\u767c\u9032\u5ea6\uff0c\u771f\u6b63\u8e10\u884c\u300c\u89e3\u6c7a\u4e2d\u570b\u4e43\u81f3\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u300d\u7684\u4f7f\u547d\uff0c\u4ee5\u9020\u798f\u66f4\u591a\u60a3\u8005\u3002 \u524d\u77bb\u6027\u8072\u660e \u672c\u65b0\u805e\u7a3f\u5305\u542b\u6839\u64da\u7f8e\u570b\u300a1995\u5e74\u79c1\u4eba\u8b49\u5238\u8a34\u8a1f\u6539\u9769\u6cd5\u6848\u300b\uff0c\u4ee5\u53ca\u7d93\u4fee\u8a02\u7684\u300a1933\u5e74\u8b49\u5238\u6cd5\u300b\u7b2c27A\u689d\u548c\u300a1934\u5e74\u8b49\u5238\u4ea4\u6613\u6cd5\u300b\u7b2c21E\u689d\u6240\u754c\u5b9a\u7684\u524d\u77bb\u6027\u9673\u8ff0\u3002\u9664\u6b77\u53f2\u4e8b\u5be6\u9673\u8ff0\u5916\uff0c\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u6240\u6709\u5167\u5bb9\u5747\u53ef\u80fd\u69cb\u6210\u524d\u77bb\u6027\u9673\u8ff0\uff0c\u5305\u62ec\u4e9e\u76db\u91ab\u85e5\u5c0d\u672a\u4f86\u4e8b\u4ef6\u3001\u7d93\u71df\u6210\u679c\u6216\u8ca1\u52d9\u72c0\u6cc1\u6240\u767c\u8868\u7684\u610f\u898b\u3001\u9810\u671f\u3001\u4fe1\u5ff5\u3001\u8a08\u5283\u3001\u76ee\u6a19\u3001\u5047\u8a2d\u6216\u9810\u6e2c\u3002 \u9019\u4e9b\u524d\u77bb\u6027\u9673\u8ff0\u53d7\u5230\u8af8\u591a\u98a8\u96aa\u548c\u4e0d\u78ba\u5b9a\u6027\u7684\u5f71\u97ff\uff0c\u5177\u9ad4\u5167\u5bb9\u5df2\u5728\u4e9e\u76db\u91ab\u85e5\u5411\u7f8e\u570b\u8b49\u5238\u4ea4\u6613\u59d4\u54e1\u6703\uff08SEC\uff09\u63d0\u4ea4\u7684\u6587\u4ef6\u4e2d\u8a73\u7d30\u8aaa\u660e\uff0c\u5305\u62ec2025\u5e741\u670821\u65e5\u63d0\u4ea4\u7684\u7d93\u4fee\u8a02\u7684F-1\u8868\u683c\u8a3b\u518a\u8aaa\u660e\u66f8\u548c2025\u5e744\u670816\u65e5\u63d0\u4ea4\u768420-F\u8868\u683c\u4e2d\u7684\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u548c\u300c\u95dc\u65bc\u524d\u77bb\u6027\u9673\u8ff0\u53ca\u884c\u696d\u6578\u64da\u7684\u7279\u5225\u8aaa\u660e\u300d\u7ae0\u7bc0\u30012019\u5e7410\u670816\u65e5\u63d0\u4ea4\u7684\u9996\u6b21\u767c\u884c\u4e0a\u5e02\u62db\u80a1\u66f8\u4e2d\u7684\u300c\u524d\u77bb\u6027\u8072\u660e\u300d\u3001\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u7ae0\u7bc0\uff0c\u4ee5\u53ca\u6211\u5011\u4e0d\u6642\u5411SEC\u6216HKEX\u63d0\u4ea4\u7684\u5176\u4ed6\u6587\u4ef6\u3002\u9019\u4e9b\u56e0\u7d20\u53ef\u80fd\u5c0e\u81f4\u5be6\u969b\u696d\u7e3e\u3001\u904b\u71df\u6c34\u5e73\u3001\u7d93\u71df\u6210\u679c\u6216\u6210\u5c31\u8207\u524d\u77bb\u6027\u9673\u8ff0\u4e2d\u660e\u793a\u6216\u6697\u793a\u7684\u4fe1\u606f\u5b58\u5728\u91cd\u5927\u5dee\u7570\u3002\u672c\u524d\u77bb\u6027\u8072\u660e\u4e2d\u7684\u9673\u8ff0\u4e0d\u69cb\u6210\u516c\u53f8\u7ba1\u7406\u5c64\u7684\u5229\u6f64\u9810\u6e2c\u3002 \u56e0\u6b64\uff0c\u8a72\u7b49\u524d\u77bb\u6027\u9673\u8ff0\u4e0d\u61c9\u88ab\u8996\u70ba\u5c0d\u672a\u4f86\u4e8b\u4ef6\u7684\u9810\u6e2c\u3002\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u524d\u77bb\u6027\u9673\u8ff0\u50c5\u57fa\u65bc\u4e9e\u76db\u91ab\u85e5\u7576\u524d\u5c0d\u672a\u4f86\u767c\u5c55\u53ca\u5176\u6f5b\u5728\u5f71\u97ff\u7684\u9810\u671f\u548c\u5224\u65b7\uff0c\u4e14\u50c5\u4ee3\u8868\u622a\u81f3\u9673\u8ff0\u767c\u8868\u4e4b\u65e5\u7684\u89c0\u9ede\u3002\u7121\u8ad6\u51fa\u73fe\u65b0\u4fe1\u606f\u3001\u672a\u4f86\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u6cc1\uff0c\u4e9e\u76db\u91ab\u85e5\u5747\u7121\u7fa9\u52d9\u66f4\u65b0\u6216\u4fee\u8a02\u4efb\u4f55\u524d\u77bb\u6027\u9673\u8ff0\u3002","breadcrumb":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=334269#breadcrumb"},"inLanguage":"zh-TW","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pingtungtimes.com.tw\/?p=334269"]}]},{"@type":"ImageObject","inLanguage":"zh-TW","@id":"https:\/\/pingtungtimes.com.tw\/?p=334269#primaryimage","url":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/Ascentage_APAC_Logo-7.jpg","contentUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/Ascentage_APAC_Logo-7.jpg","width":400,"height":150},{"@type":"BreadcrumbList","@id":"https:\/\/pingtungtimes.com.tw\/?p=334269#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u9996\u9801","item":"https:\/\/pingtungtimes.com.tw\/"},{"@type":"ListItem","position":2,"name":"\u30102025 EHA\u3011\u4e9e\u76db\u91ab\u85e5\u6838\u5fc3\u7522\u54c1\u8010\u7acb\u514b\u00ae\u548cAPG-2575\u7b4913\u9805\u9032\u5c55\u5165\u90782025\u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703\u5e74\u6703"}]},{"@type":"WebSite","@id":"https:\/\/pingtungtimes.com.tw\/#website","url":"https:\/\/pingtungtimes.com.tw\/","name":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","description":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831PingtungTimes\uff0c\u6700\u95dc\u5fc3\u5728\u5730\u7684\u5a92\u9ad4","publisher":{"@id":"https:\/\/pingtungtimes.com.tw\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pingtungtimes.com.tw\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-TW"},{"@type":"Organization","@id":"https:\/\/pingtungtimes.com.tw\/#organization","name":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","url":"https:\/\/pingtungtimes.com.tw\/","logo":{"@type":"ImageObject","inLanguage":"zh-TW","@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/logo\/image\/","url":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","contentUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","width":150,"height":150,"caption":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831"},"image":{"@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/pingtungnews"]},{"@type":"Person","@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/person\/683b937f29ec1537972f6c41e22a2cf3","name":"\u7f8e\u901a\u793e","image":{"@type":"ImageObject","inLanguage":"zh-TW","@id":"https:\/\/secure.gravatar.com\/avatar\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g","caption":"\u7f8e\u901a\u793e"},"url":"https:\/\/pingtungtimes.com.tw\/?author=16"}]}},"_links":{"self":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/334269","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=334269"}],"version-history":[{"count":0,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/334269\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/media\/334270"}],"wp:attachment":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=334269"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=334269"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=334269"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}